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SUMMARY.
1. Systemically administered kainic acid causes a dose dependent increase in the 
amount of peripheral benzodiazepine receptor in the rat hippocampus, as assessed 
by pH]PK11195 binding.
2. This increase in binding is due to an increase in and not K .^ The increase in 
PK11195 binding indicates that reactive gliosis has occurred and, by inference, 
neuronal loss.
3. The kainic acid induced elevation in binding is blocked by the non-NMDA 
antagonist GYKI 52466 and the NMD A antagonists MK801 and GPP.
4. The adenosine Aj receptor agonist R-phenylisopropyladenosine (R-PIA) is able to 
attenuate the kainic acid induced neuronal loss in a dose dependent and time 
dependent manner.
5. The R-PIA response is blocked by 8-cyclopentyl,-l,3- dipropylxanthine (DPCPX) 
in a dose dependent manner, although DPCPX is unable to potentiate kainate 
induced neurotoxicity.
6 . 8 -p-sulfophenyltheophylline (8 -SPT), is unable to cross the blood-brain barrier, and 
is unable to block the R-PIA induced neuroprotection indicating that the R-PIA 
effect is centrally mediated.
7. Kynurenine, but not kynurenic acid or tryptophan is able to attenuate kainic acid 
induced neurotoxicity in a dose dependent manner.
8 . Kainic acid and potassium chloride (KCl) are able to release [^H] glutamate from 
hippocampal slices in a dose dependent manner.
II
9. The kainic acid induced elevation induces a period o f heightened release after the 
first, but not second or third stimulations, and this is not seen after either KCl 
or kainic acid/KCl stimulations.
10, The adenosine A1 agonist 2-chloroadenosine (5juM) is unable to block the kainic 
acid induced release of f  H] glutamate.
11. DPCPX (5nM) is able to induce a significant decrease in KCl stimulated release 
of pH] glutamate but not the kainic acid induced release.
12, In conclusion, kainic acid is causing neurotoxicity in a dose dependent manner that 
is mediated through both non-NMDA and NMD A receptors, and can be attenuated 
by R-PIA, and ascorbate.
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o f  the universe. "
Terry Pratchet. EQ U A L R ITES, 1987.
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1.0. INTRODUCTION:
1.1 Neurotoxicity.
There are numerous ways to damage neurones in the CNS, but in general they can 
be divided into either acute or chronic insults depending on the time scale o f the insult.
Acute insults result from rapid changes in the brain’s microenvironment, be it 
either reduced blood flow (global or focal ischaemia), decreased blood oxygen or 
increased carboxyhaemoglobin (hypoxia), traumatic head injury (fractured skull, 
concussion or missile impact) or chemical poisoning (e.g. 1 -methyl-4-phenyl-1,2,3,6 - 
tetrahydropyridine (MPTP), kainate, domoate, cyanide). In almost all cases of acute insult 
the biochemical and pharmacological mechanisms appear to be similar, and this means that 
they are easier to model.
Chronic neurotoxicity, however, varies in time course from days up to decades. 
Some forms have genetic origins (e.g. Huntington’s disease (HD)), others are viral (e.g. 
AIDS dementia complex (ADC)) and others are of unknown origin (e.g. Alzheimer’s 
disease (AD) or Parkinson’s disease (PD)), and also exhibit species differences. One of 
the main complications in modelling chronic insults is that in human cases there is usually 
a marked and progressive impairment o f cognitive function.
Unlike the acute models, which usually involve large scale neuronal lesioning, the 
chronic diseases may only affect a small population of neurones in a single region but 
result in specific behavioural or neurological disturbances that would not be predicted 
from the same degree of damage in the acute models. This cellular or region specificity 
adds a further level o f complication to chronic neurotoxicity modelling. Unlike the acute 
models there appears to be no common pathway, but there does appear to be a common 
final step, that o f metabolic failure.
1.1.1 Acute Insults.
As mentioned in the earlier section there are several different types o f acute insult 
and these include; traumatic brain injury, ischaemia, myocardial infarction, poisoning, 
hypoxia or tonic-clonic seizures. Each o f these insults has different pathological and 
anatomical outcomes but virtually all have a similar biochemical/pharmacological pathway. 
The exception to this is the acute poisoning. Some neurotoxins are thought to mediate 
their actions by a mechanism that is analogous to acute insults (e.g. kainate) , whilst 
others act by a mechanism that is similar to chronic degeneration (e.g. MPTP). In both 
cases the time course of the ‘actual’ insult is acute rather than chronic and hence will be 
dealt with in this section.
1.1.1.1 Traumatic Brain Injury.
Unlike most of the cases of neurotoxicity in human, traumatic brain injury (TBI) 
occurs predominantly in young adults (late teens to mid 30’s), TBI is usually caused by 
transport accidents, and involves either a fracturing of the skull or severe concussion and 
brain bruising. In the cases that do not involve missile impacts (ie bullets) there is bruising 
to the cerebral cortex and damage in the hippocampus. Kotapka et al. (1992) reported that 
in 84% o f fatal non-missile cases there was damage in the hippocampus (C Al most 
pronounced). As well as this damage, 74% o f the cases displayed hypoxic damage in other 
regions o f the brain, in a pattern that is similar to those damaged by experimental head 
injury models. The model which is mainly used for TBI is that o f either solid or fluid 
percussion.
1.1.1.2 Ischaemia
There are two forms of ischaemia, global or focal, and the type depends on the 
causative events. Global ischaemia is usually caused by perturbations in either the 
peripheral blood flow, i.e. by myocardial infarction, or by a perturbation in the blood 
flow in the main carotid artery. Focal ischaemia occurs if  there is a reduction in blood 
flow along arteries within the brain, be it by haemorrhage or occlusion. Both types of 
insult result in reduced blood volume, reduced cranial perfusion pressure, and reduced 
oxygen and glucose availability. Global ischaemia will result in damage to large areas of 
the brain, and the duration o f the perturbation will determine the degree of damage within 
the affected areas. In general global ischaemia is more likely to prove fatal than focal due 
to the regions affected, although a focal insult in the hind brain will usually be fatal.
There are several animal models used for both types o f ischaemia, and are usually 
based around either permanent occlusion of a blood vessel or occlusion followed by 
reperfusion. The middle cerebral artery is the main artery used in the focal ischaemic 
models, in that the majority o f focal ischaemic insults in man are associated with this 
artery.
Regan & Choi (1994) recently reported that in an in vitro traumatic insult model, 
antagonists o f NMDA but not non-NMDA receptors were able to attenuate the neuronal 
loss, and this suggests that mechanisms o f damage caused by TBI differ from those of 
ischaemic damage.
1.1.1.3 Seizures.
Seizures occur when specific regions o f the brain are undergoing continuous, 
unregulated neuronal depolarisation, which are epileptiform activities. Epileptiform 
activity is usually o f short duration, and can be combatted by 7 - aminobutyric acid 
(GABA) agonists (specifically GABA^), G ABA uptake blockers and inhibitors of the 
G ABA metabolism (GABA transaminase). However if  the duration of the epileptiform 
activity is prolonged, or other brain regions are invaded then there is the possibility of 
brain damage occurring. Again it is possible to treat these types o f seizures with GABA^ 
agonists. Tonic-clonic seizures are also potentially fatal, and are usually the cause of 
seizure induced fatalities that do not involve suffocation. j
1 .1 .1 .4  Poisoning
There are numerous artificial and naturally occurring agents that are able to cause 
brain damage in humans. However the brain is protected against most of these agents by 
the properties of the blood brain barrier (BBB). Five agents are o f specific interest and 
are useful tools in studying neurotoxicity in vivo. They are kainic acid (found in Japanese 
seaweed Digenea simplex), domoic acid {Chondria aimata, seaweed and Nitschia 
pungens, diatom), B-N-oxalyl-L-alanine (BOAA, Lathyrus sativus, chick pea), B- 
methylamino-L-alanine (BMAA, false sago) and MPTP (a by-product of synthetic heroin 
production). These will be dealt with in a later section.
1.1.2 Chronic Insults
As with acute insults there are several different types o f chronic insults and these 
include Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, motor neurone 
disease, Guam disease and AIDS dementia complex. There are reports in the literature 
that indicate that some o f the chronic diseases have similar biochemical/pharmacological 
pathways to those o f acute insults, although the main difference is time scale (see later 
sections). For the other chronic diseases the only area of similarity is the final outcome, 
that o f metabolic failure.
1.1.2.1 Huntington’s and Parkinson’s Diseases.
Although these diseases have different outcomes, ie lack of motor activity in 
Parkinson’s disease (PD) and uncontrolled motor activity in Huntington’s disease (HD), 
they are both diseases o f the nigrostriatal system, and are examples of discrete lesions. 
The causes of these two diseases differ, with HD involving a genetic linkage (although 
other mechanisms are also implicated), whilst PD is caused by unknown (but not genetic) 
mechanisms. As with other motor related diseases (Guam disease and Motor neurone 
disease) Parkinsonism is thought to be caused by factors encountered during life, with 
aluminium or naturally occuring neurotoxins being implicated as possible causative 
factors.
Parkinson’s disease is caused by a loss of dopaminergic neurones in the substantia 
nigra, and thus degeneration of the pathway from the substantia nigra pars compacta to 
the neostriatum. A recent communication by Strange (1994) indicated that the neostriatum 
is crucial for the control o f voluntary movement, with a direct and indirect pathway 
controlling movement: activation of the direct pathway facilitates movement and activation
of the indirect pathway inhibits movement. He postulated that the direct pathway is 
regulated by the mesostriatal neurones that are affected by Parkinson’s disease. Loss of 
the direct pathway would result in an inability to facilitate movement, with the indirect 
pathway dominant, and that movement could be initiated by dopamine.
Until a chance finding in the early 80’s there was no animal model for PD, but this 
changed with the inadvertant formation of MPTP by an American chemist who was 
preparing pethidine (‘new heroin’) for use by drug addicts. MPTP is able to cross the 
blood brain barrier where it is converted to l-methyl-4-phenylpyridine (MPP*^) by 
monoamine oxidase B, this charged compound being unable to recross the blood brain 
barrier. MPP"  ^ interacts with neuromelanin, found predominatly in dopaminergic 
neurones. The MPP"  ^ /neuromelanin complex is relatively short lasting and acts as a sink 
for future leakage o f MPP"*" into the surrounding space (D ’Amato et al., 1986, Herrero 
et al., 1993). MPP"  ^ also interacts with, and inhibits, the mitochondrial respiratory 
enzyme NADH dehydrogenase causing the neurones to die due to metabolic failure 
(Ramsay et al., 1986a, 1986b, 1987). The addicts who were contaminated with MPTP 
displayed classical parkinsonian paralysis which could only be treated by L-DOPA, the 
normal treatment for PD. With the finding of MPTP, study into the cause and treatment 
o f PD intensified, but with the drawback that only primates are sensitive to this agent. To 
date this is the only effective model for PD. There are several reports that N-methyl-D- 
aspartic acid (NMDA) receptor antagonists (AP7, CPP, or MK801), can prevent MPP^ 
neuro-toxicity in the substantia nigra and the striatum (Carboni et al . , 1990; Turski et a l . , 
1991; Santiago et al., 1992; Lange. a l ,  1993), indicating that although there is 
metabolic failure, cell death also involves NMDA receptor activation. This means that cell 
death can be elicited by both metabolic failure and excitotoxicity in the MPTP model of
Parkinsonism, although whether this occurs in the disease state itself has not yet been 
determined.
Huntington’s disease results in lesions in the spiny neurones of the neostriatum, 
and this would result in the abnormal involuntary movements (chorea) displayed by HD 
sufferers. Although HD is thought to involve a genetic component, it is possible to lesion 
the spiny neurones with excitotoxins like kainate, indicating that there may be a possible 
nongenetic mechanism as well, (evidence supporting the excitotoxic component theory is 
presented in section 1.4.1. NMDA receptor blockade). It is possible, that a genetic defect 
could result in an increase in glutamate release, an increase in glutamate receptor numbers 
or a reduction in glutamate transporters numbers/defect reuptake systems, such that the 
genetic and excitotoxic theories of HD are not exclusive.
1.1.2.2 Alzheimer’s Disease.
AD patients suffer from a progressive loss of memory, both the ability to learn 
new facts and the ability to recall memories. AD is characterised by 2 distinct structures 
(plaques and tangles) which are found in large numbers in the limbic system, as well as 
in the cerebral cortex. Normal aged brain only displays small numbers o f plaques and 
tangles within the cerebral cortex, so the presence of these abnormal structures in the 
limbic system is an indication of AD.
Pharmacological analysis of AD brains indicates that there is a loss o f cholinergic 
neurones and muscarinic acetylcholine receptors. This finding has prompted research into 
the role that the cholinergic pathways have in the control of memory, and the possible use 
of cholinergic agents as memory enhancing agents. The cause o f AD is unknown 
although a rare inherited form has recently been linked to mutations of the gene coding
for amyloid precursor protein (APP). A peptide formed from APP, B amyloid protein 
(BAP or BA4) is a major component o f senile plaques. The apolipoprotein, Apo E, is able 
to bind to the BA4 and precipitates the protein complex enhancing BA4 deposits. Normally 
Apo E is involved in membrane stability, but the e4 allele o f Apo E has been reported to 
have a higher affinity than other alleles o f  Apo E for BA4 , and there appears to be linkage 
o f Apo E e4 and AD (Poirier et al. , 1993; Saunders et al. , 1993). The mechanism o f BA4 
induced cell death is unknown, but does not appear to be through the excititoxic cascade 
seen in ischaemia (Busciglio et al., 1993). To date there is no accepted animal model.
1.1.2.3 Motor Neurone Disease and Guam Disease.
Motor neurone disease (or amyotrophic lateral sclerosis (ALS)) exists both as a 
familial form (about 5% o f the total ALS patients, Lou Gehrig’s disease) and a sporadic 
form. In the western Pacific there are several areas o f high incidence o f an ALS related 
disease termed Guam amyotrophic lateral sclerosis-parkinsonism-dementia complex (ALS- 
PDC), which differs from ALS in both the incidence (50-1300 times that o f sporadic ALS 
(SALS)) and the presence o f neurofibrillary tangles (a feature implicated in AD). Indeed 
some ALS-PDC suffers also display AD symptoms (see Garruto & Yase, 1986).
The cause o f sporadic ALS is unknown although there are reports o f elevated 
glutamate levels in the spinal fluid o f  these patients (Plaitakis, 1990; Rothstein et al., 
1990). The elevated glutamate level is thought to be due to a dysfunctional glutamate 
uptake system (Rothstein et al. , 1992; Battaglioli et a l ,  1993; Rothstein et a l ,  1993) in 
that glutamic acid decarboxylase (GAD) activity is normal. The mechanism o f this 
impairement o f glutamate uptake is unknown, but may involve either an environmental
toxin, a loss o f postsynaptic motor neurones and hence a loss o f presynaptic glutamate 
transporters, or a genetic defect. Courathier ec ah, (1993) recently reported that 
cerebrospinal fluid from ALS patients is neurotoxic to cortical neurone cultures, and that 
non-NMDA antagonists can attenuate the neuronal loss. It is unlikely that there is a single 
cause o f both familial ALS (FALS) and SALS.
Recently there have been reports, from one group, o f elevated immuno­
globulin G levels (IgG) in ALS patients, and this IgG has been reported to interact with 
voltage gated Ca^ '*' channels (VGCCs) (Appel et a h , 1991; Delbono et al. , 1991, Kimura 
et al., 1994; Smith et a l ,  1994; see also Appel, 1993). Again the cause o f this elevated 
IgG is unknown. If these findings are supported, it would suggest that a possible cause 
o f motor neurone loss is due to elevated calcium influx, as the probability of the VGCCs 
being open is greater than in control patients and hence a larger calcium influx would be 
expected to occur following neuronal stimulation. Therefore in these patients, if there is 
also an impaired glutamate uptake system, the findings suggest that glutamate is more 
toxic to these patients’ motor neurones than those of unaffected patients, due to both a 
prolonged glutamatergic stimulation and an increased calcium influx.
The cause o f the familial form of ALS appears to involve free radicals, with an 
impairment in the scavenging system. There have been several recent reports that link the 
cytosolic copper/zinc superoxide dismutase (Cu/Zn SOD or SO D l) with familial ALS 
(FALS). There are several reports of a mutation in the SO D l gene, (Rosen et al., 1993; 
Rouleau, 1993; Deng et al., 1993; Elshafey et al., 1994; Jones et al., 1994) and 
Robberercht et a l . , (1994) reported decreased activity of SO D l in FALS but not sporadic 
ALS patients. Why the motor neurones are damaged whereas other neurones in the spinal 
cord are spared in FALS patients is unclear, but probably depends on non-NMDA
receptors and the levels of free radical scavengers within the cell. Motor neurones possess 
non-NMDA receptors and there is now evidence that links activation of kainate receptors 
with increased lipid peroxidation in cerebral cultures (Puttfarcken et al, 1993), and by 
implication free radicals. Although this finding was made in the brain there is evidence 
to suggest that a similar event may be occurring in the motor neurones (Curtis & Malik, 
1985; Hugon et <3 /., 1989), and Michikawa et al. (1994) recently reported that oxygen 
scavenging enzymes are able to protect spinal cord neuronal cultures in vitro.
This link with the glutamate receptors is strengthened by reports of the cause of 
ALS-PDC. However, ALS-PDC does not seem to be caused by mutations in SO D l, 
(Figlewicz et a l . , 1994) i.e. the aetiology is similar to sporadic and not FALS. ALS-PDC 
affects both motor and brain neurones and the cause appears to be an amino acid, B- 
methylamino-L-alanine (BMAA) produced by false sago (Nunn et a l ,  1968; Spencer et 
al., 1987; Seawright aZ., 1990; Rakonczay er <3 /., 1991; Duncan, 1992; Labella <3 /., 
1993). BMAA and the structurally related compound B-oxalylamino-L-alanine (BOAA) 
have been shown to be agonists for the NMDA (Ross et a l . , 1987; Spencer et al., 1987; 
Rakonczay er <3 /., 1991; Labella a /., 1993) and non-NMDA glutamate receptor subtypes 
(Ross et a l . , 1987; Bridges et a l . , 1989; Rakonczay et al., 1991) respectively and are able 
to induce neurotoxicity in cell cultures (Nunn et a l . , 1987; Ross et a l . , 1987; Spencer et 
al., 1987; Weiss & Choi, 1988, Weiss et al., 1989). In vivo work was hampered due to 
the inability of either o f these compounds to cross rodent BBB, although they can cross 
the primate BBB (Spencer et al., 1987). If these agents are able to cross the BBB and 
activate glutamate receptors in vivo, the reports that glutamate receptor activation results 
in free radical production in the brain (Dykens et al., 1987; Bondy & Lee, 1993; 
Putfarcken et al., 1993) may also suggest that similar events are occuring at motor
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neurones. However, the importance o f these agents in ALS-PDC has recently been 
questioned by some groups (Garruto et a L , 1988; Perry et a l . , 1989; Duncan et a l . , 1991) 
who are unable to reproduce the findings o f Spencer’s group (see Stone, 1993a). A further 
complication to the understanding o f ALS-PDC is that the disease is naturally dying out 
in the Western Pacific, and the cases that are occuring are not displaying any ALS 
symptoms, but only AD-like symptoms with PD-like behavioural changes (see Garruto & 
Yase, 1986; Stone, 1993a).
1 .1 .2 .4  AIDS Dementia Complex
AIDS dementia complex (ADC) is a new disease that has only been observed in 
the last few years. Unlike PD, HD and AD, ADC appears to be the result of 
excitotoxicity. ADC is caused by lesions in the limbic system, like AD, but these lesions 
are not restricted to the cholinergic pathyways. A coat protein o f the AIDS virus (gp^ °^) 
has been implicated in the formation o f these lesions. In neuronal/glia cultures gp^ °^ has 
been reported to increase nitric oxide synthesis (NOS), and induce neurotoxicity in a 
manner that involves NMD A receptors and calcium channels (Lipton, 1992; Ciardo & 
Meldolesi 1993; Dawson et al. , 1993; Diop et al. , 1994; Savio & Levi, 1993; Stefano et 
al., 1993; Sweetnam et al., 1993; Benos et al., 1994; Pietraforte et al., 1994), although 
Giulian et al. (1993) were not able to identify the neurotoxic component released by gp^ °^. 
Gp^ ®^ is also a very powerful interleukin-1 (ILl) releasing agent in the CNS (N. Rothwell 
personal communication). IL l is found in astrocytes and is released upon stimulation 
(Guilian et a l ,  1993; McMillian et a l ,  1994). IL l and 7 -interferon (7 IF) are able to 
induce indoleamine-2,3-dioxgenase (IDG) (Yoshidae^a/., 1986; Saito er oA, 1991), which 
in normal brain tissue has a very low activity (Heyes, 1993), and this enzymes converts
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tryptophan to formylkynurenine (i.e. the start of kynurenic acid and quinolinic acid 
pathway, see later). In ADC patients, there is an elevated level o f quinolinic acid (Quin) 
(20-1000 times that of the normal population (Brouwers et a l . , 1993; Heyes, 1993)), with 
no change in the kynurenate levels. However, unlike ischaemic insults, the level o f Quin, 
remains elevated for months, rather than the time o f the insult itself, although there is a 
significant increase in IDO activity in the hippocampus in ischaemic brain (Heyes, 1993). 
This time course suggests that although Quin is elevated it may not be the neurotoxic 
agent in this disorder, although based on neurological scores there is a good correlation 
between the Quin concentrations and the severity o f the dementia. Its presence may 
sensitise the neurones to non toxic levels of excitatory amino acids, such that the incidence 
rate o f minor non fatal excitotoxic insults increases, producing widespread minor lesioning 
throughout the brain.
If ILl or other cytokines play an important role in ADC, this may explain neuronal 
damage observed in some viral diseases, such as measles (Heyes et a l ,  1992c; Saito et 
ah, 1992, 1993, Heyes et ah, 1993), Simian immunodeficiency virus (Heyes et ah, 
1992a) and poliovirus (Heyes et ah, 1992b; Heyes, 1993) where there also appears to be 
a change in the functional state of IDO. This raises possibilities in the treatment of these 
diseases in adults.
1.2 Biochemical Causes o f Neurotoxicitv.
As mentioned in the preceding sections, there are several different mechanisms of 
causing neuronal lesioning, which have different initial pathways, but all appear to possess 
the same outcome, that o f metabolic failure. The biochemical causes and effects of 
metabolic failure will be dealt with in this section and the pharmacological causes in
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succeeding sections.
1.2.1 Energy Production
Under normal circumstances the metabolism of a cell is tightly regulated and is 
maintained by oxidative phosphorylation. Unlike cells in other parts of the body, neurones 
are only able to use glucose as the substrate for oxidative phosphorylation, and are unable 
to convert other carbohydrates or phospholipids to energy producing substrates. The 
astrocytic population on the other hand is able to utilise other energy rich compounds to 
maintain cellular function, be it oxidative phosphorylation or anaerobic glycolysis. 
Astrocytes are able to convert glycogen to glucose intracellularly and release it into the 
extracellular space for uptake by neurones. Whilst this mechanism is advantageous during 
normal cellular activity, it does mean that any insult/agent that either specifically or non 
specifically damages astrocytes will be detrimental to the survival o f the surrounding 
neurones.
Oxidative phosphorylation results in the production o f 38 moles of ATP for every 
mole o f glucose converted to water and carbon dioxide. The conversion of glucose to 
pyruvate (aerobic respiration) or lactic acid (anaerobic respiration) occurs in the cytoplasm 
and both result in the formation o f 2moles ATP/mole glucose (equations 1.1 and 1.2 
respectively). Pyruvate is oxidised in the mitochondria to yield a theoretical net production 
o f 38 moles ATP. mole glucose’  ^ (equation 1.1). However, lactate is not a substrate for 
either the citric acid cyle or oxidative phosphorylation and this results in a decrease in 
intracellular pH.
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Glucose +  2Pj +  2ADP +  2NAD+ - >  2 pyruvate +  2ATP +  2NADH (1.1)
Glucose +  2P; +  2ADP - >  2 lactate +  2ATP (1.2)
Glucose +  10NAD+ +  2FAD +  36ADP +  38P, +  2GDP +  12(1/20^)
- >  6COj +  6 H ,0  +  36ATP +  2GTP +  10NAD+ +  2FAD (1.3)
Whilst glucose is the preferred substrate for oxidative phosphorylation, other 
substrates are available for use including phospholipids, phosphogluconates and amino 
acids. Neurones are deficient in enzymes that allow for the full utilisation of some of 
these pathways and hence are heavily dependent on glucose, eg the hexose monophosphate 
shunt (Bohinski, 1983). Neuronal excitation results in a net loss o f glutamate, when the 
neuronal uptake of glutamate and glutamine are taken into account, and this indicates that 
for glutamatergic neurones to maintain a viable transmitter pool other precusors must be 
used, and these include alanine, citrate, a-ketoglutarate, malate and pyruvate (Yu et a l , 
1983; Shank et a l ,  1985; Kihara & Kubo, 1989; Sommerwald et a l ,  1991; Schousboe 
et a l ,  1993).
1.2.2 Causes and Effects of Metabolic Failure.
There are several ways o f causing metabolic failure including; hypoxia, 
hypogiycaemia, acidosis, hypercalcaemia and poisoning. Hypoxia and hypo-glycaemia 
both result in substrate deficiencies, and a termination o f oxidative phosphorylation and, 
i f  the hypogiycaemia is long lasting, glycolysis. Acidosis alters the tertiary structure of 
proteins and will affect the enzymes involved in ATP production. Hypercalcaemia will be 
dealt with in a later section.
Poisons that affect energy production are those that inhibit, the oxidative enzymes 
themselves. Examples of metabolic poisons include cyanide and carbon monoxide 
(inhibitors o f the cytochrome oxidase complex), MPTP (noncompetitive inhibitor o f the
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NADH dehydrogenase complex, Ramsay et a/., 1986a, 1986b, 1987) and heavy metals, 
although in this case these are nonspecific enzyme inhibitors.
Metabolic failure is a progressive feedforward mechanism, with each failure 
causing/potentiating the next failure. ATP is generated by the metabolism of glucose (and 
other energy rich complexes), but is utilised by widely different mechanisms. Maintenance 
of the intracellular ionic composition is essential for the cell’s survival and uses a large 
percentage of ATP produced. Protein synthesis, cytoskeletal organisation, signal 
transduction and, in the case of neurones, synthesis, storage and release of 
neurotransmitters also use large amounts of ATP, In the case of neurones, the astrocytes 
release substrates for neurotransmitter synthesis and oxidative phosphorylation (Brookes, 
1993;and see section 1.2.1). Again this highlights the importance of astrocytes to neuronal 
survival.
During the initial period of metabolic failure there is a reduction in de novo 
synthesis of ‘normal’ proteins, which cells are able to tolerate for short periods, as the 
catabolism of important proteins approaches and then passes the reserve capacity of these 
proteins. Whilst this is occuring there is also increased production of stress proteins, the 
presence of which are detrimental to cell survival as illustrated by the neuroprotective 
action of cycloheximide (a protein synthesis inhibitor), (Schreiber et ah, 1993). However, 
if the metabolic failure continues, then there is a loss of cellular ionic homeostasis. The 
cause of this loss of ionic homeostasis is the lack of available ATP to drive the ion 
channel linked ATPases, which are required for the maintenance of the membrane 
potential. This in turn is required for the energy-dependent ion pumps, which are required 
for ionic homeostasis. The net result of the loss of ionic homeostasis is the loss of 
membrane potential, and the permeabilisation of the plasma membrane. A complication
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to the above loss o f ionic homeostasis is the generation o f free radicals which cause lipid 
peroxidation, and results in actual holes in the plasma membrane (Thaw et a l ,  1983; 
Dietrich et a l ,  1987; Watson, 1993). This means that even if glucose and/or oxygen 
become re-available to the cell when it has lost ionic homeostasis, there may be no 
improvement in the chance o f the celTs survival (Thaw et a l , , 1983). The generation of 
free radicals will be dealt with in a separate section.
1.2.3 Calcium Homeostasis
Another cause of metabolic failure is hypercalcaemia. Under physiological 
conditions the cellular concentration of free calcium is maintained at between 0.1-lpcM. 
This intracellular concentration is maintained by three membranes; the endoplasmic 
reticulum, the mitochondria and the plasma membrane, as well as by intracellular calcium 
binding proteins (figure 1.1). The mitochondria are able to act as a calcium sink with in 
vitro experiments indicating the ability to store lOOjuM Ca^'^.mg protein"’ (as Ca^PO^) with 
no apparent deleterious effects on the mitochondrial function (Hunter et al . , 1976; 
Lotscher et a l ,  1980; Nicholls & Akerman, 1982), although in vivo excessive calcium 
uptake by the mitochondria is linked with metabolic failure (Sciamanna et a l ,  1992). 
Calcium is stored in the mitochondria in a calcium phosphate complex, and this means 
that the more calcium that the mitochondria sequester the less organic phosphate there is 
available for ATP production (Nicholls & Akerman, 1982). The mitochondria possess 2 
separate systems; a calcium ATPase and a calcium pump, driven by the inner 
mitochondrial membrane potential, and a calcium/sodium/proton exchanger. The direction 
o f calcium influx into the mitochondria via the pump reverses at [Ca^ "’"]. greater than 
lOjLtM (McCormack & Denton, 1986). This means that any large perturbation in the
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Figure 1.1 Calcium homeostasis systems in mammalian cells.
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calcium concentration would be potentiated by calcium leakage from the mitochondria.
The endoplasmic reticulum (ER) possesses a calcium ATPase, and a calcium 
channel linked to the inositol trisphosphate (IP3) receptor, IP3 is generated by cleavage of 
phosphoinositol bisphosphate by phospholipase C, which also yields diacylglycerol (DAG). 
The activation o f phospholipase C is receptor mediated, and various neurotransmitters, as 
well as other extracellular messengers, use the generation of IP3 as a mechanism of 
intracellular signalling that raises the intracellular calcium concentration. Activation o f the 
IP3 receptor opens the associated calcium channel, and calcium leaves the ER and locally 
raises the cytoplasmic calcium concentration (Berridge & Irvine, 1984; Streb et a i , 1984). 
As the amount o f calcium present in the ER is finite (Taylor & Putney, 1986) there is no 
large widespread increase in calcium: the calcium binding proteins involved in signal 
transduction are concentrated near the ER.
The plasma membrane possesses several different mechanisms for regulating the 
cytoplasmic calcium levels: voltage-gated calcium channels (dependent on membrane 
potential: activation results in calcium entry into the cell), a 3sodium/ 1 calcium exchanger 
(dependent on ion homeostasis, and normally an efflux system) and calcium ATPases 
(dependent on the metabolic state of the cell, and also an efflux system). It is the 
activation o f the plasma membrane calcium channels, rather than the ER or mitochondrial 
calcium transporters, that results in cell wide elevation in calcium. For a summary o f  the 
calcium systems see figure 1.1 and Siesjo & Bengtsson, (1989).
Loss o f calcium homeostasis will result in elevated cytoplasmic calcium 
concentrations and these can have several deleterious effects on the metabolic state of the 
cell. One o f these actions is the collapse of the inner mitochondrial membrane potential 
with the resulting loss o f the proton motive force (the proton gradient driving proton entry
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into the mitochondria) and the ensuing loss o f oxidative phosphorylation due to decreased 
N A D /N A D H  ratio. This would result in the reduction in ATP generation, such that the 
system is now functioning anaerobically. The other serious effect is the activation of 
calcium proteases. These calcium proteases will enzymically cleave target protein and, in 
the case o f xanthine dehydrogenase, this may result in new enzymic action that is 
detrimental to the cell’s survival.
Xanthine dehydrogenase (XDH) converts uric acid to xanthine and then to 
hypoxanthine, the reaction using NAD"*" as the electron acceptor. However, if  the enzyme 
is cleaved by a serine calcium protease (Parks & Granger, 1986; Engerson et aL, 1987; 
Parks et aL, 1988) the new form is termed xanthine oxidase (XO) and converts xanthine 
to uric acid, using metabolic oxygen as the electron acceptor;
XDH reaction: XO 4- NAD^ — > Uric acid H- NADH (1 .4)
XO reaction: XO +  O, — > Uric acid +  O. (1.5)
Under physiological conditions the oxygen radical will be converted to superoxide by 
reacting with water. Superoxide is normally neutralised by either its conversion to 
hydrogen peroxide, and hence oxygen and water, or by reduction by intra-cellular 
reducing agents. If the concentration of superoxide and/or other free radicals reach levels 
that saturate the neutralising systems then there is the possibility of lipid peroxidation, and 
the resulting perturbations in the plasma membrane may lead to loss of ionic homeostasis, 
and hence further reduce the survivability o f the cell (see later).
However, not all neurones have the same sensitivity to their micro-environment 
and some are very sensitive to specific insults whilst others are reasonably resilient to the 
same insult. This sensitivity appears to be dependent on both the vasculature of the region 
and the presence of certain proteins (Mattson et aL, 1991; Waldvogd et aL, 1991). Freund
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and co-workers (Freund et aL,  1990; Schmidtkastner & Freund, 1991) reported that there 
is a correlation between the amount o f certain calcium binding proteins (Calbindin and 
Parvalbumin, Leranth & Ribak, 1991; lacopino et aL, 1992) in the cell bodies and cell 
survival in the hippocampus, the higher the level of these proteins, e.g. in the CA2 cell 
layer, the greater the cells’ chances of survival after an ischaemic insult; conversely in the 
C A l and CA3 areas, and the dentate gyrus, all are very sensitive to ischaemia, and here 
there are low levels o f these proteins.
1.3 Neurochemistry of Neurotoxicity.
1.3.1 Glutamatergic Systems.
Glutamate is the main excitatory neuro transmitter in the CNS, but it is also present 
in millimolar concentrations in the cytoplasm of all cells ( «  lOmM, Greenbaum et aL, 
1971; Nicholls & Atwell, 1990). Depolarisation of glutamatergic neurones results in the 
release o f glutamate from specific secretory vesicles present near the active zone of the 
synaptic membrane. Work by Nicholls and co-workers (Nicholls & Sihra, 1986; Sanchez- 
Prieto et aL,  1987; Barrie & Nicholls, 1988; McMahon et aL,  1988; Wilkinson & 
Nicholls, 1988, 1989; Nicholls, 1993) indicates that whilst pH] glutamate and [’"€] 
aspartate can enter synaptosomes and are found in the cytoplasm only the pH] glutamate 
is found in the vesicles. Stimulation of these preloaded synaptosomes results in a calcium 
dependent release o f pH] glutamate, but if  the synaptosomes are in calcium free media 
then both pH] glutamate and p^ ’C] aspartate are released. The interpretation o f these 
experiments is that the calcium dependent release is o f vesicular contents, whilst the 
calcium independent release is by reversal of the glutamate uptake systems. This has 
supported earlier work and it now seems likely that the vesicles possess a glutamate/ATP
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transporter (DeBelleroche & Bradford, 1973; Kanner & Sharon, 1978; Kvamme & Lenda, 
1981; Disbrow et al. , 1982; Kanner & Marva, 1982; Naito & Ueda, 1983, 1985; Maycox 
et al., 1988; Winter & Ueda, 1993), which is able to maintain an in intravesiclar 
concentration of »60-100mM (Nicholls & Atwell, 1990; Laake et aL, 1993).
There are several types of glutamate receptors, and most belong to the ligand gated 
ion channel (LGIC) superfamily. There are at least three LGIC receptors (the NMD A 
receptor, and the two non-NMDA receptors (the AMPA receptor and the kainate (KA) 
receptor)) and they are classified by their sensitivity to agonists (Stone & Burton, 1988; 
CoUingridge & Lester 1989). The other type of glutamate receptor is a member of the G- 
protein mediated receptor superfamily, and is termed the metabotropic receptor (mGluR), 
of which there are now at least 6  subtypes (Nakanishi, 1992). A fourth LGIC receptor, 
the 2-Amino-4-phosphonobutyric acid (AP4) receptor, appears to be presynaptic but is 
poorly characterised (Conn & Desai, 1991), although AP4 is an antagonist at one group 
of mGluR’s (mGluRl, mGluR5) and agonists at the other group (mGluR2, mGluR3, 
mGluR4 and mGluR6 ) (Nakanishi, 1992; Tanabe et aL, 1992). It appears that it is the 
presence of the LGIC glutamate receptors that reduces neuronal survival following an 
excitotoxic insult. All three of the characterised glutamate LGIC’s contain intrinsic sodium 
channels that are closed at resting membrane potentials. Activation of the AMPA or 
kainate receptors by an agonist (thought to be either glutamate or aspartate in the brain), 
will open their intrinsic sodium channels and cause a depolarisation of the membrane.
The NMDA receptor channels are blocked by magnesium, in a voltage sensitive 
manner, in the open state and so can only be activated when the magnesium has 
dissociated from its blocking site. This disinhibition of the NMDA receptor occurs near 
OmV, i.e. when the cell is already activated, and the channel remains active for longer
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periods of time than with other glutamate receptors, (see CoUingridge & Lester 1989). 
The NM DA sodium channel is also larger than most LGIC receptor channels having a 
conductance o f about 50pS (Asher et aL, 1988) compared to the <20pS for the AMPA  
and kainate receptor-linked channels (Asher et aL, 1986; Cull-Candy & Usowicz, 1987; 
Jahr & Stevens, 1987; Cull-Candy et a/. ,1988; Asher & Nowak, 1988). The NMDA  
receptor channel is also less ion selective than most LGIC sodium channels, with about 
5-10% o f its current carried by calcium whereas most o f the AMPA and kainate LGIC 
are relatively impermeable to calcium (Pumain et al. , 1987), although there are indications 
that some subtypes of AMPA/KA receptors are also calcium permeable (Brorson et al . , 
1992; Rorig & Grantyn, 1993; Brorson et aL, 1994). The large conductance o f the 
NM DA receptors means that an over-stimulation would result in a relatively large 
calcium influx.
The kainate receptor does not possess any allosteric modulatory sites whereas the 
AMPA receptor is allosterically modulated by zinc. In the case o f the NMDA receptor 
zinc acts as a channel blocker at a site distinct from the magnesium and MK801 sites. The 
NM DA receptor is allosterically modulated by glycine, at an extracellular site, and 
occupation o f the glycine site potentiates the glutamate signal and also delays 
desensitisation.
Whilst it is possible to distinguish between NMDA and non-NMDA receptor 
subtypes by use of agonist/antagonist studies (both binding and electro-physiological 
studies), the lack o f specific antagonists that distinguish between the AMPA and the 
kainate receptors led to a possibility that the binding differences are due to different states 
o f the same receptor, with the low affinity kainate binding site being considered the 
AMPA site. The report by Johansen et aL, (1993) that there is an antagonist that can
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distinguish between the high and low affinity kainate binding sites as well as the AMPA 
binding site questions this assumption. However, with the advent of molecular biology, 
it has become clear that specific genes coding for AMPA binding sites and for kainate 
binding sites, and functional expression of these genes in the Xenopus oocyte model 
indicate that these genes will produce receptors that possess the characteristics of in vivo 
receptors (Egebjerg et aL, 1991; Werner et aL, 1991; Blakestone et aL, 1992; Petralia 
& Wenthold, 1992; see also Henley, 1994).
Control of the glutamate system is through receptor desensitisation and glutamate 
reuptake (Hu et aL, 1987), as well as presynaptic control of glutamate release. The 
glutamate is taken up into neurones and glial cells in an energy-dependent manner through 
the high affinity glutamate uptake (HAGU) system, although this is also sensitive to 
changes in the micro-environment, in that the uptake is dependent on the metabolic state 
of the cell. There are indications that neurones and glia possess different types of HAGU, 
based on their pharmacological profiles (Griffiths et al., 1992; Albrecht et al., 1993; 
Clark & Amara, 1993; Kanner, 1993; Kanner et aL, 1993; Nakamura et aL, 1993; 
Ohashi et aL, 1993, Rao & Murthy, 1993; Robinson et aL, 1993; Tanaka, 1993; Voisin 
et al., 1993; Griffiths et aL, 1994; Tanaka, 1994). The fate of transported glutamate is 
different between the glia and neurones in that in glia it is converted to glutamine by an 
enzyme that is solely non-neuronal (Norenberg & Martinez-Hemandez, 1979), with the 
neuronal glutamate being transported into vesicles. There are various reports that in 
perinatals it is also down regulated during periods of excessive glutamate release 
(Silverstein et aL, 1986; Hu et aL, 1991). However, Anderson et aL, (1993), reported 
that after bilateral common carotid occlusion combined with hypotension, there was a long 
lasting upregulation of HAGU sites. Mahl & Burgesser (1993) reported that under periods
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of low ATP uptake was impeded. Astrocytes are able to sustain glutamate uptake during 
periods of oxygen depletion provided under normo-glycaemia (Swanson, 1992; Ohashi et 
aL, 1993; Swanson & Choi, 1993). However, if glycolysis is inhibited then there is 
effectively no glutamate uptake. Volterra et aL, (1994) have recently found that oxygen 
free radicals will inhibit glutamate uptake in astrocytes, further indicating that in periods 
of oxygen/glucose deprivation glutamate homeostasis is compromised. Dysfunction of the 
HAGU system could result in glutamate being present in the synaptic cleft for prolonged 
periods, possibly causing over-stimulation of the glutamate receptors following a 
physiological stimulus. It may be that impairment of the glutamate transporters may play 
a role in progressive neurological disesase (eg maybe some forms of ALS).
1.3.2 Amino Acids and Neurotoxicity
Early work by Olney <1969) found that glutamate was neurotoxic at high 
concentrations and, that recording of cells exposed to high concentrations of glutamate 
indicated that they were being excited to death. This paper, and the report of Rothman 
(1983) that synaptic activity is required for cell death, has formed the basis for the theory 
of ‘excitotoxicity’. Various reports indicate that during neurotoxic insults there is an 
elevation of glutamate and aspartate released (Benveniste et aL, 1984; Butcher et aL, 
1987; Globus et aL, 1988; Butcher et aL, 1990, Mitani & Kataoka 1991) and these 
reports along with other in vitro experiments (Choi et aL, 1988; Koh et aL, 1990) indicate 
that there is a disturbance in the glutamatergic system during periods of insult. Similar 
disturbances may also be involved in neurodegenerative disorders of different origin (see 
reviews by Choi, 1988; Choi & Rothman, 1990; Siesjo, 1992).
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As well as an increase in glutamate release during ischaemia there are reports that 
now indicate there is also an increase in extracellular glycine, and that this elevation is 
also greater and longer lasting than the glutamate elevation (Baker et al., 1991; Cantor 
et al., 1992).
Compounds that exert their neurotoxicity by metabolic failure (e.g. MPTP), also 
appear to have a glutamatergic involvement, but in this case it appears to be secondary 
damage caused by glutamate leakage from dead/dying cells.
1.3.3 Excitotoxic Theory
If there is a period of high glutamate release, and there are NMDA receptors on 
postsynaptic membranes, then it is probable that the postsynaptic neurones would be 
exposed to excitotoxic conditions. If the levels of extracellular glutamate remain high then 
there could be a cascade effect that might be uncontrolled within a small area (see figure 
1.2). The current working hypothesis of excitotoxicity is that there is an over-stimulation 
of the postsynaptic non-NMDA glutamate receptors, either by massive release of 
glutamate or by excitotoxins, which cause a depolarisation of the neurone. This 
depolarisation causes the disinhibition of the NMDA receptors and there is a massive 
influx of calcium through the receptor-associated channel.
In the case of the ischaemic models there is also an increase in glycine release, and 
extracellular levels recorded by microdialysis, indicate that the glycine sites on the NMDA 
receptors are fully occupied. Baker et al. , (1991) and Cantor et al., (1992) reported that 
ischaemic levels of glycine and non toxic levels of NMDA would result in neurotoxicity 
in neuronal cultures. This can be explained by the report of Lerma et aL, (1990), that 
glycine decreases NMDA receptor desensitisation, therefore allowing for the
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receptor to be active longer. Calcium is also entering through the activation of VGCC’s 
(Lin et aL, 1990; Ohta et aL, 1991; Uematsu et aL, 1991; McBurney et aL, 1992). This 
elevation o f the intracellular free calcium concentration causes the activation/inhibition of 
calcium sensitive systems and a decrease in the ATP/ADP ratio (see table 1.1 for a 
summary o f calcium activated events). There would also probably be an initial increase 
in the metabolic state o f the cell to restore this ATP/ADP, by increased oxidative 
phosphorylation.
Provided there is an ample supply o f molecular oxygen and glucose, the cell might 
be able to survive the insult but possibly in a damaged condition, with an altered 
metabolic state and the presence o f stress proteins. The proteins induced include Fos (c- 
fos proto-oncogene), 70kDa heat shock/stress protein (hsp70), and Jun B and c (proto­
oncogenes c-jun and jun B), and mRNA for zif/268 , 73kDa heat shock protein (hsc73) 
and glucose regulated protein (grp78) (Nowak, 1990; Nowak et a L , 1990; Uemura et aL , 
1991a; Vendrell et aL,  1991; Robertson et aL, 1992; Dragunow et aL,  1993; Kinouchi 
et aL,  1993; Nowak et aL,  1993; Schreiber et aL, 1993; Tanno et aL, 1993; Walker & 
Carlock, 1993; Wang et aL, 1993; Massamiri et a L , 1994). As well as the appearance of 
these stress proteins there are also abnormal proteins (eg xanthine oxidase) and this might 
be explained by the observation that after ischaemia there is a reduction in ubiquitin 
synthesis, resulting in the loss of this indispensible repair protein (Magnusson & Wieloch, 
1989; Yamashita et a L , 1991). These damaged cells might die at a later date, possibly due 
to a smaller ischaemic insult, and might explain the phenomenon of delayed neuronal 
death (Mitani & Kataoka, 1991; Haba et aL,  1991). If the supply o f oxygen is reduced, 
then the cells’ metabolism would switch from oxidative phosphorylation (38 moles of 
ATP/ mole glucose) to that o f glycolysis (2 moles ATP and 2 moles lactate/ mole
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glucose),(see section 1.2.1). This shift would result in decreased ATP production but also 
a decrease in intracellular pH, both of which are detrimental to the cells’ survival. The 
reduced ATP would mean that the membrane potential would fall and the membrane 
would become permeable to ions. Whilst this is occurring there would be a failure o f the 
HAGU system, resulting in the prolongation of the excitotoxic stimulus, as well as the 
production o f cytotoxic substances in the cell itself e.g. free radicals, (see figure 1 .2 ).
Table 1.1. Calcium activated events potentially detrimental to neuronal viability.
1) Proteases:
Calpains I & II (breakdown o f spectrin)
Formation of xanthine oxidase 
Generalised cytoskeletal disassembly
2) Protein kinases
Protein kinase C enhancement o f glutamate release 
Calcium-calmodulin-dependent kinase
3) Phosphatases
4) Phospholipases
Phospholipase A2 
Phospholipase C
5) Ornithine decarboxylase
6 ) Nitric oxide synthase
7) Endonucleases
8 ) Induction o f stress protein synthesis.
One complication to the theory o f glutamate toxicity is the large amount of 
glutamate ( ~  500mM) needed to cause neuronal death both in vivo and in vitro (Choi et 
aL,  1988; Koh et aL, 1990). This may be explained by the functioning o f the HAGU  
system: if  exogenous glutamate is supplied the HAGU system would be expected to 
remove large amounts o f it as there has been no associated impairment o f the metabolic 
state of the neurones that usually accompanies acute neurotoxicity.
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1.3.4 Free Radical Formation and Damage
Free radicals (PR) are short lived reactive atoms or molecules containing an 
unpaired electron in an outer shell. FRs are produced in the cell by normal reactions and 
are either intermediates or byproducts. Systems generating free radicals include the 
respiratory chain in the mitochondria (usually in the vicinity of coenzyme Q) which is 
where it is terminated by oxygen, prostaglandin synthesis (an intermediate between 
prostaglandin 0% and prostaglandin Hj) where it is terminated by either NAD+ or NADP^, 
nitric oxide synthesis where it is terminated by oxygen and the monoamine oxidase 
induced oxidation of catecholamines and dopamine. In these cases the FR are formed in 
the hydrophillic zone of the cell away from the phospholipids, buried deep in the 
hydrophobic zone of membranes, that are very susceptible to peroxidation, the ER and 
mitochondrial membranes being the most susceptible. FRs can also be produced outside 
of cells in the extracellular fliud by the Fenton iron catalysis, as well as by activation of 
microglial cells.
Lipid peroxidation would result in perturbations in the membranes resulting in loss 
of ion homeostasis among the deleterious effects. FR reactions are essentially immortal 
and can continue to react with any adjacent molecule unless neutralised by reacting with 
another FR, reacting with an electron donating compound (called antioxidants) or being 
neutralised enzymatically. FRs can also react with DNA and result in mutations of the 
bases or cleavage of the DNA strands.
The cellular defences against FR damage involve iron chelators (eg 
camosine and hydrocamosine) to prevent/reduce the Fenton reaction, neutralising enzymes 
(superoxide dismutase (SOD), catalase, various peroxidases and the glutathione (GSH) 
oxidase/reductase related enzymes) and FR scavengers (FRS) to ‘mop up’ the produced
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enzymes are found predominantly in astrocytes, and the other enzymes are present in low  
levels, as is vitamin E. The CSF is also relatively low in iron chelators compai'ed to other 
extracellular fluids, although there is an active ascorbate carrier system that crosses both 
the blood brain barrier and the brain CSF barrier (Spector, 1981). The importance of the 
FRS’s to maintaining cell viability was highlighted by Demopoulos et a l ,  (1977) who 
reported that following middle cerebral artery ligation, there was a reduction in ascorbate 
concentrations which they postulated was due to its reaction with oxygen free radicals 
formed in the respiratory chain and that hypoxic tissue damage may be accompanied by 
FR production. Whilst this postulate has not been proven, the experimental evidence from 
several hypoxic tissues including gut, heart and brain, that FRS’s and/or FR neutralising 
enzymes reduce the amount of damage, may indicate that FRs are involved in hypoxic 
damage (see sections 1.4.4 and Discussion).
1.3.5 Excitotoxic Models
1.3.5.1 Ischaemic Models
There are various mechanisms for causing in vivo excitotoxic insults, but they can 
be separated into two groups; those involving a physical occlusion of cerebral blood 
vessels and those that cause damage by injections of neurotoxic chemicals. Both methods 
w ill cause neuronal damage but result in differing pathological conditions. Middle cerebral 
artery occlusion models will cause focal ischaemia, four vessel occlusion models will 
cause global ischaemia and chemical injections will have differing actions depending on 
the route given.
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1.3.5.2 Excitotoxic Models In Vivo
Several compounds, structurally related to glutamate and/or aspartate, are also 
neurotoxic (see figure 1.3). One o f the most potent neurotoxins is kainic acid, a dicarboxy 
containing pyrrolidine (Shinozaki & Konishi, 1970; Olney et a l ,  1974; Coyle, 1987). In 
a recent report Winn et al. (1991) compared kainate to other neurotoxins, and reported 
that the excitotoxic potency order in the rodent basal forebrain was:
KA >  >  Quinolinate >  Ibotenate =  NMDA.
A report by Stewart el al. (1991) reported that domoate, another naturally 
occurring dicarboxy containing pyrrolidine, is more potent than kainate, and ingestion by 
humans resulted in behavioural disturbances similar to those reported in the kainate studies 
(see Heggli et a l ,  1981; Lothman & Collins, 1981; Sperk et a l ,  1985). The postmortem 
pathology is also similar to kainate. This finding now means that the potency order should 
read as follows:
domoate >  kainate >  >  Quinolinate >  Ibotenate =  NM DA >  glutamate.
The areas sensitive to kainic acid induced damage differ from those affected by other 
neurotoxins, in that the limbic system is very sensitive to kainic acid but other regions are 
relatively insensitive. However the behavioural effects o f the cerebrovasculature occlusion 
differ from that of kainic acid injections: after the initial seizures the rat becomes 
hypersensitive after ip KA injections (Heggli et a l ,  1981), but they do not exhibit any of 
the motor dysfunctions associated with an ischaemic insult e.g. loss o f limb tone, motor 
coordination (rope platform climbing), balancing and walking (Hoffman et a l ,  1991). 
These kainic acid sensitive areas are similar to those affected by Huntington’s disease, 
temporal lobe epilepsy, and global ischaemia but differ from those sensitive to focal 
ischaemic insult (Heggli et a l ,  1981; Kish et a l ,  1983; see Coyle, 1987; Sperk, 1994 for
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Chemical structures of A) glutamate agonists and antagonists
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reviews). Kainic acid (and domoic acid) also differ from other neurotoxins in that central 
damage can result from systemic injections, as well as from direct intracerebral 
administration (see earlier references and, Stewart et aL, 1991; Strain & Tasker, 1991; 
Scallet et a l ,  1993).
1.3 .5 .3  Excitotoxin Models In Vitro
Two preparations for studying excitotoxicity in vitro are those of brain slices and 
cell cultures. In the brain slice experiments only short term changes can be monitored due 
to the nature of the tissue preparation. Slices have been used to examine the effects of 
excitatory amino acid agonists and antagonists, as well as the effect of chemical ischaemia 
(cynanide and low/zero glucose) or hypoxia (95% N^/ 5% CO2), on the functioning of 
pathways as measured by electrophysiological methods (Reiner et al., 1990).
Cell cultures have the advantage over slice preparations that a longer time scale 
is available for study, and similar techniques are used to brain slices to induce/reduce 
neuronal- and nonneuronal-toxicity. Damage in cell cultures can be measured by a variety 
of methods including lactate ' dehydrogenase leakage, loss of neuronal markers and 
induction o f genes. However, there are serious drawbacks to the study of neuroprotection 
in cell cultures, and these are based around:
a) lack o f intraregional organisation, and
b) lack of extraregional pathways,
both o f which may influence the degree o f protection and the areas damaged. However 
cell cultures do provide an understanding of the biochemical mechanisms o f excitotoxicity, 
that is not possible in other methods o f study.
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1.4 Sites for Potential Neuroprotective Drugs.
The present theories o f EAA induced excitotoxicity indicate that there may be 
several sites where drugs might be targeted to produce varying degrees o f neuroprotection, 
and. these include: blockade of the NMD A receptor, calcium channel blockers, reducing 
glutamate release and free radical scavengers.
1.4.1 NMDA Receptor Blockade
The main area of interest in neuroprotection against acute neurotoxicity has been 
blocking the activation of the NMDA receptor or blocking the associated channels, hence 
preventing the influx o f calcium and the neurotoxic cascade that follows over stimulation 
o f this receptor. Several drugs have been tried with varying degrees of success, with the 
best experimental drug being MK801. Various studies have shown that this compound can 
reduce the area o f damage following Middle Cerebral Artery Occlusion (MCAO), a model 
that mirrors cerebrovascular occlusion in humans, up to 8  hours after the incident (Foster 
et al . , 1987; Gill et al. , 1987; Ozyurt et al . , 1988; Park et al. , 1988; Michenfelder et al . , 
1989; Gill & Woodruff, 1990; Uematsu et a l ,  1991; Massieu et al., 1993). However 
MK801 and other related compounds (e.g. phencyclidine) have several side effects 
including psychological disturbances (interaction with the sigma receptor), as well as 
peripheral vasoactive perturbations and respiratory impairment (Mcmanigle et al., 1994; 
Pechnick & Hiramatsu, 1994). These side effects are thought to occur because these 
compounds are non-competitive NMDA receptor channel blockers and studies performed 
in other laboratories indicate that they will block any receptor mediated sodium channel 
e.g . both the central and peripheral types of nicotinic Acetylcholine channels (S. 
Wonnacott, personal communication). The main reason that these drugs are still being
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used in experimental models is that they are all lipophilic and can cross the blood brain 
barrier very easily. The more specific competitive NMDA receptor antagonists (e.g. AP5 
and APT) do not produce any major psychological side effects but the use of these drugs 
is hampered by the fact that they are unable to cross the blood brain barrier. There are 
now several second generation AP5-like compounds that are able to cross the blood brain 
barrier, including: CGP 37849 (Schmutz et ah, 1989; Fagg et ah, 1989; Massieu et ah, 
1993), CGS 19755 (Boast a/., 1988; GroiVà et ah, 1990; Aizenman & Hartnett, 1992; 
Hogan et ah, 1992; Massieu et ah, 1993) and CPP and CPPene (Boast et ah, 1988; 
Bullock et ah, 1990; Massieu et ah, 1993).
Another area of interest is in the regulation of tryptophan metabolism. Recent 
reports have shown that various metabolites of tryptophan metabolism are active in the 
CNS (Perkins & Stone 1985; Beal et ah , 1988; Stone 1990; Jhamandas et ah, 1990; Beal 
et ah, 1991; Pearson & Reynolds, 1992; Roberts et ah, 1993; see Stone, 1993b). At 
present there are 2  metabolites that are known to be active (kynurenic acid and quinolinic 
acid). What is of interest is that kynurenic acid is an NMDA antagonist whilst quinolinic 
acid is an agonist. As quinolinic acid is produced endogenously (albeit in very small 
amounts) it has been postulated to be involved in neuro-degenerative diseases e.g. 
Huntington’s chorea, (Connick & Stone 1988; Beal et ah, 1990). If this is the case, then 
any drug that reduces the formation of quinolinic acid wiU provide some degree of 
neuroprotection and conversely any drug that increases the formation of quinolinic acid 
will increase neuronal damage. The opposite seems to be true for kynurenic acid, in that 
increasing kynurenic acid production should increase neuroprotection whilst decreasing 
production should lessen its protection. Germano et ah, (1988) indicated that treating 
animals with kynurenic acid produced smaller lesions, in a global ischaemic model.
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Various papers have recently indicated that kynurenate only poorly crosses the blood brain 
barrier (Swartz et al., 1990; Moroni et al., 1991; Wu et al., 1991), although various 
precursors can (tryptophan and kynurenine) and that treating rats with either o f these 
precursors will elevate brain kynurenic acid levels as assessed by microdialysis. However, 
after an ischaemic insult there is usually a period o f BBB permeabilisation (Dietrich et al. , 
1993a), and it may be this permeabilisation that is allowing kynurenic acid to exert its 
neuroprotective action, in that several papers seem to support Germano's report but use 
different models (Labella et al., 1993 (BOAA); Smith et al., 1993, (TBI); Ghribi et al., 
1994, (forebrain ischaemia)). Kynurenic acid is a competitive antagonist of the glycine 
regulatory site of the NMDA receptor (Kessler et a l ,  1987; Watson et al., 1988; 
Williams et al., 1988; Kessler et al., 1989) and there are now several synthetic 
kynurenines (including 7 chlorokynurenic acid, 5,7-dichloro-kynurenic acid and 7 
chlorothiokynurenic acid) that have improved selectivity for the glycine site, and are 
potentially neuroprotective (Brugger et a l . , 1990; Pralong et a l . , 1992; Chen é t a l ,  1993; 
Lehmann et a l ,  1993; Wood et a l ,  1993).
1.4.2 Calcium Channel Blockade
Another main area of interest has been in the blockade o f the calcium channels 
themselves (Sauter & Rudin, 1986; Block et al., 1990; Jacewicz et a l . , 1990; Lin et al., 
1990; Uematsu et a l ,  1991). The idea behind this is to reduce the influx of calcium 
through the voltage gated channels and hence reduce the elevation in intracellular calcium 
(see reviews by Choi & Rothman, 1990; Seisjo, 1993a, 1993b). Although this works well 
in experimental models it has the drawback o f a very short therapeutic time window and 
is most effective when the drugs are administered prior to the neurotoxic insult.
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1.4.3 Regulation of Glutamate Release
Another possible target for neuroprotective drugs is the control of glutamate 
release. There are various reports in the literature of adenosine reducing the release of 
glutamate from neurones (Corradetti et al,, 1984; Fastbom & Fredholm, 1985; Burke & 
Nadler, 1988; Arvin et al., 1989; Lekieffre et ah, 1991; Heron et al,, 1992; Miller & 
Hsu, 1992; Simpson et ah, 1992, Lloyd et al., 1994), or Ca^ "^  uptake (Gonènçalves et 
ah, 1991, Chem et ah, 1992; Gonènçalves & Riberio, 1994). In the hippocampus there 
appear to be three types of adenosine receptors, of which the main two are; the A^  
receptor, which appears to be an inhibitory receptor, linked via G-proteins to potassium 
channels, and the Ag. which appears to be linked to botli excitatory and inhibitory G- 
protein pathways (Cunha et al., 1994). Recently the A3  receptor has been cloned, and is 
found to be 80% homologous to the A^  receptor. Although it is present in the 
hippocampus, the levels of expression are low (Zhou et al., 1992), and no central function 
has been found for this receptor. The major problem in the study of this receptor subtype 
is the lack of selective agonists/antagonists, in that all the agonists reported are have only 
a lOfold greater specific for the A3  than the Aj (Carruthers & Fozard, 1993; Fozard & 
Camithers, 1993; Jacobson et ah, 1993; Linden et ah, 1993, Daly & Jacobson, 1994; 
Jacobson et al., 1994; Von Lubitz et al., 1994).
Deckert & Jorgensen (1988), reported that after an intraventricular injection of 
0.5/tg/2fil KA there was a loss in pH] cyclohexyladenosine (CHA) binding associated 
with axonal terminals in the CA3 pyramidal cell layer, one of the KA sensitive areas. This 
location of adenosine Aj receptors would be able to modulate the amount of glutamate 
released from the presynaptic terminals and possibly reduce the extracelluar glutamate to 
a less neurotoxic concentration. It seems that the purinergic system may have a
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modulatory action on glutamate excitation and drugs that modulate this system will have 
an effect on glutamate excitotoxicity. Recently there have been several reports indicating 
that pretreatment o f animals with adenosine agonists or uptake blockers may provide 
varying degrees of protection against both chemically and physically induced neuronal 
damage, (Block & Pulsinelli, 1987; DeLeo et a l ,  1987; Evans et ah,  1987; DeLeo et 
ah,  1988; Dragunow & Faull, 1988; Goldberg et ah,  1988; von Lubitz et ah,  1988; 
Arvin et ah,  1989; Bielenberg, 1989; Connick & Stone, 1989; von Lubitz et ah,  1989; 
Andiné et a l ,  1990; Finn et a l ,  1991; Miller & Hsu, 1992; Mori et a l ,  1992; Simpson 
et a l ,  1992; Tominaga et a l ,  1992; Danielisova et al., 1994; Kano et a l ,  1994; 
Stanimirovic et a l ,  1994; Zhou et a l ,  1994). Recent reports also indicate that activation 
of both NMDA and non-NMDA receptors will cause the release of adenosine in the 
hippocampus (Jhamandas & Dumbrille, 1980; Phillis et a l ,  1989; Hoehn & White, 
1990b; Chen et a l ,  1992, Sciotti et a l ,  1993; Ogilvy et a l ,  1994). In most cases, 
however, the purines were delivered intracerebrally, whereas any development o f purines 
therapeutically would need to be centred on peripheral administration.
As well as purines, other drugs acting at calcium channels, kappa opioid and 
GABAa receptors as well as other, as yet unidentified sites are also able to attenuate 
glutamate/aspartate release during hypoxic conditions, and hence have therapeutic potential 
(Brailowsky et a l ,  1986; Sternau et a l ,  1989; Gannon & Terrian, 1992; Lyden & 
Hedges, 1992; Graham et a l ,  1993a, 1993b; Hayward et a l ,  1993; Leach et a l ,  1993; 
Martin et a l ,  1993; Lyden & Lonzo, 1994). The sites o f adenosine and G ABA 
modulation o f KA induced neurotoxicity are shown in figure 1.4.
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1.4.4 Free Radical Scavengers
Recently there has been interest in the role that free radicals may have in 
neurotoxicity, with the main focus being tîiat of nitric oxide (Andreeva et ah, 1991; 
Dawson et al., 1991; Lebel & Bondy 1991). There are various reports that activation of 
NMDA receptors in various parts of the brain will cause the activation of the guanylate 
cyclase in postsynaptic cells (Garthwaite, 1982; Wood et al., 1982; Garthwaite et al., 
1988; East & Garthwaite, 1991). This activation can be inhibited by L-Nitroarginine, 
which acts by inhibiting the nitric oxide synthase (NOS). Analogues of arginine, e.g. L- 
nitroarginine can cross the blood brain barrier and inhibit NOS (Haberny et a l ,  1992; 
Nagafuji et a l ,  1992; Nagafuji et a l ,  1993). However, as further studies are performed, 
it is becoming apparent that NO has both neuroprotective and neurotoxic actions, 
dependent on both the model used, time of administration of the NO active agent(s) and 
the identity of the agents used (Haberney et a l ,  1992; Lipton et a l,  1993; Regan et a l, 
1993; Snyder, 1993; Tanaka efû/., 1993; Maiese gf o/., 1994; Przegalinski a/., 1994).
The interest in the free radicals is that they will be formed by uncontrolled 
enzymic activity, anaerobic conditions, depleted levels of anti-oxidants (both intra- and 
extra-ceUularly) and cell death. This may mean that free radicals are not essential in the 
death of cells expressing excitatory amino acids (EAA) receptors (the cells most at risk), 
in that they are formed in these compromised cells, but may be involved in spreading the 
damage to cells that were initially spared from the damage, (delayed spreading neuronal 
damage) (Haba et a l,  1991; Peunova & Enikolopov, 1993; Maiese et a l,  1994). If this 
is the case, then it might mean that drugs that will inhibit the production of free radicals 
are only effective for a short time period (if at all) (Nagafuji et a l ,  1993), and it may 
be that free radical scavengers ( e.g. vitamins C and E, and glutathione) are more
42
effective (Sato et al . , 1993 Reiber et al . , 1994; Saija et al , , 1994). Aspirin (acetylsalicylic 
acid) has also been reported to be very effective in reducing ischaemic brain damage 
(Bellavance, 1993), and its protective action may involve both the inhibition o f eicosanoid 
production (and hence free radical formation) and possibly a free radical scavenging 
action.
1.5 Markers for Neurotoxicity:
1.5.1 Histological
Histological techniques can be employed to study both long and short term changes 
in the shape and presence o f cells within the area o f study, and in conjuction with 
immunocytochemical, ligand binding, and in situ mRNA hydridisation techniques can 
show changes in the biochemical/pharmacological activity o f the cells of interest. Although 
the data obtained from ‘normal’ histology is important, the technique is not able to 
identify either the neurones that are still present or the type o f neurotransmitter(s) 
released. If it is used in conjunction with the above techniques then it is a very powerful 
tool, with the major drawback o f the time taken to process each individual animal: 
histology is therefore usually used to confirm findings used by biochemical/ 
pharmacological/behavioural studies.
1.5.2 Neuronal
Markers for neurones involve either immunocytochemical, in situ hybridisation (see 
1.5.1) or pharmacological techniques. The immunocytochemical analysis o f neurones can 
be either specific (eg transmitter synthesis/ uptake/ degradation and receptors) or 
nonspecific (eg cytoskeletal or synaptic specific proteins). Pharmacological analysis of
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neurones usually targets specific populations of neurones, (eg Choline actyltransferase 
(ChAT) for cholinergic neurones), and hence using specific neuronal markers for 
neurotoxic studies requires careful interpretation of the results, in that agents that do not 
alter the presence of these specific markers are not necessarily not neurotoxic, but might 
just fail to affect the population studied. However the use of several neurone specific 
markers (eg ChAT and glutamic acid decarboxylase (GAD)) will cover several different 
neuronal populations. As yet there is no generalised non-specific neuronal marker that is 
available to neurotoxic studies, although recently there are assays for the widespread 
voltage dependent sodium channels (Sashihara et aL, 1992). The use of this marker will 
therefore allow neuroscientists to study the actions of neurotoxic agents on the neuronal 
populations in general, and will provide a model similar to that of the nonneuronal 
markers (see section 1.5.3.).
1.5.3 Non-neuronal
Following a neurotoxic insult to the brain, by either physical or chemical means, 
there is a period of neuronal death and ‘reactive gliosis’. During gliosis there is a rapid 
invasion (of the area of damage) by phagocytes, followed by a delayed proliferation of 
astroglial cells and hence an increase in biochemical markers for glial cells (Andersson 
et al., 1991, J</>rgensen et al., 1993). Benavides et al. (1987), have indicated that the 
increase in peripheral benzodiazepine receptors (PBR), which are associated mainly with 
glial cells in the CNS, is a more sensitive indirect index for neuronal death than the loss 
of neuronal markers. The exact location and role of the PBRs are not known except that 
they purify with the mitochondrial and synaptosomal fractions, (Basile et a l ,  1986; 
O’Beime & Williams, 1988; see Verma & Snyder 1989) and they may to be involved in
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the calcium buffering capacity of the mitochondria, and hence energy metabolism 
(Moreno-Sanchez et aL, 1991), although there are also reports that they may be involve 
in steroidogenesis (Korneyev et aL, 1993). There are now numerous reports of studies 
using ligands for the PBR binding site (PK11195 and Ro5-4864), which have confirmed 
a significant increase in PBR binding associated with neurodegeneration, (Schoemaker et 
ah,  1982; Benavides et aL, 1987; Altar & Baudry, 1990; Bourdiol et a l ,  1991).
Other nonneuronal markers for neurotoxic study include glial fibrillary acidic 
protein and related proteins. Recently the findings that kynurenic acid, homocysteic acid 
and quinolinic acid are synthesised almost exclusively in astrocytes (Roberts et a l , 1992; 
Zhang & Ottersen, 1992; Du et a l ,  1993 respectively) suggests that these may also be 
used as indirect markers for damage in later studies.
1.6. Aims
The aims of this project where as follows:
a) to set up a kainate model of neurotoxicity, as quantified by peripheral 
benzodiazepine binding,
b) to determine the degree o f involvement of
i) the NMDA receptor,
ii) purine receptors, and
iii) free radicals,
in the propagation o f neuronal loss caused by systemic kainate 
administration.
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2.0 METHODS
2.1 Kainate Toxicity - Binding
2.1.1 Injection Protocol:
In the in vivo experiments 8  week old male Wistar rats, 190 -220g, were used. For 
the release experiments, section 2.3.1., 210-240g male Wistar rats were used. All animals 
were either bred in house or purchased from Harlan Olac, and kept under the same 
conditions, 12hr light/dark regime, with food and water available ad lib. All animals used 
for each group of experiments came from the same source.
Animals were injected i.p., with drugs in a volume not normally exceeding 1ml. 
kg '\ The maximal volume advised for i.p. injection was 5ml. for rats of this weight. 
Kainic acid (lOmg.kg )^ was dissolved in 0.9% NaCl (saline), R-PIA, normally 25/^g.ml \  
in methanol/saline (24/1), APNEA in 10% DMSO in saline, allopurinol in 2% Tween 80/ 
saline. 8 -phenyltheophyUine (8 PT), (Img.mU), was initially dissolved in ethanol and then 
diluted with saline, and brought to pH 7.4 with NaOH to give final concentrations of 
17.5% ethanol and 19.3mM NaOH in 0.9% NaCl. All other drugs were dissolved in 
saline. Rivotril for injection (clonazepam) was supplied in commercially available 
ampoules and diluted with the diluent provided. In all cases vehicles were used as control 
injections. In the experiments using clonazepam the animals were injected 10-15 minutes 
prior to kainate injection.
2.1.2 Rectal Temperature:
In the 8 PT experiments the rectal temperatures were recorded prior to R- 
PIA/vehicle injection (to), and every hour, for 5 hours, after the kainic acid injection, with 
a digital thermometer probe.
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2.1.3 Behavioural Studies
In all experiments the animals were left for 60-90 minutes after the kainate 
injection before any behavioural observations. The behavioural scores were initially based 
on those used by Hoffman et al. (1991), scoring for consciousness, grip, limb tone, 
walking and pain reflex. This was repeated 2hr later and on the day of death. This method 
was discarded as its emphasis is on motor control, which is not affected by kainate 
lesioning and because scoring caused stress in the handled animals. The replacement 
method involved simple observation without handling of the animals every hour after 
kainate injection. Animals were examined for the presence of wet dog shakes, seizures and 
seizure-like activity, fore-paw elevation, excessive salivation, Straub tail, head weaving 
and circling. No scoring was used in this test but the presence or absence of these 
behavioural disturbances was noted.
2.1.4 P? Preparation:
The method used was that of Eshleman & Murray (1989) for the preparation of P2 
membranes, with slight modifications. On the seventh day of the experiment the animals 
were killed, within the same 4hr period of the day over the course of the experiments and 
within 2hrs 30min of each other on the day.
The animals were killed by stunning followed by cervical dislocation and 
decapitation. The skull was then opened, the dura mater membrane cut and the brain 
placed in 30ml ice-cold 0.27M sucrose pH7.4. The cerebellum was then dissected away 
and the brain bisected along the corpus callosum. The hippocampi were then removed and 
placed in 5ml ice-cold sucrose. This normally took 2.5-4 minutes. In the concentration 
curve experiments only one animal was killed at any one time; for all other experiments
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two animals were used.
The hippocampi were then homogenised with a Braun Homogeniser, 10 X 500 
rpm. The crude homogenate was stored on ice, while the homogeniser vessel and pestle 
were washed twice with 5ml ice-cold sucrose and the washes added to the initial 
homogenate. This was brought to 100 volumes with sucrose solution and was then stored 
at -20°C for 2-4hrs.
After completing the preparation o f tissue from a group o f animals the samples 
were defrosted at room temperature, centrifuged for 10 min. at 4°C, 1000 x g (lEC DPR  
6000 centrifuge), the pellet discarded and the supernatant centrifuged for 20min. at 4^ *0, 
23245X g (Sorval RC 5B Refrigerated Superspeed Centrifuge, SS 34 Rotor). After this 
step the supernatant was discarded and the pellet was resuspended in ice-cold 50mM Tris 
HCl buffer pH 7.8 (50 mM Tris salt, brought to pH 7.8 with IIM  HCl) 100 volumes and 
then centrifuged for 20min. at 4°C, 43146 x g (Sorval RC 5B). The new pellet was 
resuspended in Tris HCl buffer at 100 volumes and stored at -20°C, normally for no more 
than 24 hrs.
On the day o f the assay the samples were defrosted at room temperature and 
centrifuged for 20min. at 4°C 43146 x g, and the supernatant discarded. The pellet was 
then homogenised in 5ml Tris HCl buffer 7x1500 ipm, the homogenate kept on ice and 
the homogeniser chamber and pestle washed twice with 3-5ml Tris HCl buffer. The 
washes were pooled with the homogenate and the volume brought to 100 volumes, this 
being the ? 2  membrane fraction, and stored on ice until needed.
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2.1 .5  r m  PKI 1195 Assay.
All assays were performed at 4°C (on ice) and samples were incubated for 60min 
( +  1 min). For the concentration experiments the assay was performed in triplicates 
over the concentration range 0.1 nM - 50 nM pH]-PK11195, with 10 PK11195 as
displacing agent, to define non-specific binding, using 250)ul Pg membranes. Both vehicle- 
treated and kainate-treated animals were examined. The test experiments were performed 
in duplicates with 500;ul ? 2  membranes.
The volume o f the assay chamber was 2ml, and contained 5jLil [^H] PK11195, 5(A 
cold ligand, and membranes. The volume was brought to 2ml with Tris HCl buffer. 
Final assay conditions were 1.75nM pH] PK11195 in ethanol (0.25% final), 0.25% 
DMSO ±  10 f M  PK11195 and 100-150/^g protein. The assay samples were vortexed at 
the start o f their incubation and approximately every 20 minutes before filtration.
The incubation was terminated by vacuum filtration, with all o f the sample being 
filtered through pre-wetted Whatman GF/C glass filters using a Millipore 12 well 1225 
Sampling Manifold. Filters were washed twice with 12ml ice-cold Tris HCl Buffer and 
vacuum dried, before being placed in scintillation vials. 5ml Ecoscint scintillation fluid 
was then added, the samples left overnight and then counted using a Packard 2000 
Scintillation Counter for DPM, (quenching and efficiency o f counting was calculated as 
being 32% using external standards).
Protein concentrations were measured using the Lowry method (Lowry et al. 
1951), following solubilisation with 0.25M  NaOH and with Bovine Serum Albumin as the 
standard.
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2.1.6 Data Analysis:
Specific binding was calculated by the normal method. Specific binding was also 
calculated as percent same day control to minimise day to day variations. All values are 
mean ±  S.E.M. Statistical significance was assessed by unpaired Student’s t-test (unequal 
variance), significance being considered when p<0.05. Selected experiments were also 
analysed by Anova and post-tested with the Student-Newman-Keuls mutlicomparison test. 
If there was any disparities between the two tests, the Student-Newman-Keuls 
mutlicomparison test results were used.
2.2 Endogenous Glutamate Release.
Hippocampal slices (450/nm thick) were prepared as in section 2.3.1 and were 
allowed to recover for one hour in an oxygenated ACSF chamber at room temperature. 
After this hour the slices were transfered to a perfusion chamber and superfused with 
oxygenated ACSF (Iml.minute ^ ). The slices were allowed to recover from this transfer 
for 60 minutes before stimulation with 1ml 50mM KCl. All fractions were collected every 
2 minutes and placed on ice before freezing (-20°C). Samples were analysed by an OPA- 
derivatisation reverse phase ion exchange Gilson HPLC-gradient method.
Solvent A: 90% O.IM sodium acetate pH 7.2,, 9.5% methanol, 0.5% tetrahydrofuran. 
Solvent B; 100% methanol.
40fd samples of perfusate were derivatised with 40/* OPA/2-mecaptoethanol 
(37mM/5mM respectively) in lOOmM borate buffer pH 9.5, and 40/*l lOOmM borate 
buffer. The samples were mixed at room temperature and injected into the sample loop 
30 seconds after the reaction was initiated. This was performed using a computer
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controlled Gilson HPLC 231 Autosampler. The samples were flushed into the HPLC 
system using a Rheodyne 7010 sample injector. The ratio o f solvent A: solvent B was 
controlled by computer using the Gilson GME_712 programme, each assay run was 25 
minutes in duration and the gradient is shown in table 2.1, The amino acids were 
separated using a Microsorb Cig, 3/*m, 4.6mm internal diamter, 5cm long column and 
were detected using a Gilson Spectra/glo fluorimeter, (excitation wave length 390nm: 
emission cutoff filter 475nm) set at maximum sensitivity.
Time (minutes) Flow rate (ml.min"^) % B
0 1.7 0
2 1.7 20
3 1.7 20
9 1.7 45
12 1.7 45
14 1.7 85
16 1.7 85
18 1.7 0
2.3 r^Hl Glutamate Release
2.3.1 Hippocampal Slice Preparation.
(The hippocampal slices were prepared by Doctor M.J. Higgins, Department of 
Pharmacology).
The methods used for these sets o f experiments are modifications o f Ferkany & 
Coyle (1983a,b), Connick (1987) and Palmer et aL (1992). Male Wistar rats (8 weeks old 
and 210-240g) were used throughout, either bred in house or bought from Harlan Olac.
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In each experiment 5 slices were used from any one animal. The rat was killed by 
cervical dislocation and decapitation, the skull opened and the dura cut. The brain was 
then placed in about 30ml ice-cold oxygenated ACSF, the cerebellum removed and the 
brain bisected along the corpus callosum. The hippocampi were then gently teased away 
from the surrounding tissue and laid longitudinally upon Whatman filter paper and 300/*m 
slices cut with a Mcllwain Tissue Chopper. The hippocampi were then transferred to fresh 
ice-cold ACSF, the slices teased apart and placed in an oxygen-saturated ACSF 
environment and left to recover for 90-120 minutes at room temperature.
At the end of this stabilisation period, the slices were transferred to another 
incubation chamber at 30‘’C in a temperature controlled water bath (TE-7 Telcom water 
controller) and left for 15 minutes. After the 15 minutes 10 slices were transferred using 
a paintbrush from the normal ACSF to 3ml ACSF containing 200nM L-[2,3-^H]-glutamic 
acid (17-20 Ci/mmol). The slices were then incubated at 30‘’C for a further 30 minutes.
2 .3 .2  pH] Glutamate Release Protocol.
The incubation period with pH]-glutamate was terminated by the transfer, by 
paintbrush, of slices to a series o f perfusion chambers, 1 slice/ chamber. The incubation 
chambers were airtight Nuclepore Filtration chambers, with 13mm P o p -T o p p la s t ic  
filtration holder 420100 (volume 250/*l), and the slice was placed on a 0.5cm  diameter 
Whatman CF/C glass microfibre disc filter, (figure 2.1). Upon insertion o f the slices the 
chambers were closed and were continuously perfused with oxygenated ACSF at Iml/min, 
over the course o f the experiment. All solutions were maintained at 30°C and were gassed 
with 95 % O J  5 % CO2 for a minimum of 30 minutes prior to introduction into the system
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Fig 2.1 : Perfusion chamber used in release experiments
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(figure 2.2). Samples were collected at various time points (see table 2.2). Solutions were 
changed 35 seconds prior to their arrival at the perfusion chamber and were preceded and 
followed by a 3-4 second air bubble. Stimulations were 1 minute duration, and the 
bracketing with the air bubbles ensured a bolus delivery. During the time when the air 
bubbles were formed the outside of the tubing was wiped to reduce solution 
contamination.
Stimulations (S) were timed to arrive every 30 minutes starting at 60 minutes after 
the start of perfusion. The time taken for a bubble to travel the length of the tubing was 
timed and solution changes were always calculated to arrive 5-10 seconds after a fraction 
had started, the time taken was usually 35-40 seconds. The last stimulation was usually 
50mM KCl and the slices were left for a further 30 minutes before termination of the 
experiment. The antagonist(s) were perfused in ACSF over 1 or 2 stimulations (S2 or S3), 
starting 12 minutes after SI or S2 and finishing 12 minutes before S3 or S4. In all the 
stimulations during the antagonist perfusion the stimulating solutions also contained the 
antagonist.
For detection 4ml Ecoscint scintillation fluid was added to 2ml of perfusate, 
vortexed and counted using an Kontron 3000 scintillation counter (5 minutes for CPM). 
Due to the large number of vials produced per experiment (200+) the Kontron counter 
was used in favour of the Packard 200CA counter used in the binding studies.
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Table 2.2. Release experiment protocol.
TIME (minutes) EVENT.
0 Start Perfusion.
50 Change fraction time 5 to 2  min,
59.30 Start SI perfusion.
60.05 SI arrives in chamber.
60.30 Stop SI perfusion.
61.05 SI terminates in chamber.
(71.30) (Start perfusion of drug
affecting S2).
89.30 Start S2 perfusion.
90.05 S2 arrives in Chamber.
90.30 Stop S2 perfusion.
91.05 S2 terminates in Chamber.
(101.30) (stop perfusion of drug
affecting S2).
(101.30) (Start perfusion for drug
affecting S3).
119.30 Start S3 perfusion.
120.05 S3 arrives in chamber.
120.30 Stop S3 perfusion.
121.05 S3 terminates in chamber.
(131.30) (stop perfusion of drug
affecting S3).
149.30 Start S4 perfusion.
150.05 S4 arrives in chamber.
150.30 Stop S4 perfusion.
151.05 S4 terminates in chamber.
(163.30) (Stop perfusion of drug
affecting S4).
(181) (Start perfusing air)
184 Terminate perfusion, end
experiment.
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2.3.3 Data Analysis.
The data were converted to DPM using an external standard, taking into account 
efficiency of counting and quenching. The DPM values were then plotted against time 
using Graph Pad v 2.0. Time points between 54 and 134 (164) were removed and an 
exponential decay curve (Y=A®**’^ ®^+ (^ cxp(-dx) was fitted to the remaining values, 
using the curve fitting by nonlinear regression mode, weighted by 1/Y, least sum of 
squares (figure 2.3a). The edited-out data points were then returned to the plot and 
residuals from the curve were then calculated (figure 2.3b & c). The residuals were then 
loaded into a statistical package (Minitab) and analyzed for change in pattern over time 
within an experiment and between experimental groups at specific time points. The 
residuals were also used to determine Sx/Sy ratios. To determine the amount released 
during a stimulation period, the baseline under the stimulation peak was calculated by 
averaging 3 time points before and after the peak, and subtracting from the peak values, 
this value being termed ‘stimulated release’. The Sx/Sy ratios were statistically analyzed 
by U-test, significance being assumed when p <  0.05 (Mann Whitney U-test).
Slices were discarded if either the SI was less than 2.27pmol (100 D.P.M. 2 x 
baseline noise) or if the release showed an unstable baseline.
2.3.4 Solutions and Materials.
The composition of ACSF was as follows (mM): NaCl 125, KCl 2.5, KH2 PO4  0.5, 
NaHCOg 27, MgS0 4 .7 H2 0  1.2, CaClj 1.2 and glucose 10. High KCl solutions were as 
control ACSF with the exception that KCl replaced NaCl giving the composition KCl 
50mM, NaCl 77.5mM or KCl 25mM, NaCl 102.5mM.
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50mM KCl evoked release of [3H] glutamate 
from a hippocampal slice.
60 90
Time (minutes)
Figure 2.3
Curve fitting of an exponential decay curve to release data.
The data is an example o f a single release experiment profile obtained by 50mM KCl 
stimulation o f a hippocampal slice. Time corresponds to time from the start of the 
perfusion o f ACSF through the filtration chambers. The points are joined by a cubic spline 
calculated curve to connect the fractions collected. The three peaks correspond to SI, S2 
and S3 (all 50mM KCl).
A) The initial release profile, obtained after scintillation counting. The data have not been 
corrected either for efficiency or quenching, this is performed after the residuals have 
been calculated (100 DPM = 7 .7 5  fmol).
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50mM KCl evoked release of [3H] glutamate 
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B) The same data expressed overlying the calculated exponential decay curve. The dotted 
line corresponds to the exponential curve and the solid line to the cubic spline curve.
5 9
50mM KCl evoked release of [3H] glutamate 
from a hippocampal slice (residuals) .
3  100
60 90
Time (minutes)
C) The data are expressed as residual DPM. The method of calculation is described in the 
methods section, but basically the data values are subtracted from the exponential curve 
values for that point. The resulting residual values are plotted against time, and the 
resulting graph represents release above the mathematically determined basal release ( 0  
DPM). The profile illustrates the degree of instability of the release during the initial 
period of perfusion, (5-50 minutes), after which the fluctuations are smaller and less 
pronounced.
6 0
The Silescol (silica) tubing 1mm inner diameter, 1mm thick wall was used 
throughout the experiments. The solutions were maintained at 30°C using a Tecam TE-7 
Tempette immersion thermostat controlling a Tecam water bath. A Desaga (Heidelberg) 
PLG-Peristaltic pump was used to pump the solutions from their reservoirs to the release 
chambers, and the perfusate was collected in 6 ml mini-scintillation vials placed in an LKB 
(Bromma) 2070 Ultrarac® II fraction collector.
2.4 Materials
pH] PK11195 (specific activity = 80-86 Ci/mmol) was purchased from 
DuPont/NEN (Stevenage, Herts., U.K.). pH] glutamate (specific activity — 20-40 
Ci/mmol) was purchased from Amersham International pic (Amersham, Bucks., U.K.). 
8 PT, ascorbic acid, kainic acid, kynreninic acid, L-kynurenine, MK801, R-PIA and 
tryptophan were from Sigma Chemical Co. (Poole, Dorset, U.K.). 2CA, 8 SPT, and 
DPCPX were from Research Biochemicals Incorporated (Stevenage, Herts., U.K.), 
Clonazepam and unlabelled PK11195 were gifts from Roche, Switzerland and Pharmuka, 
France respectively. Chlormethiazole sulphate was a kind gift from Astra Arcus, Sweden. 
APNEA was a kind gift from Professor R. A. Olsson (University of South Florida, Tampa 
USA). GYKI 52466 was a kind gift from Egis, Hungary. Rivotril (clonazepam for 
injection) was purchased commercially.
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3.0. RESULTS - NEUROTOXICITY EXPERIMENTS.
3.1 Neurotoxicity
3.1.1 Behavioural Studies:
The behavioural responses observed following lOmg.kg * kainic acid i.p. 
correlated well with those in the literature (Ben-Ari et ah, 1979; Schwob et ah, 1980; 
Heggli et ah, 1981; Lothman & Collins, 1981; Heggli & Malthe-Sorvensen, 1982; Sperk 
et ah, 1983; Ben-Ari 1985; Sperk et ah, 1985), with wet dog shakes (wds) appearing 
before the onset of seizures and salivation, fore paw elevation, Straub tail, circling and 
penile erection. Each of these different types of behaviour are well characterised in the 
literature (see above references). A wet dog shake is a whole body shake (not affecting 
the limbs) of usually a few seconds in duration, seizures being a rapid onset whole body 
spasm, sometimes involving a vertical translocation. Forepaw elevation involved the 
animal raising either one or both of its forepaws, until they were level with the rib cage 
and parallel to the ground, and resting on its haunches to maintain balance. When the 
animal was displaying forepaw elevation, it rarely moved and any locomotor activity that 
was observed, usually occurred when only one of the paws was raised. When the animal 
was displaying Straub tail, its tail was raised off the ground, sometimes vertically but also 
horizontally, and was rigid, but not necessarily straight. Animals were able to display 
several behavioural disturbances at the same time, although wet dog shakes were never 
seen in conjunction with forepaw elevation or seizures. The initial survival rate also agrees 
well with the previous reports (see above), in that approximately 15% of the kainate 
injected animals died within the first 6  hour period, with the cause of death probably due 
to excessive seizure like activity. The onset of wet dog shakes usually occurred within the 
first hour after the kainate injections and most of the animals had ceased to exhibit
62
behavioural disturbances six hours after injections. The kainate injected animals showed 
seizures on the day of injection, but the severity and duration was variable and by the day 
of killing they showed no signs of motor disturbances as seen in most stroke models. 
However the animals were hypersensitive to tactile stimuli, in that even a slight pressure 
resulted in a marked locomotive response, (in some cases the animal leaping 12-18 inches 
in the air and landing on the ground running).
In general the animals which had been given test drugs, at doses sufficient to 
afford some degree of neuroprotection, did not display this hypersensitivity and were 
usually behaviourally similar to the vehicle treated animals. All the animals showed some 
form of behavioural disturbances following kainate injections, even if they were given 
drugs that either reduced seizures (clonazepam l- 0 .2 mg/kg) or gave apparent 
neuroprotection (i.e. R-PIA). In addition chlormethiazole, clonazepam (1 mg/kg), 
magnesium sulphate or MK801 treated animals were markedly sedated, with little or no 
WDS activity during this period, but the later onset behavioural disturbances were 
observed (except for clonic-tonic seizures).
3.2 Binding Studies
3.2.1 Saturation Experiments.
Binding parameters were calculated using Scatchard analysis. The values obtained 
showed that there was no change in (7.35 ±  0.27 and 13.44 +  3.34 nM vehicle (n==4 
animals) and kainate (n=3 animals) respectively), but there was a significant increase 
(p=0.008) in B,omx in the kainate treated animals (693.2 ±  139.2 and 2917.0 ±  319.2 
fmol.mg'^ for vehicle and treated animals respectively), (figure 3.1). All subsequent assays 
were performed using 1.75nM pH] PKl 1195 as at this concentration acceptable sensitivity
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Figure 3.1.
Scatchard analysis of pH] PKl 1195 binding to rat hippocampal P2 membranes. 
The data represents a single experiment prepared as in the methods; #  saline treated rat, 
▼ kainate 1 0  mg kg * treated rat.
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was achieved at a reasonable cost. In the control animals approximately 40% of the total 
binding was nonspecific, falling to <10%  of total binding with some kainate treated 
animals.
3.3 Kainate Induced Neurotoxicity.
3.3.1 Kainate Dose Response Curve lUnsedated!
Initial experiments were performed using three groups o f animals treated with 
vehicle, 5mg.kg'* and lOmg.kg* ip kainic acid respectively. Vehicle (control) and 
lOmg.kg'* kainic acid groups gave a single tight population o f binding, 111.2 ±  21.1 
fmol.mg'* protein (n =  12) and 356.8 ±  49.6 fmol.mg'* protein (n =  19) respectively. The 
5mg.kg‘* kainic acid injected animals showed greater variability and no significant increase 
in binding was detected, (176.6 +  55.8 fmol m g'\ n= 9) (see figure 3.2). The lOmgkg'^ 
dose was therefore used for all other experiments as it was most consistent and the 
increase in binding to 350-500% of control was highly significant, (p < 0 .001).
When the total amount o f protein in the fraction was examined there was a significant 
reduction in the lOmg.kg'* but not the 5 mg.kg'* treated groups compared to control (4.16  
+  0.14mg (n =  19), 4.79 ±  0.16mg (n=9) and 4.92 ±  0.21mg (n -1 2 )  respectively) 
(figure 3.3).
3 .3 .2  Clonazepam Treatment.
In the initial experiments about 15% of rats injected with kainic acid 10 mg 
kg'* died during tonic clonic seizures, and a preliminary study was therefore performed 
to determine whether protection could be afforded against seizures without compromising 
hippocampal toxicity.
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Figure 3.2.
Increase in pH] PKl 1195 binding in hippocampal Pg membranes of kainate treated
rats.
Columns indicate mean ±  S.E.M. KA — kainic acid, Veh = saline.
*** p < 0.001 versus lOmg.kg^ kainate group. Student-Newman-Keuls multiple comparison 
test.
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Figure 3.3.
Change in total protein content in kainate treated rats.
Columns indicate means ±  SEM KA = kainate.
The total protein was calculated for each animal by calculating the concentration in the 
? 2  fraction (obtained by protein Lowry), by the volume of the Pg sample.
* p<0.05, ** p<0.01, versus lOmg.kg'^ kainate, Student-Newman-Keuls multiple 
comparison test.
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3.3.2.1 Behaviour
Groups of animals were preinjected with Img kg'  ^clonazepam or 1ml kg'  ^vehicle 
i.p. alone or followed after 10 minutes by an injection of 10 mg kg'  ^ kainic acid. There 
was a reduction in both the severity of the seizure activity and the duration of seizure, 
with a marked sedative effect, but the animals still displayed wet dog shakes, salivation, 
circling and forepaw elevation as observed in kainate control animals.
3.3.2.2. Binding
The pH]PK11195 binding was significantly different between the kainate and 
vehicle treated groups, but no significant difference was obtained between clonazepam and 
vehicle treated animals in the presence of kainate (figure 3.4). When the dose of 
clonazepam was reduced to 0.2mg kg"^  seizure activity was stiU reduced but with less 
apparent sedation and still no effect on pH]PK11195 binding (240.18 ±  13.43 (n=12)). 
The smaller dose was therefore used routinely in subsequent experiments.
3.3.3 Kainate Dose Response Curve fSedatedl.
The use of the anticonvulsant, clonazepam, at a dose sufficient to reduce seizure 
activity but not to affect kainate toxicity, allowed for the re-evaluation of kainate evoked 
toxicity at higher doses. Even though there was little or no seizure activity the highest 
dose of kainate used (20mg.kg *) resulted in 2/8 fatalities. In one of the survivors there 
was total loss of the hippocampus, striatum and limbic system, although this animal 
appeared behaviourally normal prior to termination. Ihe  dose of 7.5mg.kg'^ gave an 
intermediate level of damage that was significantly different from both the control and the 
lOmg.kg^ groups but not from the 5mg.kg'^ group. The levels of binding obtained after
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Figure 3.4.
Comparison of clonazepam or vehicle treatment on kainate induced increase in 
pH] PKl 1195 binding to hippocampal membranes.
Rats were pretreated with clonazepam or vehicle ip 10 minutes prior to kainate 10 
mgkg"  ^ or saline ip injection. Animals were left for 7 days and binding performed as in 
methods. Columns indicate mean ±  s.e.m. sal = saline 1 mlkg"\ KA ~  kainate 10 mgkg-1 Veh = clonazepam vehicle 1 mlkg * or
0,2 mlkg'\ Clon = clonazepam.
*** p <  0.001 versus saline control. +  +  +  p <0.001 versus clonazepam control. Student- 
Newman-Keuls multiple comparison test.
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the doses o f 12.5, 15 and 20mg.kg‘* were not significantly different from the lOmg.kg"^ 
group (figure 3.5).
3 .3 .4  Non-NMDA Antagonism of Kainate Induced Neurotoxicity.
The non-NMDA antagonist GYKI 52466 is reported to be able to antagonise 
kainate induced toxicity better than AMPA induced toxicity in in vivo studies (Moncada 
et al., 1991), and was so used in preference to the other non-NMDA antagonists which 
can cross the blood brain barrier (CNQX, DNQX, NBQX). The same time administration 
and dosage as o f Moncada et al., (1991) was used.
GYKI 52466 was suspended in 2% tween 80 and 30mg.kg"‘ was administered at 
times t.3o, to and t+30. The control animals received 2% tween 80 solution at the same 
time. The GYKI 52466 treated animals displayed behavioural disturbances similar to those 
o f the kainate treated rats, but were behaviourally normal by the seventh day. The level 
o f pH] PK l 1195 binding in the GYKI 52466 treated animals was significantly less than 
the kainate/vehicle treated animals (104.61 +  23.22 fmol.mg protein'^ (n = 4) and 234.16  
+  15.43 fmol.mg protein ' (n=4) respectively, p < 0 .0 5  Student’s unpaired t-test). The 
binding in the GYKI 52466 group was not significantly different from the control group 
(figure 3.6).
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Figure 3.5.
Re-evaluation of kainate dose response curve in clonazepam treated rats.
The animals were pretreated with 0.2mg.kg"^ clonazepam 15 minutes prior 
to kainate/ vehicle injection, and left to recover for 7 days. fraction prepared as in 
methods.
Colunrn indicate means ±  SEM, KA = kainate, Veh = vehicle. * p <0.05, 
** p<0.01, *** p < 0.001 versus control. Student-Newman-Keuls multiple comparison 
test.
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Figure 3.6.
Effect of GYKI 52466 on kainate induced toxicity.
Animals were pretreated with 0.2mg.kg  ^ clonazepam 10 minutes prior to lOmg.kg'^ 
kainate administration (to). GYKI 52466 or vehicle (2% tween 80, Iml.kg'^) was 
administered at times
t.3 0 min> tomin &nd t+30œia- The animals were allowed to recover for 7 days before hippocampal 
Pg membranes were prepared as in methods.
KA= kainate, KA veh =  saline, GYKI veh = 2% tween 80 in saline.
* p<0.05 versus kainate group. Student-Newman-Keuls multiple comparison test.
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3.4 Purine Neiiroiriodulation.
3.4.1 Adenosine Agonist Injections
3.4.1.1 Adenosine A , Agonist Injections.
3 .4 .1 .1 .1  Dose Response Curve.
The adenosine analogue R-PIA was injected i.p. at doses of lm g.k g '\ lOO^g.kg'^ 
25^g.kg'\ 10/Lig.kg'* and 2.5 jug.kg'\ but the combination o f the Img.kg'^ with kainic acid 
was toxic to all the animals treated, with all the animals in this group failing to survive 
the V'- day and therefore no brains were analyzed from this group (n=4). With the 
exception o f the 2.5jLtg.kg'  ^ dose o f R-PIA (which was not neuroprotective), the amount 
of binding was not significantly different from the control or any of the groups treated 
with combinations of R-PIA and kainate. However, all the effective doses of R-PIA 
significantly reduced the binding caused after treatment with lOmg.kg;' kainic acid, (see 
figure 3.7). When R-PIA was injected i.p. (25/xg.kg'^ and lO^g.kg'^) in the absence of 
kainic acid injections there was no significant difference in the pH] PKl 1195 binding 
compared with the control values (figure 3.7).
3 .4 .1 .1 .2  Time Curve (This was performed in conjunction with W.J. Miller, 
Department o f Pharmacology, the University o f Glasgow).
As with the other experiments, clonazepam (0.2 mg. k g '/ was co-ad ministered with 
kainate lOmgkg'^ ( to ) , and not with the R-PIA administration, which was injected at times 
up to 3 hours preceding or following the kainate administration. Injection of R-PIA at 1 
or 2 hours before or after the kainate induced a significant (p <  0.001) protection against 
the neuronal damage (figure 3.8), whereas administration at the 3 hour time points was 
ineffective. Protection was greater within 1 hour o f kainate injection with the maximal
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Figure 3.7.
The effect of R-PIA on the kainate evoked increase in pH] PKl 1195 binding to 
hippocampal ? 2  membranes.
These experiments were performed without clonazepam 
Columns indicate mean ±  S.E.M. KA Veh = saline, R-PIA Veh = methanol and saline, 
KA = kainate.
* p<0.05, *** p < 0.001 significance versus 10 mg kg'  ^kainic acid. + 4- p<0.01 versus 
25/xg.kg'^ R-PIA/lOmg.kg'^ kainate. Student-Newman-Keuls multiple comparison test.
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Figure 3.8.
Time course of R-PIA protection against kainate toxicity.
Rats were injected ip with a single dose of 25jUg kg ' R-PIA at various times before 
or after kainate injection. Clonazepam (0.2 mgkg"/ was injected ip 10 minutes prior to 
ip kainate injection (to ) . Tissue preparation and binding as in methods. Binding as % same 
day controls.
Columns indicate mean +  s.e.m .
V =  saline and methanol/saline treatment ( to ) , KA =  kainic acid 10 mgkg"' and 
methanol/saline treatment ( to ) .
** p < 0 .0 1 , *** p <  0.001 significance versus vehicle.
+  +  p < 0 .0 1 , +  +  +  p < 0 .0 0 1  significance versus 10 mgkg"' kainate.
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protection occurring when R-PIA was co administered with kainate (p <  0.001), (see figure 
3.8).
3 .4 .1 .2  Adenosine A  ^ Agonist Injections
The A / A3 agonist APNEA has recently been reported to cause hypotension in 
anaesthetised rats (Carruthers & Fozard, 1993), although in this study APNEA was 
administered iv. APNEA was dissolved in 2% DMSO/saline and administered at t^ . Three 
doses were initially administered; 2,1 and 0.3 mg.kg ', as well as 0.3m g.kg ' APNEA  
with SOjLtg.kg ' DPCPX. The 2mg.kg ' dose proved to be fatal to all the animals receiving 
both it and kainate (n = 4). The dose o f Img.kg ' resulted in 6 / 8  fatalities, whilst the 
0.3m g.kg' dose caused no fatalities. The 0.3mg,kg ' dose resulted in a small but 
significant reduction in the level o f kainate induced binding (200.26 ±  23.11 fmol.mg 
protein ' (n = 8 ) compared with the control kainate group o f 339.87 ±  68.34 fmol.mg 
protein' (n = 5) respectively). This treatment was also significantly different from the 
vehicle control group, indicating incomplete protection p = 0.0179. Treatment with 
Img.kg ' APNEA also resulted in a reduction in the mean value o f binding (198.76 and
89.06 (mean 143.91) fmol.mg protein"' (n = 2)) compared to the control but this reduction 
was not significant. Due to the large number o f fatalities it was considered unethical to 
obtain a larger sample number without excessive animal use (figure 3.9). The animals 
treated with 50/>cg.kg ' DPCPX and 0.3mg.kg"' APNEA, as well as kainate, showed a level 
o f binding that was significantly different from the kainate/APNEA group alone, but not 
from the kainate group (326.98 ±  43.29 fmol.mg protein' (n = 5 ) p < 0 .0 5  Student’s 
unpaired t-test), figure 3.9).
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Figure 3.9.
Effect of APNEA on the kainate induced neurotoxicity.
Animals were injected with 0.2mg.kg ' clonazepam 15 minutes before kainate 
(lOmg.kg / ,  APNEA or vehicle saline/0.2 % DMSO. Animals injected with the vehicle 
received the same volume as for the Img.kg ' APNEA group.
0 =  vehicle injected, KA = kainate. Columns = means ±  SEM.
*** p <  0 . 0 0 1  versus control ( 0  kainate) group, 
t t  p<0.01 versus 0.3mg.kg ' APNEA/kainate group.
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3.4.2 Adenosine Antagonist Injections.
3.4.2.1 Non-specific Adenosine Antagonist Injections
The 8 -PT vehicle, (ethanol and NaOH) did not significantly alter the level of 
control or kainic acid binding (figure 3.10). Similarly the vehicle did not significantly 
reduce the ‘protective’ action of 25/ig/kg R-PIA. The protective action of R-PIA was fully 
prevented by treatment with 8 -PT at the dose of Img.kg ' (p < 0.05) (see figure 3.10). The 
kainic acid/8 -PT group of rats yielded greater mean levels of binding than that of the 
kainic acid/vehicles group although the differences were not significant (figure 3.10).
3.4.2.2 Rectal Temperature Experiments
To examine whether any change in body temperature is correlated to final 
neurotoxicity, a series of experiments was performed using R-PIA + 8 -PT in kainate 
treated rats. Contrary to expectations, kainate caused a significant decrease in actual body 
temperature at the 1  hour time point, but this change was transient and the mean body 
temperature returned to the starting/normal temperature by the 2 hour time point. In the 
presence of R-PIA there was no significant change in actual or initial body temperature 
over the course of the experiment (5 hours). The same was observed for the kainate/R- 
PIA vehicle/8 -PT group, although in this case there was an underlying upward trend over 
the course of the whole experiment. The kainate/R-PIA/8 -PT group displayed a significant 
decrease in temperature at the 3 hour time point, which returned to normal before being 
significantly elevated at the 5 hour time point, although the shape of the graph indicates 
that there may have been an inability to regulate the core temperature, (see figure 3 . 1 1 ).
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Figure 3,10.
Comparison of the binding o f [^H] PKl 1195 to hippocampal P^  membranes of 
KA/8PT treated rats and controls.
Columns indicate mean +  S.E.M .
Veh =  vehicle, KA =  kainate. * p < 0 .0 5 , ** p < 0 .0 1  versus kainate group.
+  p < 0 .0 5  versus kainate/R-PIA/8-PT group.
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Figure 3.11.
Actual body temperature following I.P. administration of 10 mg.kg'’ kainic 
acid and/or R-PIA/8-PT/vehicles.
a) vehicle treated animals (Im g.kg’’ methanol (R-PIA vehicle) and 1 ml.kg"’ 8-PT vehicle) 
(n—7); b) 10 mg.kg"’ kainic acid, 1 ml.kg"’ methanol and 1 ml.kg’’ 8-PT vehicle (n=7); 
c) kainic acid, 25 /ig.kg"’ R-PIA,and 8-PT vehicle (n =  8); d) kainic acid, R-PIA and 1 
mg.kg'’ 8-PT (n =  10); e) kainic acid, 8-PT and methanol (n = 9).
Points indicate mean ±  SEM, students paired t-test.
* p < 0 .0 5 ,  * * p < 0 .0 1  versus preceeding time point.
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The data were further examined to observe any correlation with the core 
temperature and binding. There was only significant correlation between temperature and 
binding at the 5hr time point with increasing core temperature correlating to an increase 
in pH] PK l 1195 binding (p=0.0191, r^=0.1810, (n=41) Student’s t-test), (figure 3.12  
a-f). However, there is no correlation between binding and temperature in the groups at 
5hrs when examined seperately (data not shown).
If the data are expressed as a change in starting temperature against pH] PKl 1195 
binding, there is no siginifant correlation, at any of the time points, although the 4hour 
time point was tending towards significance (p=0.0738, r^=0.0738 (n=41) figure 3.13).
3 .4 .2 .3  Centrally Active Adenosine Antagonist Injections.
In the group o f animals treated with kainate alone in this series of experiments, the 
total binding was increased to 300% of control binding (figure 3.14). There was no 
overall change in the behaviour of the DPCPX treated animals when compared to the 
kainate treated or kainate/R-PIA treated animals. Animals injected with 250 /ig.kg"’ 
DPCPX and saline showed no increase in pH] PKl 1195 binding when compared to 
control (p= 0 .494), indicating that there was no induced gliosis or neurodegeneration 
induced by the antagonist itself.
When DPCPX was co-administered with kainate at doses o f 2 to 250jug.kg'’, in the 
absence o f R-PIA, only the dose o f 250jLig.kg’’ resulted in a significant increase in pH] 
PK l 1195 binding (figure 3.14).
However, DPCPX was able to reduce significantly the neuroprotective effects of 
25jug.kg'’ R-PIA at the dose o f lOjug.kg"’, although this level o f binding was significantly 
different from both the vehicle control and the kainate control groups (figure 3.15). At
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Figure 3.12.
Correlation between actual body temperature and pH]PK11195 binding in 
control animals.
The rectal temperature o f each animal was plotted against the pH]PKl 1195 
fmol.mg protein"  ^ binding at each time point. A) starting temperature (to drug injection). 
B) C) T^ Hr, D) E) 4,,, F) 5,,.
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Figure 3.13.
Correlation between change in body temperature and [^H]PK11195 binding in for 
each injection group (t; - t^hours).
The change in rectal temperature o f each animal was plotted against the 
pH]PK11195 fmol.mg protein'' binding at each time point, the pH]PK11195 fmol.mg 
protein'* binding at each time point, (to drug injection). A) B) Tg^ r, C) D)
E)
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Figure 3.14.
Effect of DPCPX on kainate induced increase of pH] PKl 1195 binding.
Rats were pretreated with 0.2 mgkg‘^  clonazepam 10 minutes prior to kainate 
(10 mgkg'^) and/or R-PIA/vehicle, DPCPX/saline ip. Binding as in methods. Binding has 
been calculated as % same day pH] PKl 1195 controls. Columns indicate mean ±  s.e.m. 
KA “  kainic acid, KA v = saline, R-PIA v = methanol/saline, DPCPX v ~ saline.
* p<0.05, *** p <  0.001 versus vehicles control,
Student-Newman-Keuls multiple comparison test.
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Figure 3.15.
DPCPX dose response curve in kainate/ R-PIA treated rats.
Animals were preinjected with 0.2mg.kg‘^  clonazepam as per normal, 15 minutes 
prior to lOmg.kg'^ kainate, R-PIA 25jug.kg"  ^and DPCPX/saline injection. Animals left to 
recover 7 days before the hippocampi were removed and prepared as P  ^ membrane 
fraction.
Columns indicate means ±  SEM, Student’s t-test. Con = vehicles injected, KA= kainate. 
* p <0.05, *** p <  0.001 versus control. +4-4- p <  0.001 versus kainate control. Student- 
Newman-Keuls multiple comparison test.
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higher doses o f DPCPX there was complete attenuation of the R-PIA protective action, 
although there was no difference from the kainate control group, as seen in the 
experiments without R-PIA (figure 3.14).
3 .4 .2 .4  Peripherally Active Adenosine A , Antagonist Injections.
The injection o f 20mg.kg'^ 8-SPT or Iml.kg'^ saline induced no change in the pH] 
PK11195 binding when compared to same day controls (p—0.638), though the binding 
was significantly less than the kainate\saline group ( p < 0.001) (figure 3.16), indicating 
that there was no gliosis or neuronal damage produced by the xanthine alone. Kainate 
again produced a 3-fold elevation in pH] PK11195 binding, which could be prevented by 
R-PIA at 25(xg.kg'\ but the additional presence of 8-SPT at 20mg.kg"' did not prevent that 
protection. The combined administration of kainate and 8-SPT resulted in a significantly 
greater degree o f binding than obtained with kainate alone (figure 3.16).
3 .4 .2 .5 . Comparison o f the Potentiation of Kainate
Neurotoxicitv Induced bv Xanthines.
The data from the xanthine experiments were reanalysed, and expressed as percent 
same day kainate binding, to remove day to day variation. The DPCPX data used were 
those o f 250jug.kg'^ (the dose that potentiated kainate toxicity). When the data were 
expressed in this form, it was found that all the xanthines induced an increase o f 140- 
170% kainate binding (figure 3.17). There was no significant difference between the 
elevations induced by any o f the xanthines.
8 6
4 5 0
O 4 0 0
ë 350
m
j  3 0 0  o
% o  o
%n
2 5 0
200
150
<  100
50
0
Veh Veh Veh 25 25 Veh /^g /kg R-PIA
Veh 20 Veh Veh 20 20 m g / k g 8 - S P T
Veh Veh 10 10 10 10 m g / k g KA
9 3 10 9 B 4 n
Figure 3,16.
Effect of 8 -SPT on kainate evoked increase in pH] PK11195 binding.
Rats were pretreated with 0.2 mgkg'^ clonazepam 10 minutes prior to kainate (10 
mgkg'^) and/or R-PIA/vehicle, 8 -SPT/saline injection ip. Hippocampal P2  membranes were 
prepared as in methods. Binding was calculated as % same day control pH] PK11195 
binding.
Columns indicate mean ±  s.e.m. KA veh = saline, KA = kainate, R-PIA veh ~ 
methanol/saline, 8 -SPT veh = saline.
*** p <  0.001 versus kainate control, Student-Newman-Keuls multiple comparison test.
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Figure 3.17,
Xanthine attenuation of kainate-induced gliosis.
Data is pooled from the 8-PT, DPCPX and 8-SPT experiments. Data is expressed 
as same day kainate binding values, and columns represent means ±  sem.
C=control, K=kainate control, KD = kainate/adenosine antagonist (drug).
* p:^0.05, ** p<0.01, *** p<0.001 versus same day kainate control group, with 
experimental groups. Student-Newman-Keuls multiple comparison test.
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3.5. NMDA Modulation o f Kainate Neurotoxicity.
3.5.1 Exogenous NMD A Antagonists.
3 .5 .1 .1  Non-competitive Antagonists
The non-competitive channel blocking antagonist, MK801 was able to attenuate the 
kainate evoked increase in pH] PKl 1195 binding in a dose dependent manner. At the dose 
o f 3mg.kg'^ MK801 was able to protect against the kainate actions significantly, the levels 
o f binding being not significantly different from the control values. The lower dose of 
0.3m g.kg‘  ^ was also able to reduce the kainate evoked changes, to a lesser extent resulting 
in a binding level that was significantly different from the kainate but not the vehicle 
control groups (figure 3.18).
Magnesium sulphate is also a non-competitive channel blocking antagonist o f the 
NM DA receptor complex. At the single dose used here (600mg.kg‘ )^ the animals were 
markedly sedated and did not display any of the reported behavioural disturbances. After 
the 7 day recovery period these animals were behaviourally indistinguishable from the 
vehicle control group. The level o f binding in these animals was also similar to that o f the 
vehicle group but was significantly different from the kainate group (figure 3.19).
3 .5 .1 .2  Competitive Antagonist
The competitive antagonist, CPP, was able to reduce the kainate-evoked elevation 
in pH]PK11195 binding in a dose dependent manner. Kainate at the dose o f lOmg.kg'* 
was able to elevate the pH]PKl 1195 binding from 70.74 ±  21.37 (control, n = 4) to 
234.16 +  15.43 (n=4) fmol.mg protein ' (p < 0 .001).
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Figure 3.18.
Dose response curve of MK801 attenuation of kainate toxicity.
Animals were injected with 0.2mg.kg'^ clonazepam, 15 minutes before kainate and 
MK801/saline injection. Pg membranes prepared as in methods.
Columns indicate mean ±  SEM.
Veh -  vehicles injected, KA = kainate.
*** p <  0.001 versus kainate group, t t t  p <0.001 versus control group. Student-Newman- 
Keuls multiple comparison test.
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Figure 3.19.
Magnesium attenuation o f kainate toxicity.
Animals were injected with 0.2mg.kg‘‘ clonazepam 15 minutes before kainate 
lOmg.kg'^ and magnesium sulphate heptahydrate 600mg.kg'Vsaline injection. Pj 
membranes prepared as in methods. Columns indicate mean ±  SEM.
Veh =  saline, KA — kainate.
*** p < 0 .0 0 1  versus kainate group. Student’s t-test.
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When CPP was co administered, the elevation in binding decreased as the dose of CPP 
increased, with both 3 and 30mg.kg'^ CPP significantly reducing the kainate-induced 
elevation such that the level of binding was 125.21 ±  36.49 (n=4) and 95.29 ±  44.86 
fmol.mg protein'^ (n=3) (respectively), (figure 3.20).
3.5.2 Endogenous NMDA Antagonists.
Two approaches were used in these experiments, the first was systemic 
administration of kynurenic acid, and the second was the administration of the precursors 
tryptophan or kynurenine.
Kynurenic acid 300mg.kg'^ administered at t^, to and t + 4  failed to alter the kainate 
induced elevation in binding (311.08 ±  64.40 (n=4) and 357.73 ±  40.1 fmol.mg protein' 
* (n=4) respectively) (figure 3.21) .
One group of animals was treated with a single dose of 
L-tryptophan 4 hours prior to kainate injection, at the dose of 200mg.kg'\ The mean level 
of binding of the tryptophan group appeared less than that of the kainate group but, due 
to the large variation and the small n-number, the two groups were not significantly 
different (figure 3.22). However, of the four animals injected, 1 died during the course 
of the recovery, one animal displayed behavioural characteristics similar to kainate treated 
animals during the recovery period, and the other two were behaviourally normal. Of the 
3 surviving animals, the animal which was behaviourally similar to the kainate control 
gave the highest level of pH]PK11195 binding whilst the other two gave binding levels 
in the control range.
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Figure 3.20.
Dose response curve of CPP action on kainate toxicity.
Animals were pretreated with 0.2mg.kg'^ clonazepam, 15 minutes prior to 
lOmg.kg'^ kainate administration (tO). CPP or saline was injected at tO. Animals were 
allowed 7 days to recover before hippocampal P^  membranes were prepared as in mthods. 
Columns indicate mean ±  s.e.m .
Con =  control (saline injected), KA =  kainate.
* p < 0 .0 5 , *** p < 0.001 versus kainate group. Student’s t-test.
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Figure 3.21.
Effect o f kynurenic acid treatment on kainate induced toxicity.
Kynurenic acid (300mg.kg"^) was injected at three time points (t^, tg and t+J in 
animals injected with kainate lOmg.kg'* ( to ) . Columns indicate mean ±  SEM.
KA =  kainate, Veh =  vehicle injected and KynA ~  kynurenic acid.
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Figure 3.22. . . .
Effect of pretreatment o f tryptophan on kainate induced toxicity.
Tryptophan was administered 4 hours prior to lOmg.kg"^ 
kainate injection. Animals were left to recover for 7 days prior to killing and the 
hippocampi prepared as P2 membrane fractions as in methods. Columns indicate means
±  SEM.
Veh == vehicles injected, KA =  kainate, Trp — tryptophan.
* * * p < 0 .0 0 1  versus kainate group. Student’s t-test.
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If the animals were pretreated with L-kynurenine, a slightly different picture was 
observed. Two time points were used to examine the effect o f kynurenine. The initial 
group o f four animals was injected with 150 mg,kg'* L-kynurenine at t  ^ hours. As with 
the L-tryptophan 200mg.kg'* group, one animal died, one was both behaviourally and 
pharmacologically similar to the kainate group and the other two were similar to the 
control groups. This resulted in an intermediate level of [^H] PK l 1195 binding that was 
not significantly different from either the kainate or the control groups (figure 3.23).
However, if the kynurenine was administered simultaneously with kainate at doses 
of 30, 75, or 225mg.kg'* a different pattern of binding was observed (figure 3.24). The 
doses o f 75 and 225mg.kg'* produced reasonably consistent binding that was significantly 
different from the kainate group (figure 3.24). It is interesting to note that at the 
225mg.kg'* dose there was no improvement in outcome but there was a smaller variation 
in the mean than in the 75mg,kg'* group (159.7 ±  9.75% (n = 5) and 150.51 ±  49.82%  
(n = 5) same day control respectively). The lower dose o f 30mg.kg'* (n = 5) was not 
significantly different from the kainate group (231.19 ±  55.85% same day control 
(n = 4)).
3 .6 Modulation of Free Radical Action.
3.6.1 Xanthine Oxidase Inhibition.
The xanthine oxidase inhibitor allopurinol was administered at tg in relation to 
kainate injection. Allopurinol (lOmg.ml *) was prepared in a saline solution containing 2% 
Tween 80. The control groups received 3.5ml of 2% Tween 80/ saline. All the animals 
displayed behavioural disturbances similar to those in the kainate control group. Nine 
animals were injected with a dose o f 175mg.kg * allopurinol, of which six died.
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Figure 3.23.Effect o f kynurenine pretreatment on kainate induced damage.  ^ ^
Animais were injected with kynurenine 4 hours prior to kainate lOmg.kg 
injection, and p2membranes prepared as in the methods. Columns indicate means ±  SEM. 
Veh — vehicles injected, KA =  kainate, Kyn =  kynurenine.
*** p < 0 .001  versus kainate group. Student’s t-test.
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neurotoxicity. . , r iAnimals were pretreated with 0.2mg.kg ‘ clonazepam 15 minutes before kainate
lOmg.kg-' and kynurenine/vehicle injections. The animals were left to recover for 7 days 
before the hippocampi were prepared as P; membrane fractions as in methods. Columns 
indicate means ±  SEM.Veh = vehicles injected, KA = kainate, Kyn = kynurenine.
* p <0.05, ** p<0.01, versus kainate group. Student-Newan-Keuls multiple comparison 
test.
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The time course o f the fatalities differed from that of the kainate treatment alone, 
in that all animals survived the first day, although all the animals were lethargic during 
the first 4 days o f recovery (when the fatalities occurred). The actual cause o f death in 
these animals has not been determined, but is probably due to the intrinsic toxicity o f  
allopurinol itself and not kainate. At a lower dose of lOOmg.kg'^ there was only one 
fatality in a group of six rats and the dose of 17.5mg.kg‘  ^ produced no fatalities in the 
five rats treated.
The level of binding mirrored the fatalities in that the 17.5 or lOOmg.kg'* groups 
were not significantly different from the kainate group whilst the 175mg.kg'' group was 
significantly different (281.03 ±  23.9 (n =  6 ), 287.06 ±  33.31 (n =  5) and 125.46 ±  21.69  
fmol.mg protein’^ p < 0 .0 0 1 , (n=3) respectively figure 3.25).
3 .6 .2  Ascorbate Administration.
3.6.2.1 Ascorbate Dose Response Curve.
The systemic kainate administration caused a significant (p < 0 .001) increase in 
pH]PK11195 binding to hippocampal membranes (250.95 ±  22.89 fmol.mg protein'  ^
(n—6 )) compared to the saline control (81.5 ±  5.11 fmol.mg'* protein (n =  8 )). 
Ascorbate, administered at t^  produced a dose-dependent reduction in the kainate induced 
[^H] PKl 1195 binding with an estimated EC50 of 12.9mg.kg'*, and maximal protection at 
50m g.kg‘* (figure 3.26). The ascorbate gave a significant reduction in pH]PK11195 
binding at 30, 50 and 100 mg.kg'*. As with other drug treatments there was no apparent 
difference in the behaviour o f the ascorbate treated and kainate treated animals during the 
first 6  hours after kainate administration.
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Figure 3,25.
Effect of increasing dose of allopurinol on kainate toxicity.
Animals were injected with clonazepam (0.2mg.kg'‘) 15 minutes before kainate 
lOmg.kg'^ ? 2  membranes prepared as in methods. Columns indicate mean +  SEM. 
Student’s t-test.
Veh — vehicles injected, KA =  kainate. ALLO =  allopurinol.
* p < 0 .0 5 , *** p < 0 ,0 0 1  versus kainate group. +  p < 0 .0 5 , + +  p < 0 .0 1  versus 
kainate/allopurinol 175mg.kg'^ group. Student’s t-test.
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Figure 3.26.
Dose response curve of ascorbate action on kainate toxicity.
Animals were injected with 0.2mg.kg  ^ clonazepam 15 minutes before kainate 
lOmg.kg'^ and ascorbate/saline injection. Pg membranes prepared as in methods. Columns 
indicate mean ±  SEM.
Veh = vehicles injected, KA = kainate. ASC = ascorbate 
* p<0.05, ** p<0.01, *** p<0.001 versus kainate group,
Student-Newman-Keuls multiple comparison test.
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3.6.2.2 Time Course o f Ascorbate Neuroprotection.
In the time course experiments ascorbate 50mg.kg"^ was administered as a single 
injection either before or after kainate injection (to). Ascorbate only gave significant 
protection when administered 1 hour before, or simultaneously with, kainate injection 
(143.14 ±  22.51 (n=8) p = 0.036, and 85.45 ±  10.64 fmol.mg protein’^  (n=8) 
p “ 0.002, respectively), but not when given 2 hours before kainate (197.77 ±  45.89 
fmol.mg protein'^ (n=6) p =0.573) (figure 3.27). Ascorbate treatment 1 hour after kainate 
administration resulted in an intermediate level of pH]PK11195 binding but tliis was not 
significantly different from kainate treatment (175.20 ± 38.71 (n=6) and 229.51 ±  28.88 
fmol.mg protein'^ (n=7) respectively p =0.287).
3.7 Modulation of the Gabaergic System.
The anticonvulsant, chlormethiazole (CMZ), has been reported to reduce 
neurotoxicity in several ischaemic models (Cross et al., 1991), and was tested in the 
present system. CMZ was dissolved in saline and administered simultaneously with 
lOmg.kg'^ kainate ip. CMZ administration resulted in sedation of the animal, the duration 
depending on the dose, but once the animals had recovered they displayed classical kainate 
induced behavioural disturbances, without any observed clonic-tonic seizures.
CMZ was found to attenuate the kainate induced elevation in pH] PKl 1195 
binding, in a dose dependent manner. Binding after the lowest dose lOmg.kg"  ^ was not 
significantly different from the kainate group, but was from the control group 
(p<0.01),(173 ±  14.70 (n=3), 260 ±  28.91 (n=4) and 77.51 ±  8.23 (n=4), 
respectively), (figure 3.28). Binding after treatment with 30mg.kg'^ CMZ (118.80 ± 
26.78 fmol.mg protein^ (n=4) p<0.05) was significantly different from kainate control,
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Figure 3.27,
Time course o f ascorbate action.
Ascorbate (50mg.kg'^) was injected as a single dose either before or after kainate 
administration. Clonazepam (0.2mg.kg'^) was administered 15 minutes before kainate 
lOmg.kg'^ ? 2  membranes prepared as in methods. Columns indicate mean ±  SEM. 
Student’s t-test. Veh =  vehicles injected, KA = kainate. ASC =  ascorbate.
+  p < 0 ,0 5 , + +  p < 0 .0 1  versus kainate group.
* p < Q .05 , p < 0 .0 1  versus control group.
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Figure 3.28.
Dose response curve of chlormethiazole induced neuroprotection.
Animals were pretreated with 0.2mg.kg“^ clonazepam 10 minutes prior to lOmg. 
kg'  ^ kainate treatment (to). Chlormethiazole or saline (Iml.kg'^) were administered at to. 
Animals were left to recover for 7 days before hippocampal membranes were prepared 
as in methods. Columns indicate mean ±  s.e.m.
CMZ = chlormethiazole, CON = control (saline) injections, KA= kainate .
* p<0.05, ** p<0.01, *** p < 0.001 versus kainate control group.
t  p <  0.05 versus lOmg.kg"  ^CMZ/KA group, Student-Newman-Keuls multiple comparison
test.
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whilst after lOOmg.kg"  ^ CMZ binding (59.35 <  15.69 fmol.mg protein'^ (n =4)) was 
significantly different from both the kainate control and the kainate/lOmg.kg'^ CMZ 
groups (p < 0 .0 1  and p < 0 .0 5  respectively).
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4.0 RESULTS - GLUTAMATE RELEASE EXPERIMENTS
4.1 Endogenous Glutamate Release
Due to unforseen complications with the HPLC fluorimeter, basal levels of 
aspartate, glutamate or G ABA did not register, the peaks being lost in the base line noise. 
Whilst there were some indications of stimulated release, the peaks were small and non 
reproducible. To try and overcome the problem of small amounts of amines, samples were 
concentrated 50 times, by using a vacuum centrifugation step (Gyrovap). Whilst this step 
gave reproducible standard concentrations, it was unable to concentrate the experimental 
samples to a concentration such that reproducibility in peaks or a better signal:noise ratio 
for the basal release was achieved (no results presented).
4.2 Exogenous Glutamate Release.
4.2.1 Potassium Stimulated Release.
High potassium ACSF was able to stimulate pH] glutamate release from the 
hippocampal slice to release when containing either 25 or 50mM potassium (figure 4.1 
and 4.2, respectively). The stimulations were significantly different from the basal release 
(40-58 minutes) with a significance level of p <0.001. The release was significantly 
different from basal for 7 fractions after SI (p<0.05), but only 2 after S2 (p<0.05) and 
S3 (p<0.05). The extended period of significance following the initial SI peak was 
termed the ‘Hump’ and the release was calculated as the total area under this hump, but 
this was not significant between 25 and 50mM KCl (table 4.1).
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Figure 4.1.
25mM KCl stimulated pH] glutamate release from hippocampal slices.
A) release above predicted basal release (see methods) n = l l ,  * p:^0.05 versus basal 
noise (see methods). B) Total release during stimulation, columns indicate mean ±  sem. 
** p<0.01 versus SI (Mann Whitney U-test). C) Ratio of total stimulated release.
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Figure 4.2.
50mM KCl stimulated pH] glutamate release from hippocampal slices.
A) release above predicted basal release (see methods) n = 9 , ** p < 0 .0 1 , *** p < 0.001 
versus basal noise (see methods) Mann Whitney U-test. Points indicate mean ±  sem. B) 
Total release during stimulation, columns indicate mean ±  sem. C) Ratio o f total 
stimulated release.
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Table 4.1. Comparison of kainate and KCl on stimulated glutamate release.
TYPE / PEAK SI (test) S2 (test) S3 (KCl)
50mM KCl 16.9 ±  5.8 11.0 ±  3.4 8.6 i  2.6
25mM KCl 7.4 ±  1.2* 3.5 ±  0.6* 2.8 ±  0.4**
5/25mM KA/KCl 8.6 i  2.0 4.5 + 0.8 2.8 ±  0.7*
5mMKA 11.5 ±  2.7 15.4 ±  7.2“f 35.2 ±  lO.O^ f^
ImMKA 3.7 ±  0.4*^ 3.2 ±  0.6“* 9.4 ±  2.1‘^ ‘^
Legend: The figures correspond to total release fmol/slice at each stimulus mean ±  sem. 
The data were obtained as in Methods.
KCl 50mM (n==9), KCl 25mM (n = ll) , KA/KCl 5/25mM (n==10), KA 5mM (n -6 ) and 
KA ImM (n=10). KA = kainic acid.
* p <0.05,  ^p<0.01, versus same column 50mM KCl 
p<0.01, versus same column 25mM KCl 
p<0.05, p<0.01 versus same column 5/25mM KA/KCl 
® p<0.05, * p<0.01 versus same column 5 KA 
(Mann Whitney U-test).
There was an apparent dose dependency of the release with 50mM KCl releasing 
16.93 ±  5.77 fmol/slice (SI, n~9) and 25mM KCl releasing (7.42 ±  1.22, fmol/slice 
SI, n=6) although this was not significant (except S3 p <0.05, Mann Whitney U-test), 
due to the variability of the slices (table 4.1). Both concentrations, though, resulted in a 
decreased release with successive stimulations (SI >S2>S3), and the degree of decrease 
was similar for both doses (table 4.2).
4.2.2. Kainate Evoked Release.
Like KCl, kainate was able to evoke pH] glutamate release from the hippocampal 
slice in a dose dependent manner. However, unlike the KCl the area of heightened release 
after SI was marked, and prolonged (lasting for 30 minutes in both cases and significantly 
different from basal, p<0.05 for both 1 and 5mM). After the second stimulation (S2) 
there was no long lasting period of heightened release (lasting only 3 (ImM) and 5 (5mM)
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fractions). If the hump (HI) is compared against the KCl humps, the 5mM kainate HI is 
significantly different from the humps following both KCl concentrations (p<0.05), but 
the ImM kainate hump was not significantly different from these or the 5mM kainate HI 
(table 4.3). In both experiments there was no period of heightened release after S3 (50mM 
KCl).
ImM kainate caused a small release (3.71 ±  0.45 fmol/slice SI, n=6), with a 
slightly smaller S2 release (3.21 ±  0.62 fmol/slice) (figure 4.3.). The SI and S2 values 
were not significantly different but both were different from the S3 values (p<0.01).
Table 4.2. Comparison of the effect of kainate or KCl on the evoked release ratios.
GROUP/PEAK S2/S1 S3/S1 S3/S2
50mM KCl 69 +  5 6 1 + 7 90 + 11
25mM KCl 58 +  12* 47 +  11* 99 + 21
5/25mM KA/KCl 72 +  19 51 + 14 68 + 22
5mM KA 138 +  44" 341 ±  71*^ 318 ±  73*^
ImM KA 90 ±  17 318 + 41*^ 553 ±  179“"
Legend: Values are the percentage of Sx/Sy, as calculated in Methods, and are mean ± 
sem. KA = kainic acid. 5omM KCl, n=9; 25mM KCl, n = l l ;  5/25mM KA/KCl n=10; 
5mM KA, n=6 and ImM KA, n~  10.
* p<0.05, * p<0.01 versus same column 50mM KCl;
p<0.01, ‘‘ p <0.001 versus same column 25mM KCl;
® p<0.01 versus same column 5/25mM KA/KCl (Mann Whitney U-test).
5mM kainate also caused release from the slices (11.52 ±  2.7 and 15.37 ±  7.21 
fmol/slice (n=6) SI and S2 respectively, figure 4.4). Tire SI value for the 5mM kainate 
group was significantly different from that of the ImM group (p < 0.025, and the S2 or 
S3 values were also significantly different (p<0.01), (table 4.1).
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Table 4.3. Total stimulated release and between SI and S2.
GROUP Total stimulated Total ‘Hump’
50mM KCl (9) 36.5 ±  11.5 5.1 ±  1.8
25mM KCl (11) 13.7 ±  1.6* 8.4 ±  3.5
5/25mM KA/KCl (10) 15.8 ±  2.8* 11.5 ±  3.8*
5mM KA (6) 62.1 ±  18.3"" 29.3 ±  10.0*’‘‘
ImM KA (10) 18.6 ±  2.8^ 9.1 ±  2.2“
Legend: Total stimulated release was calculated as SI + S2 +  S3, whilst total ‘Hump’ 
release was calculated as total residuals between 68 and 84 minutes. KA = kainic acid. 
Numbers in parenthesis are the number of slices.
* p<0.05 versus same colunm 50mM KCl; 
p<0.05, p<0.01 versus same column 25mM KCl; 
p<0.01 versus same column 5/25mM KA/KCl;
® p<0.05, p<0.01 versus same column 5mM KA, (Mann Whitney U-test).
When the Sx/Sy ratios were examined it was observed that there was an apparent 
potentiation in the release of S2 at 5mM kainate (1.38 ±  0.44) compared to either ImM 
kainate (0.90 ±  0.17) or the KCl experiments (0.69 ±  0.05, (50mM KCl) and 0.58 + 
0.12 (25mM KCl)) (table 4.2). However, this was only significantly different from the 
25mM KCl S2/S1 ratio (p<0.05).
In both ImM and 5mM kainate stimulated slices the S3 value was larger than the 
S2 or SI (as expected) and was significantly different from both (p<0.05). An 
unexpected finding was that the S3 from 5mM kainate treated slices was significantly 
different from the S3 of 50mM KCl treated slices (p<0.01), but that in ImM kainate 
treated slices was not (table 4.1).
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Figure 4.3.
ImM kainate stimulated pH] glutamate release from hippocampal slices.
A) release above predicted basal release (see methods) n - 1 0 ,  points indicate mean ±  
sem, * p < 0 .0 5  versus versus basal noise (see methods) Mann Whitney U-test. KA =  
kainate. B) Total release during stimulation, columns indicate mean ±  sem, ** p < 0 .0 1  
versus both SI and S2. C) Ratio o f total stimulated release, ** p < 0 .0 1  versus S2/S1, 
columns indicate mean +  sem.
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Figure 4.4.
5mM kainate stimulated pH] glutamate release from hippocampal slices.
A) release above predicted basal release (see methods) n==6, * p < 0 .0 5  versus basal noise 
(see methods) Mann Whitney U-test points indicate mean ±  sem, KA =  kainate. B) Total 
release during stimulation, columns indicate mean ±  sem. * p < 0 .0 5  versus both SI and 
S2. C) Ratio o f total stimulated release.
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To observe what effect, if any, kainate had on KCl stimulated release 2 
experiments were performed using 5mM kainate and 25mM KCl as the stimulus for SI 
and S2, with S3 being just 25mM KCl. When the actual release was examined (figure 
4.5b), the SI was significantly greater than S2 (p<0.05) and S3 (p<0.01), but S2 was 
not different from S3. The release profile obtained from these slices was similar to that 
of just 25mM KCl and not that from 5mM kainate (figure 4.5a, 4.1a and 4.4a 
respectively). Even though there was an apparent period of heightened release, this was 
also of similar shape to 25mM KCl (i,e, tailing off) rather than 5mM kainate (i.e. hump­
like).
Indeed, when the actual release is compared for all three groups (table 4,3) this 
is apparent, but again due to the variability within the 5mM kainate group there is no 
significance at SI, but both S2 and S3 are different (p<0.01). When compared against 
the 25mM KCl stimulated slices there is no significance. The Sx/Sy ratios also show this 
tendency with S2/S1 not being significant, but S3/S1 and S3/S2 being significantly 
different for both groups (p=0.01 for S3/S1 and S3/S2 against 5mM kainate), but no 
significance against the 25mM KCl stimulated slices (table 4.2).
A comparison of the potencies of kainate and KCl is shown in table 4.3. If the 
total stimulated release is examined (excluding the ‘hump’), then the 5mM kainate 
experiments are significantly different from the 5/25mM kainate/KCl experiments (p 
<0.01,) (table 4,3). If the time period corresponding to the Hump in kainate slices (68-84 
minutes) is also examined, then the 5/25mM kainate/KCl is also significant against the 
5mM kainate experiments (p<0.01), (table 4.3).
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Figure 4.5.
5/25mM  kainate/KCl stimulated pH] glutamate release from hippocampal slices. 
A) release above predicted basal release (see methods) n = 1 0 , * p < 0 .0 5  versus basal 
noise (see methods) Mann Whitney U-test, points indicate mean ±  sem. KA/KCl 
“ kainate/KCl stimulation B) Total release during stimulation, columns indicate mean +  
sem,* p < 0 .0 5 , ** p < 0 .0 1  versus SI . C) Ratio o f total stimulated release, ** p < 0 .0 1  
versus S2/S1.
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4.2.3 The Effect of 2-Chloroadenosine on the Kainate Evoked Release.
In the neurotoxicity experiments, R-PIA was used as the adenosine A^  agonist due 
to its long lasting action, but this attribute was not desirable in the release experiments and 
so 2-chloroadenosine was used instead. 2-chloro-adenosine (2CA) was tested against both 
1 and 5mM kainate (figures 4.6 and 4.7 respectively), and was perfused during the time 
period 72 to 102 minutes (stimulus S2, which was in the 92 minute fraction, was delivered 
in 2CA containing ACSF/kainate).
In the ImM kainate group the initial SI was significantly greater than that of the 
ImM kainate control experiments (p < 0.025), as was the S2 (p<0.01), but the S3 peaks 
were not significantly different from the control experiments (table 4.4). The S2/S1 and 
the S3/S1 ratios were both significantly different from the control (p<0.01 and p<0.05 
respectively), but the S3/S2 was not (table 4.5). Surprisingly, HI was also significantly 
greater than the control (p<0.01) even though there was a large degree of variability 
between slices (table 4.6).
Table 4.4 Comparison of the effects of 5^M 2-chloroadenosine on kainate stimulated 
hippocampal slices.
TYPE /DRUG SI (KA) S2 (KA ±  2CA) S3 (50mM KCl)
ImM KA (10) 3.71 ±  0.45 3.21 + 0.62 9.37 ±  2.08
ImM KA/CA (6) 6.29 ±  1.46* 4.44 ± 1.25'’ 10.42 ±  2.08
5mM KA (6) 11.51 ±  2.70 15.37 ±  7.21 35.18 ±  9.95
5mM KA/CA (6) 4.60 ±  0.88* 4.77 ±  1.32* 14.49 ±  5.92*
Legend: Figures indicate total release, above basal, following stimulation (fmol pH] 
glutamate/slice). Numbers in parenthesis indicates number of slices.
KA = kainic acid, CA = 2-chloroadenosine (5^M).
* p<0.05, * p<0.01 versus same column controls (Mann Whitney U-test).
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Figure 4.6.
Effect o f 2-chloroadenosine on ImM kainate stimulated hippocampal slices.
A) release above predicted basal release (see methods) n = 6 , * p < 0 .0 5  versus basal noise 
(see methods) Mann Whitney U-test. Points indicate mean ±  sem.
KA =  kainate stimulation, 2CA =  2-chloradenosine perfusion. B) Total release during 
stimulation, columns indicate mean ±  sem, ** p < 0 .0 1  versus both SI and S2. C) Ratio 
of total stimulated release.
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EFFECT OF 2 CHLOROADENOSINE ON 5mM KAINATE EVOKED RELEASE
OF [3H] GLUTAMATE FROM HIPPOCAMPAL SLICES.
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Figure 4.7.
Effect o f 2-chloroadenosine on 5mM kainate stimulated hippocampal slices.
A) release above predicted basal release (see methods) n = 6 , * p < 0 .0 5  versus basal noise 
(see methods) Mann Whitney U-test points indicate mean ±  sem. KA =  kainate 
stimulation, 2CA =  2-chloradenosine perfusion. B) Total release during stimulation, 
columns indicate mean ±  sem. * p < 0 .0 5  versus both SI and S2. C) Ratio o f total 
stimulated release.
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stimulated hippocampal slices.
GROUP / PEAK S2/S1 S3/S1 S3/S2
ImM KA (10) 90 ±  17 318 +  41 553 ±  179
ImM KA/CA (6) 74 ±  18* 196 ±  43* 367 ±  126
5mM KA (6) 138 ±  44 341 ±  71 318 ±  73
5mM KA/CA (6) 133 ±  52 412 ±  200 388 ±  125
Legend: Figures indicate the ratio of Sx/Sy mean ±  sem, as calculated in the methods. 
KA = kainic acid, CA = 2-chloradenosine (5/aM).
* p<0.01 versus same column ImM KA (Mann Whitney U-test)
Table 4,6, Total stimulated release and hump release in slices treated with 2 
chloroadenosine (5^ML
GROUP TOTAL HUMP
ImM KA (10) 18.57 ±  2.81 9.07 ±  2.18
ImM KA/CA (6) 21.15 ±  3.65 12.55 ±  6.00"
5mM KA (6) 62.06 ±  18.34 29.29 ±  9.95
5mM KA/CA (6) 23.86 ±  6.04* 10.52 ±  1.28
Legend: Columns indicate mean + sem. Total indicates total stimulated release, whilst 
Hump indicates release during the time period 68-84 minutes. Numbers in parenthesis 
indicates number of slices used.
• p<0.05 and  ^p<0.01 versus same column controls (Mann Whitney U-test).
A complication with interpreting the 5mM kainate group arose due to the low 
amount released compared to the control experiments (SI 4.6 ±  0.88 and 11.52 ±  2.7 
fmol/slice respectively) and this is shown in tables 4.4 and 4.6. The low levels of release 
from these slices resulted in all the peaks, the total release and HI, being significantly 
smaller than those of the control group. This low level of release did not affect the Sx/Sy 
ratios and there was no significant difference between the kainate and the kainate/2CA 
groups at any of the levels tested (table 4.5).
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4 .2 .4  The Effect o f 8-Cyclopentyl-L3-dipropylxanthine on Evoked Release.
To determine whether the lack o f response to 2CA was due to 
the adenosine Aj receptors already being maximally active the selective Ai antagonist 8- 
cyclopentyl-1,3-dipropylxanthine (DPCPX) was used at 5nM (K^  0.46nM , Bruns, et a l ,  
1987). Due to the large variability in the SI peak with 5mM kainate, and also the 
presence o f the ‘hump’, a third kainate stimulation was added to the experiment, such that 
S1,S2 and S3 were all kainate and S4 was 50mM KCl (figure 4.8).
Two sets o f  experiments were performed, the first with DPCPX being washed out 
15 minutes after S3, and the second set with the DPCPX present until the end of the 
perfusion (figure 4.9  and 4 .10 respectively).
Unlike the previous 5mM kainate experiments, during the course o f these 
experiments SI was greater than S2, but again this was not significant (S2/S1 0.87 ±  0.18  
(n—18) and 1.38 +  0.44 (n = 6) respectively). The amount released during SI was similar 
for all three groups (table 4 .7), There was a significant difference between the amount 
released during S3 in the presence o f DPCPX (washout experiment) and the kainate 
control group, but as the S2 amount was also low for the washout group, the importance 
o f this is unclear. However, there was a significant reduction in the amount released by 
S4 (50mM KCl) compared to the kainate control group (table 4 .8 , p < 0 .0 1  for both 
groups).
When the Sx/Sy ratios were examined it was noticed that there was a significant 
reduction in the S3 /S1 in the washout experiment compared to the control group (p <  0.01) 
but not the continuous DPCPX perfusion group (S3/S1 0.37 ±  0.14, 0 .87 ±  0.18 and 
1.18 ±  0.57 respectively) (table 4 .8).
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Figure 4.8.
5mM kainate stimulated pH] glutamate release from hippocampal slices (3 kainate
peaks).
A) release above predicted basal release (see methods) n —18, * p < 0 .0 5  versus basal 
noise (see methods) Mann Whitney U-test. Points indicate mean ±  sem.
KA ~  kainate B) Total release during stimulation, columns indicate mean +  sem. ** 
p < 0 .0 1  versus S4. C) Ratio o f  total stimulated release. ** p < 0 .0 1  versus S2/S1.
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Figure 4.9.
Effect of cyclopentylxanthine on 5mM kainate stimulated pH] glutamate release 
from hippocampal slices (washout).
A) release above predicted basal release (see methods) n=6, * p <0.05 versus basal noise 
(see methods) Mann Whitney U-test. Points indicate mean ±  sem. KA = kainate, 
DPCPX = cyclopentylxanthine perfusion. B) Total release during stimulation, columns 
indicate mean ±  sem. ** p<0.01 versus S3. C) Ratio of total stimulated release, * 
p<0.05 versus S2/S1.
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EFFECT OF CYCLOPENTYLXANTHINE ON 5mM KAINATE OR 50m M  KCl EVOKED RELEASE 
OF [3H] GLUTAMATE FROM HIPPOCAMPAL SLICES
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Figure 4.10.
Effect of cyclopentylxantnine on 5mM kainate stimulated pH] glutamate release 
from hippocampal slices.
A) release above predicted basal release (see methods) n = l l ,  * p<0.05
versus basal noise (see methods) Mann Whitney U-test. Points indicate mean ±  sem. KA 
= kainate, DPCPX = cyclopentylxanthine perfusion.
B) Total release during stimulation, columns indicate mean ±  sem. p<0.01 versus SI.
C) Ratio of total stimulated release.
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Table 4.7. Comparison of the effect of cyclopentylxanthine on kainate treated slices.
GROUP/DRU
G
SI
KA
S2
KA
S3
KA/DPCPX
S4
KCl/DPCPX
5m M K A
(control)
8 . 6  ±  2 . 1 6.3 ±  1.0 5 .7  ±  1.0 19.3 ±  3.5
5mM
KA/DPCPX
(washout)
6.5 ±  2.5 2 . 8  ±  1 . 0 1 . 6  ±  0.4" 4 .7  ±  0.9"
5mM
KA/DPCPX  
(S3 & S4)
10.2 ±  2.7 7 .0  ±  L4<= 7.7  ±  3 .L 7.3 ±  1.8-
Legend:
Figures indicate total release (fmol [^H] glutamate/slice, mean ±  sem). KA 
kainic acid, DPCPX =  cyclopentylxanthine (5nM).
KA control n = 1 8 , KA/DPCPX washout n = 6 , KA/DPCPX (continuous) n =  l l .
* p < 0 .0 5 , p < 0 .1  versus same column control,
 ^ p < 0 .0 5  versus same column DPCPX washout (Mann Whitney U-test).
Table 4 .8 . Comparison o f the effects o f cyclopentvlxanthine on the peak ratios o f kainate 
stimulated slices.
GROUP/
PEAK
S2/S1 S3/S1 S4/S1 S3/S2 S4/S2 S4/S3
KA (Con) 87 ± 94 ± 340 ± 174 ± 598 + 428 ±
18 16 71 52 195 94
DPCPX 44 ± 37 ± 94 + 106 ± 2 2 2  + 423 ±
(Wash) 6 14" 15" 55 38 1 2 0
DPCPX 103 ± 118 i 144 ± 1 1 0  ± 145 + 198 ±
(End) 23 57 50" 33 45"^ 5 7 .0
Legend
Figures indicate the percentage o f Sx/Sy, mean +  SEM.
KA (Con) =  control slices, 5mM kainate stimulation, no DPCPX (n=18). DPCPX (wash) 
=  5mM kainate stimulated slices, DPCPX present between S2 and S3 (S3 in 
DPCPX/ACSF) (n = 6 ). DPCPX (end) =  5mM kainate stimulated slices, DPCPX present 
from 102 minutes to end (S3 and S4 in DPCPX/ACSF) (n—11).
KA=kainate, DPCPX =  cyclopentylxanthine (5nM).
* p < 0 .0 5 ,  ^p < 0 .0 1  versus same column control,
" p < 0 .0 5  versus same column DPCPX washout, (Mann Whitney U-test).
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DPCPX did not significantly alter the S3/S2 ratios, although it did affect the S4/Sy 
ratios. In slices perfused with DPCPX the S4/S1 ratio was significantly different from the 
control slices, but the two DPCPX groups were not different. Although the S4/S2 ratio 
for the DPCPX washout was lower than that o f the control it was not significantly 
different, and the S4/S3 ratio was the same as the control. If the DPCPX was continuously 
perfused the S4/S2 and the S4/S3 values were significantly lower than the control 
(p < 0 .0 5  table 4 .9).
When the total stimulated release was examined there was no significant difference 
between the control and the continuous DPCPX perfusion but both were significantly 
greater than the DPCPX washout experiment (table 4.10). Even though the slices were 
following a trend similar to the KCl treated slices (SI > S 2 > S 3 ) ,  there was still a period 
of heightened release after S I, that was significantly greater than the basal release (from 
SI to 80 minutes for the control and continuous DPCPX perfusion, none for the washout 
group, see figures 4 .8 , 4 .9 , 4.10) and the HI values are shown in table 4 .9 .
Table 4 .9 . Effect o f cyclopentylxanthine on total stimulated release and heightened release
(!hump’),.
GROUP / RELEASE TOTAL STIMULATED HUMP RELEASE
KA (control) 39.84 ±  7.37 13.75 ±  4.78
KA/DPCPX (washout) 15,71 ±  4.34 3.37 ±  2.57
KA/DPCPX (continuous) 32.14 ±  4.95 8.84 ±  3.15
Legend: Figures indicate fmol pH] glutamate release (mean ±  sem). Hump release is all 
the release during time 68-84 minutes.
KA =  kainic acid, DPCPX =  cyclopentylxanthine (5nM).
* p < 0 .0 5 , " p < 0 .0 1  versus same column control, 
p < 0 .0 5 ,  ^p < 0 .0 1  versus same column washout (Mann Whitney U-test).
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5.0 DISCUSSION
5.1 Discussion o f Methods
5.1.1 Neurotoxicity
Previous studies have employed histological or neurochemical analyses to 
demonstrate that systemic injections o f kainic acid to mature rats can induce hippocampal 
damage (Schwob et al.  ^ 1980; Fuller et a l ,  1981; Lothman and Collins, 1981; Fariello 
et ah,  1989). The present results indicate that the damage induced by kainate is also 
reflected in an elevation o f pH] PK11195 binding to hippocampal membranes. Gliosis 
always accompanies the degeneration o f neurones induced by excitotoxins or ischaemia 
(Schwarcz & Coyle, 1977; Andersson et al . , 1991; Haglid et a l . , 1991; Jc^rgensen et al . , 
1993) and the demonstration that binding sites for the peripheral benzodiazepine receptor 
ligands occur in central glial cells has been proposed as a sensitive (indirect) indicator of 
neuronal damage (Benavides et a l ,  1987; Dubois et a l ,  1988; Altar & Baudry, 1990; 
Price et a l ,  1990). Comparative analyses have shown an excellent correlation between 
the distribution o f PK11195 binding studied by autoradiography, and conventional 
histology (Dubois et a l , 1988, Price et a l . , 1990). Binding techniques, however, eure more 
sensitive, and can reveal changes following concentrations o f excitotoxins that are 
insufficient to cause significant alterations o f enzyme markers such as glutamate 
decarboxylase or choline acetyltransferase (Benavides et a l , 1987).
However, although binding is more sensitive than most methods, it should never 
be used in isolation in neuroprotective studies. Binding is subject to misinterpretation, in 
that the lack o f change in a neuronal marker, for example, does not necessarily indicate 
that there is no neuronal damage. In this case it may be that the neurones in question are 
not affected. Another possibility is that there is a change in both the and such that
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there is no apparent change in saturated binding. Whilst this scenario is unlikely, it should 
be noted that several receptor subtypes have both high and low affinity binding (eg kainate 
receptors). To compensate for this possibility, it is usually advisable to perform saturation 
binding experiments to remove any doubt, by obtaining both Kq and although cost 
prevented this being performed routinely in the present study, apart from the intial kainate 
experiments.
Histology is another method o f validating results obtained in binding experiments, 
in that changes in structure are easy to observe, and it is possible to examine areas outwith 
the areas of study in binding experiments, or to examine if  there is any variation in the 
degree o f damage within a region. This is especially true for the hippocampus, where all 
the regions (C A l -CA4) and the dentate gyrus are all sensitive to ischaemic-type damage 
to differing degrees. Histology, though, can only show morphological changes and should 
be performed in conjunction with other techniques to allow a broader picture to be 
formed.
5 .1 .2  Kainate Induced Damage
There are several advantages o f using a systemic route for injecting kainate. 
Firstly, no surgery is required as it is for direct intrahippocampal injections, and the 
variability inherent in the stereotaxic procedure is avoided. Secondly, the neurotoxin is 
likely to be more evenly distributed throughout the hippocampus than following localised 
injections. Thirdly, the concentration o f kainate achieved is likely to be lower after 
intraperitoneal injection, and hence only high affinity kainate binding sites should be 
affected. The dose o f lOmg.kg'^ would yield a tissue concentration o f approximately 38 
fxM if  it were evenly distributed around the body, and probably much less than this in the
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brain due to the restrictive permeability o f  the blood-brain barrier (BBB). Nadler e( al 
(1980) and Berger et al, (1986) reported that after systemic injection the concentration of 
kainate in the brain is <  1 % o f the predicted concentration, and this means that assuming 
the 200g rat has a brain o f 3g then the amount in the brain is <  1.75nmoles. This is of 
similar dosage to those used when kainate is administered intrahippocampally / 
intraventricularly (l-20nmoles; see Schwarcz et al., 1978; Franck & Roberts, 1990; 
Tanaka et al.,  1990; Borg, 1991; Moncada et al. 1991; Phelps et a l . , 1991). To achieve 
neuronal loss in cell culture appoximately 500fjiM is usually used (Choi et a l . , 1988; Koh 
et al.,  1990; Koh & Choi, 1991; Puttfarcken et al., 1993). The advantage in the present 
study is that there is probably an even distribution of kainate in the hippocampus rather 
than a concentration gradient decreasing from the point o f hippocampal administration 
(600nM throughout the brain compared to l-20mM  at the site o f administration, 
respectively). The doses o f kainate used in the present work are comparable with those 
used by others (e.g. Fariello et al.,  1989) but less than the 12mg/kg dose which can 
induce severe seizure activity (Fuller & Olney, 1981; Altar & Baudry, 1990). 
Intrahippocampal injections o f kainate result in a more severe degree o f damage than i.p. 
injections probably because the dose for a particular area is greater than that achieved by 
ip injections, and this may mean that some of the damage caused by intrahippocampal 
injections is mediated by the low affinity kainate receptors/AMP A receptors (Moncada et 
a l ,  (1991)).
However, this said, the peripheral administration probably has several potential 
side effects. These include: change in body pH, release of stress hormones, cardiac and 
respiratory disturbances, temperature changes and, probably most importantly, the 
behavioural disturbances. All o f these have been examined during the initial validation o f
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kainate as a neurotoxic tool (Schwob et al , , 1980; Lothman & Collins, 1981; Sperk et al . , 
1985; Sperk, 1994). However each o f these side effects will be examined in this section.
1) the effect o f kainate pH on neurotoxicity:
Although in the present study the kainate was not buffered (pH « 4 .0 ) ,  the damage 
was similar in magnitude and specific in location to previous reports that used buffered 
kainate systemically (Schwob et al. ,  1980; Lothman & Collins, 1981; Heggli & Mathe- 
S</>renssen, 1982; Baran et a t ,  1994). Several groups have also used unbuffered kainate 
(Berg et al., 1993, Altagracia et a t ,  1994) and have also reported the same pattern o f  
damage. As with central administration, in vitro studies also indicate that kainate is able 
to induce neurotoxicity at physiological pH (Schwob et a l . , 1980; Kato et a t ,  1991). All 
these reports indicate that, whilst buffering the kainate when administering centrally is 
essential, systemically administered unbuffered kainate produces damage that is 
indistinguishable from buffered kainate, and suggsets that it is not important in the present 
situation.
2) the effect o f kainate on body temperature:
In experiments where kainate is administered centrally the animals are aesthetised 
and their body temperature is maintained by a homeothermic blanket. This means that the 
temperature is maintained in the region of 37°C. The findings in the present report and 
those o f Lin et al . , 1993, indicate that kainate does not alter the systemic temperature over 
the course o f the experiment, and this argues against the damage being mediated through 
change in body temperature. However, as mentioned later changes in brain temperature 
will significantly alter the degree o f damage.
3) Behavioural changes:
The importance o f the behavioural changes over the whole course o f the
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experiment is still unclear. The initial disturbances (ie the seizures, the wet dog shakes 
and the SBS) appear following either systemic or central administration (see Sperk, 1994 
for review). This may suggest that the same pathways are activated following either type 
o f administration and that the outcomes are the same but this is still being investigated. 
The hyperresponsiveness o f the kainate damage animals observed after 2-3 days suggests 
that the animals have elevated levels o f the stress hormones (glucocorticoids 
mineralocorticoids), although there are as yet no reports on the levels o f these hormones. 
Indeed the importance o f the stress response is debatable in that adrenalectomony 
attenuates kainate induced damage (Stein & Sapolsky, 1988; Lee et a l ,  1989) whilst 
dexamethasome treatment enhances it (Lenique et a l ,  1979; Sztriha et ah,  1986, Lee et 
al.,  1989). This needs to be further evaluated.
4) the effect o f kainate on the cardiac and respiratory systems:
There apppears to be no effect on either o f these systems as observed in the present 
study or reported in previous studies (Schwob et a l ,  1980; Lothman & Collins, 1981) 
indicating that damage is not due to respiratory or cardiavascular perturbations.
So, whilst systemic kainate causes behavioural disturbances which are distinct from those 
observed in the MCAO stroke models, these also occur following central administration. 
As both the central and systemic administrations result in these behavioural disturbances, 
and they do not appear to be pH- or body temperature-dependent, these may be important 
in the mechanism o f kainate induced brain damage.
In the present study kainate caused a dose-dependent increase in pH]PK11195 
binding, which was maximal at lOmg.kg'k This elevated binding was due to an increase 
in Bjjiax but not K^. Both the Kg and B,„ax are higher than those reported in the literature 
(in some cases the Kg is 10-100 times greater see table 5.1).
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Table 5.1 Experimental conditions used in FHI PK11195 experiments.
nM fmol.
m g'
SPECIES TISSUE SOLUTION pH AIC.
hr/°C
CL. REF
NR NR mouse cortex 120mM NaCl 
50mM Tris HCl
7 .4 1/25 IjuM
PK11195
1
2.8  - 
17.6
NR human BCG PBS +  0.1% BSA 7.4 0.5/25 IjitM
PK11195
2
2.1 255 human cortex 50mM Tris HCl 7.4 1/4 lOjttM
PK11195
3
0.96
0.63
2998
131
rat kidney
cortex
50mM Tris HCl 7.4 1/4 lOfdU
PK11I95
4
2.3 0.010 rat heart PPB 7.4 0.5/25 ljUM
PK11211
5
1.83 0.012 rat heart 5mM Tris HCl, 
ImM MgCl^, 
0.25mM  Sue.
7.4 0,5/25 1(jM
PK11211
6
0.87
2.71
128
0.002
rat cortex
O.BuIb
PBS 7.4 1/4
2/4
IjttM
Ro5-4864
7
1.88 26300 bovine pineal
gland
50mM PPB 7.4 0 .5 /
25
lOjuM
PK11195
8
1.07 0.010 rat kidney 50mM PPB 7.0 1/4 lOjtiM
PK11195
9
1.1 NR rat cortex 50mM Tris HCl 7.4 1/4 IOmM
PK11195
10
1.16 NR rat kidney 50mm Tris HCl 7.4 1/4 IpM
PK11195
11
5 .2 268 rabbit bladder lOmM Tris HCl 7.5 2/4 10/aM
PK11195
12
0 .74
1.01
20.1
18.3
rat hippo.
cortex
50mM Tris HCl, 
120mM NaCl
7.4 1/25 l^iM
PK11195
13
NR NR rat stiatum 50mM Tris HCl, 
120mM NaCl
7.4 2/4 IpM
PK11195
14
0.58 445 mouse fore
brain
50mM Tris HCl 7.8 1.5/4 1 0  ( M  
PK11195
15
7 14500 human lympo 50mM Tris HCl 7.4 1/4 lOgM
PK11195
16
1.71
15.2
6345
13575
rat
human
prost. 50mM Tris HCl 7.4 2/4 lOjuM
PK11194
17
NR NR rat hippo.
cortex
striatum
O.IM PH,PO„ O.IM 
NaCl.
7 .4 1.5/4 lOOjuM
Diaz.
18/
19
7.35 693 rat hippo. 50mM Tris HCl 7.8 1/4 lOjuM
PK11195
20
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Abbreviations: AIC: assay incubation conditions, BCC: blood cell culture, BSA: bovine 
serum albumin, CL: cold ligand, Diaz.: diazepam, hippo.: hippocampus, lympo.: 
lymphocytes, NR.: not reported, O.Bulb: olfactory bulb, PBS: phosphate buffered saline, 
PPB: potassium phosphate buffer, prost. : prostrate, ref: references, sue: sucrose. 
References 1 Poignet et a l , 1992; 2 Canat et a l , 1993; 3 A wad & Gavish, 1991 ; 4 Awad 
& Gavaish, 1987; 5 Doble et a l ,  1985; 6 Doble et a l ,  1987; 7 Benavides et a l ,  1983; 
8 Basile et a l ,  1986; 9 Lueddens & Skolnick, 1987; 10 Skowronski et a l ,  1987; 11 
Skowronski et a l ,  1988; 12 S myth et a l ,  1994; 13 Demerlé-Pallardy et a l ,  1991; 14 
Benavides et a l , 1987; Eshlemen & Murray, 1989; 16 Ferrarese et a l , 1990; 17 Camins 
et a l ,  1994; 18 Baldwin et a l ,  1993a; 19 Baldwin et a l ,  1993c; 20 MacGregor, this 
thesis.
Whilst the differences between the reported here and in other reports can be 
due to species/strain variation and possible underlying infections, the difference in Kg is 
harder to explain away. Possible explanations are differences in the incubation temperature 
and time, type and concentration o f cold ligand, the composition o f the buffer itself and 
the cell type examined (see table 5 .1). In the present study the differences were not 
considered important as the receptor was used as a marker and was not o f interest itself.
The elevation in B„,ax indicates that there may be an increase in glia and conversely 
a loss o f neurones but, without any histology it would be impossible to validate that. 
However the histology experiments also show a loss o f neurones in the hippocampus 
following the kainate injection, and the areas o f damage are consistent with previous 
reports (Schwob et a l ,  1980; Fuller & Olney, 1981; Lothman & Collins, 1981; Fariello 
e t a l ,  1989).
In the present study histology was performed in conjuction with Professor 
D .I. Graham, Department of Neuropathology and Doctor W. Maxwell, Department of 
Anatomy, The University o f  Glasgow. In this study, described in appendix 1, the areas 
of damage caused by the ip administration o f lOmg.kg"^ kainate agreed with reports 
elsewhere in the literature (e.g. Lothman & Collins, 1981; Heggli et a l ,  1981; Sperk et 
a l ,  1983), with the hippocampal C A l and CA3 pyramidal cell layers extensively
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damaged, widespread damage in the entorhinal cortex, with the entorhinal fissure devoid 
o f cells, as well as damage to the midline thalamus and the amygdala.
5 .1 .3  Use o f Clonazepam.
In the present study clonazepam, at low doses, did not significantly protect against 
kainate induced damage measured in the hippocampus, but did abolish the tonic-clonic 
limbic seizures and reduced the frequency o f the mild seizure-like activity such as tremor 
as reported by several other studies (Heggli et al, 1981; Lothman & Collins, 1981; Braun 
& Feed, 1990). There was no apparent effect on wet dog shakes or other behavioural 
effects o f kainate suggesting that these may be initiated in a non-limbic locus by a 
mechanism independent o f seizure activity. At the higher dose used (1 mg.kg'^ 
clonazepam) there was marked sedation but still a significant increase in pH] PK11195 
binding with kainate, a result consistent with the interpretation o f Heggli et al (1981) that 
the degree o f seizure activity did not correspond to neuronal damage following 12 mg.kg"  ^
kainate. Conversely Lerner-Natoli e ta l  (1991) reported that N-[l-(2-Thienyl)cyclohexyl]- 
piperidine (TCP) was able to block kainate damage, but was unable to block the induced 
seizures. One possible explanation for the TCP block is that kainate is mediating its 
neurotoxic but not its convulsive action through glutamate and hence NM DA receptor 
activation (see later for a full discusion o f this).
Several groups have reported that only certain anticonvulsants protect against 
kainate damage (Zaczek et al, 1978; Fuller & Olney, 1981; Voll & Auer, 1991). 
Benzodiazepines seem unable to prevent kainate damage in the hippocampus (Ben-Ari et 
a l ,  1979, Heggli & Malthe-Sorenssen, 1982) and Koh & Choi (1987) found that 
diazepam or phenobarbitone were not neuroprotective against glutamate neurotoxicity in
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cell culture. This separation o f convulsions and neuronal damage contradicts the popular 
view that seizures are needed for the damage (Fuller & Olney, 1981; Lothman & Collins, 
1981; O’Shaughnessy & Gerber, 1986). One possible explanation for the difference in 
effect o f anticonvulsants may depend on the experimental technique. Several groups have 
used high doses o f anticonvulsants in the presence o f anaesthetics, which themselves have 
been reported to alter the release o f amino acids (Kendall & Minchin, 1982; Richards, 
1983; Carla & Moroni, 1992). These alterations may enhance the action o f  
anticonvulsants. Since the present study is based on the change in a glial marker, another 
possible explanation is that there is an increase either o f or with no actual 
neuronal loss. This technique also means that no information could be drawn on the 
development of damage in different CA areas o f the hippocampus. However parallel 
histological studies support the conclusions presented here and indicate that there is still 
widespread necrosis in the hippocampus 7 days following 10 mg.kg"' kainate with 0.2  
mg.kg'' clonazepam ip (see appendix 1).
As mentioned in the previous section histology was performed in collaboration with 
several departments and the effect o f 0.2mg.kg"' clonazepam was examined by blind 
analysis. Of the 11 kainate injected animals 2 received 0.2m g.kg ' clonazepam and the 
others received saline, and there was no observable qualitative difference between these 
two groups (see Appendix 1).
5 .1 .4  Behavioural Studies
The behavioural scores were initially based on those used by Hoffman et al. 
(1991), scoring for consciousness, grip, limb tone, walking and pain reflex. This was 
repeated 2hr later and on the day o f death. This score was discarded as its emphasis is on
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motor control, which is not affected by kainate lesioning, and because o f the stress 
involved in handling the animals. The replacement method involved simple observation 
without handling o f the animals every hour after kainate injection. Animals were examined 
for the presence o f wet dog shakes, seizures and seizure-like activity, fore-paw abduction, 
excessive salivation, Straub tail, head weaving and circling. No scoring was used in this 
test but the presence or absence o f  these behavioural disturbances was noted.
The behavioural disturbances induced by kainate can be classified into 3 groups; 
seizures and fits, wet dog shakes, and salivation - fore paw abduction - Straub tail - 
circling. The use o f clonazepam may indicate that the seizure like activity is due to 
inactivation o f the central benzodiazepine binding sites, and hence, by inference the 
GABA^ receptors. Inhibition o f the GABAergic system by kainate has been recently 
reported (Miligram et al. 1992). The wet dog shakes (WDS) behavioural disturbance has 
been attributed to serotonin receptor activation (specifically the 5 HT2 receptor), a proposal 
made by Worms et al. (1981). There are reports that ketanserin (5 HT2 antagonist) is able 
to reduce the infarction size, in both the middle cerebral artery occlusion model (Prehn 
et al . , 1993), and transient bilateral carotid occlusion model (Klish & Bode-Greuel, 1992), 
although Baldwin et al. (1993b) failed to get neuroprotection with ritan serin in the 
photochemical model o f focal ischaemia. There is also evidence that 5 HT2 receptors also 
inhibit glutamate transmission in the in vitro cerebellar slice preparation (Thellung et al . ,
1993). The implications for serotonergic modulation in the present model remain to be 
examined and determined, although Velisek et al . , (1994) reported that ritanserin (5HT2 
antagonist) failed to suppress kainate induced WDS in developing rats. The third group 
o f behavioural disturbances also indicate a serotonergic involvement since these comprise 
the serotonergic behaviour syndrome which can be mimicked by 5HTja agonists. As
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indicated previously, the involvement o f the serotonergic pathway in kainate induced 
behavioural disturbances and toxicity has not been fully examined and work is underway 
to evaluate the importance o f these behavioural disturbances in kainate induced 
neurotoxicity.
To determine whether there is any loss or impairment o f memory and cognitive 
function in the kainate model and what, if  any, effect neuroprotective agents have on any 
impairment, complex studies need to be initiated. The most widely used is the Morris 
water maze, (Morris et a l ,  1986; Rogers & Tilson, 1990) which examines spatial 
memory. This model allows for the manipulation o f both the learning and retrieval 
mechanisms, in that NM DA antagonists block learning but not retrieval. This technique 
was unavailable during the course o f the study, but further work should be performed in 
conjunction with both behavioural and learning models.
5 .2 Neurotoxicity.
5.2 .1  Glutamate and Kainate Mediated Toxicity.
Intraperitoneally administered kainic acid causes an early increase in local cerebral 
glucose utilisation, increased neuronal firing, transient permeabilisation o f the blood brain 
barrier and tonic seizures, with associated behavioural disturbances (see Heggli et al, 
1981; Lothman & Collins, 1981). During this stage there is a transient increase in 
extracellular glutamate, similar to that seen in ischaemia, probably caused by activation 
o f presynaptic receptors (Ferkany e? 1982; Benveniste er a/, 1984; Globus et at, 1988, 
1990, 1991). The released glutamate acts on receptors located both on neurones and glia, 
(Ferkany et al, 1982; Ferkany & Coyle, 1983a,b) to cause the further release of  
neuroactive substances and depolarisation o f the postsynaptic membrane through NMDA
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and non-NMDA receptors (Choi, 1988; Choi & Rothman, 1990). Overstimulation o f the 
NM DA receptor is thought to be a critical step in the initiation o f excitotoxicity (Butcher 
et al, 1990; Globus et al, 1990) and several groups have shown that NM DA antagonists 
can block kainate evoked neurotoxicity (Fariello et ah,  1989; Lerner-Natoli et ah 1991; 
W olf et a h , 1991). The pattern o f cell damage which results from this sequence has been 
detailed in histological work by several groups (Schwob et al, 1980; Heggli et al, 1981; 
Lothman & Collins 1981; Altar & Baudry, 1990).
Kainate causes the release o f radiolabelled and endogenous excitatory amino acids 
from intact neurones or synaptosomes (Ferkany et a h , 1982; Ferkany & Coyle, 1983a,b; 
Notman et ah,  1984; Gallo & Levi, 1986; Hamberger et ah,  1986; Roberts, 1986; 
Connick, 1987) an effeet which may contribute substantially to its excitotoxic properties 
(McGeer et ah,  1978). As well as the release o f amino acids, ischaemia causes an 
increase in extracellular purines (Berne et a l . , 1974; Winn et a h , 1979; Zetterstrom et a h , 
1982; van Wylen et ah,  1986; Hagberg et ah,  1987; Phillis et ah,  1987, 1988, 1989; 
Andine et a h , 1990; Phillis et a h , 1991). Hoehn & White (1990a) reported that elevation 
in extracelluar adenosine originated from two sources, receptor mediated release of 
adenosine and a calcium independent release o f nucleotides that are broken down to 
adenosine. The calcium independent release appears to be dependent on glutamate uptake 
and may be from glial cells. Although this nucleotide component o f  the total releasable 
adenosine is small ( —10%) it is probably more sensitive to ischaemia than the receptor 
mediated release, in that the high affinity glutamate uptake systems are down regulated 
by high extraeellular glutamate concentrations (Silverstein et a h , 1986; Hu et ah,  1991). 
If, as it seems, there is a reduction in the glutamate uptake during a period of 
neurotoxicity and there is also a reduction in the adenosine release, then the control o f
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excitatory amino acid release w ill decrease and the neuronal damage increase accordingly.
However there is a reeent report (Andersen et a l . , 1993) that raises doubts over 
the importance o f the high affinity glutamate uptake (HAGU) system in attenuating any 
glutamate induced damage, as it was found that the HAGU system was upregulated in the 
rat common carotid artery occlusion model used. Again, if  this is the case, this highlights 
the problem of neurotoxicity, in that there are several models for focal ischaemia, several 
different ones for global ischaemia, and more pharmacological methods o f causing 
damage, and direct comparison between models should be performed with a high degree 
of caution (see section 5 .2 .2).
It is possible, however, that any drug, or combination o f drugs, that restores 
control o f excitatory amino acid release will possess a neuroprotective component.
5 .2 .2  Global versus Focal ischaemia.
Although both global ischaemia (GI) and focal ischaemia (FI) result in neuronal 
death in a calcium dependent manner there is some debate over the differing roles o f the 
NM DA receptor in these two cases. Both scenarios involve a substantial elevation in the 
extracellular glutamate concentration. The site o f action o f this glutamate is debated in the 
GI models. The general consensus is that there is non-NMDA receptor activation, and that 
non-NMDA antagonists (e.g. GYKI 52466 and NBQX) are neuroprotective (Sheardown 
et al.,  1990; Buchan et al., 1991; Judge et al., 1991; Diemer et al., 1992; Le Peillet et 
al.,  1992; Phillis et a l ,  1993; Pulsinelli et a l ,  1993; Sheardown et a l ,  1993). However 
it is the NM DA receptor involvement that is uncertain with several reports that find that 
MK801 is ineffective in severe GI models (4 vessel occlusion (4VO) or bilateral carotid 
artery occlusion (BCAO)) (Buchan & Pulsinelli, 1990; Diemer et a l ,  1993; Pulsinelli et
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al . , 1993; Sheardown et a l . , 1993), but Lin et al . , 1993 found some effect in a less severe 
form o f the 4VO GI model.
There are several reports that in the common carotid artery occlusion GI model 
MK801 is effective at doses compareable to FI models, (Lawerence et a l ,  1987; Gill et 
a l ,  1988; Kato et a l ,  1990), although Corbett et a l ,  (1990), Buchan et a l ,  (1991b) and 
Yao et a l ,  (1993) failed to obtain significant neuroprotection. As well as MK801, the 
GABAergic agent CMZ is also able to distinguish between GI and FI models (Cross et 
a l ,  1991).
A possible explaination for the differing actions o f the NM DA receptors in the GI 
and FI models probably involves extracelular acidosis. In the GI model the CSF becomes 
acidic (p h < 7 ) and there are reports that the NM DA receptor is desensitised by H +  ions 
(Morad et a l ,  1988; Gifford et a l ,  1990; Tombaugh & Sapolsky, 1990) and this may 
explain the differences. If this is the case, this would suggest that for GI cases (i.e. 
cardiac arrest) non-NMDA receptor antagonists are more beneficial than NM DA receptor 
antagonists (Fleischer et a l ,  1989; Buchan et al., 1991a; Pulsinelli et a l ,  1993; 
Sheardown et al., 1993).
5.3 Kainie Acid Induced Glutamate Release
5.3 .1  Endogenous Release Experiments.
In the present system 50mM KCl was unable to release detectable amounts o f  
exeitatory amino acids from hippocampal slices, a finding that is at odds with previous 
reports that endogenous glutamate is releasable from preparations prepared from various 
brain regions (Ferkany e t a l ,  1982; Collins et al., 1983; Ferkany & Coyle, 1983a, 1983b; 
Nicholls et al., 1987; Sanchez-Prieto et al.,  1987; Nadler et al., 1990; Martin et al.,
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1991; Rubio et al., 1991; Palmer et ah,  1992; Raiteri et a l ,  1992; Solyakov et a l ,  
1992). The probable reason for this discrepancy is that the HPLC detector used in the 
present study was not sensitive enough to measure the small amounts released (fmoles). 
A further complication with the system was that the signal;noise ratio was such that there 
was little reproducibility in the peak area o f the standards below lOpmoles (amount 
injected into the HPLC column). These problems prompted the use o f pH] glutamate 
instead o f endogenous glutamate, even though there were reports in the literature that 
events controlling exogenous transmitter release may be different from those controlling 
endogenous release (Ferkany & Coyle 1983a,b. Palmer et a l ,  1992; Solyakov et al., 
1992).
5 .3 .2  Ph i  Glutamate Release Experiments
As mentioned in an earlier section (5.2. Kainate toxicity), kainate causes glutamate 
release (both endogenous and tritiated) from in vivo hippocampal preparations (Ferkany 
& Coyle 1983a,b; Roberts, 1986; Connick; Palmer et al. 1992). Using a method that was 
modified from Ferkany & Coyle, (1983a), Connick (1987) and Palmer et al. (1992) it was 
possible to cause the release o f pH] from hippocampal slices in a dose dependent manner. 
However, there was no significant attenuation o f the release caused by 5^M 2CA. This 
does not mean though that R-PIA is not acting by attenuating the release o f glutamate, as 
only a single concentration o f 2 CA was used, and there was a large degree o f variability, 
between slices from the same animal and also between experiments. Even if  the S2/S1 or 
S3/S2 ratios were used (a method that usually reduces the variability between experiments, 
S. Wonnacott, personal communication) the degree o f variability was still too great. This 
probably suggests that there is either an instrinsic flaw in the method used, or that the
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exogenous transmitter pool is different from that o f the endogenous pool. Indeed there are 
reports in the literature that indicate that there are problems measuring exogenous 
transmitter release (Ferkany & Coyle, 1983a,b) caused by kainate stimulation. It is 
concluded that for a clearer evaluation o f R-PIA action in affecting glutamate release 
endogenous glutamate (and/or aspartate and glycine) should be measured using an 
improved HPLC system. During an ischaemic insult the purines do appear to reduce the 
release o f either glutamate or glycine (Baker et a l ,  1991; Cantor et al, 1992), and it is 
likely that R-PIA also does this in the kainate model.
5.3 .3  Ph i  Glutamate Release: Kainate and Potassium Stimulation.
Using pH] glutamate, instead o f endogenous glutamate, KCl was able to stimulate 
release from hippocampal slices at the same flow rate used in the endogenous studies 
(Iml.min"^), in a manner that suggested dose dependency. As expected the S2/S1 ratio was 
approximately 0.80, with the S3/S1 about 0.60 agreeing with other reports on pH] 
transmitter release (e.g. Chen et a l ,  1992; S. Wonnacott personal communication). The 
findings that KCl is able to stimulate exogenous glutamate release from the hippocampus 
agrees with reports in the literature (Ferkany et a l ,  1982; Ferkany & Coyle, 1983a,b; 
Connick 1987; Palmer et a l ,  1992).
Kainate was also able to stimulate pH] glutamate release from hippocampal slices, 
at both 1 and 5mM (concentrations similar to those used in other reports (Ferkany & 
Coyle, 1983a,b; Roberts, 1986; Coyle, 1987; Gannon & Terrian, 1991; Palmer et a l ,  
1992)), and this was dose dependent (5mM >  ImM). The amount released by 5mM 
kainate was not significantly different from the 50mM KCl stimulation (SI and S2, see 
table 4 .2 .1 .1 ). What was unexpected was that in the 5mM kainate treated slices, the S2
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stimulation appeared to release more transmitter than the SI, with the ratio o f S2/S1 =  
1.38 +  0.44 compared to the KCl S2/S1 ratio o f 0.69 ±  0.55 (50mM) and 0.58 ±  0.12  
(25mM), although this was only significant against the 25mM KCl group. The actual 
release o f S2 was not significantly different from that o f the SI in the 5mM kainate treated 
slices though. The kainate treated slices also displayed a period o f heightened release just 
after S 1 that deviated significantly away from the predicted basal release. The amount of  
glutamate released during this period was dose dependent with the ImM kainate not being 
significantly different from the KCl treated slices, but the 5mM kainate releasing 
significant amounts (greater than 250% SI) compared to either the ImM kainate or the 
50mM KCl treated slices (see sections 4.2.1 and 4 .2 .2). Kainate did not appear to be 
delaying the return to basal levels, which would be seen as a tailing off o f the peak, but 
rather as a decrease after the peak and then a humpback shape that slowly returns to basal, 
in a manner that appears linear. A complication in evaluating this decay o f the hump is 
that S2 usually occurs just after the decay has reached basal. It may have been interesting 
to determine the time course o f this hump, but during the course o f the experiments it was 
not considered important enough to investigate; this may have been an error.
There are several reports that kainate inhibits KCl evoked release o f glutamate 
from synaptosomes (Solyakov et aL,  1992, Barnes & Henley, 1994), although the report 
of Collins et aL, (1983) found that kainate enhances K +  evoked glutamate release from 
rat olfactory cortex. In the present study 5mM kainate did not inhibit 25mM KCl evoked 
glutamate release, although the release pattern (5mM KA/25mM KCl) was similar to KCl 
treated slices and not kainate treated slices (i.e. SI >  82 >  S3, with no SI hump). This was 
unexpected, in that the slice either behaved as a KCl or a kainate treated slice, with the 
KCl effect dominant over the kainate effect, and the total release was similar to 25mM
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KCl and not 5mM kainate.
Neither this potentiation o f kainate evoked glutamate release, nor the period of 
heightened release following SI, appears to have been reported before, with previous 
studies usually only performing a single stimulation (Matsui & Yamamoto, 1975; Ferkany 
e ta l . ,  1982; Coll im e ta l . ,  1983; Ferkany & Coyle, 1983a, 1983b; Sanchez-Prieto a /., 
1987; Palmer et al., 1992; Raiteri et al., 1992; Solyakov et al., 1992). Another 
unexpected finding was that the 50mM KCl S3 stimulation in kainate treated slices was 
sensitive to the concentration o f kainate used to stimulate SI and S2 (5mM >  ImM), with 
the ImM kainate stimulated slices releasing similar amounts to the 50mM KCl stimulated 
slices. Again, this potentiation o f KCl stimulated release has not been reported.
A possible interpretation o f these findings is that kainate may sensitise the slice, 
possibly in a manner analogous to LTP, such that more transmitter is released upon 
following stimulations. Another possible explanation is that the 5mM kainate is 
neurotoxic, even at the brief exposure, and that the slice has been damaged (either 
reversibly or irreversibly). This does not appear to be the case in that the baseline is 
relative stable and does not deviate away from an exponential decay curve. If the slice has 
been sensitised, what are the possible mechanisms o f this process?
Kainate is a known high affinity glutamate uptake blocker, with activity in the 
micromolar range (IC50 302/aM, Johnston et al, 1979) and it is possible that this may be 
one o f the mechanisms by which kainate is sensitising the slice. Evidence in favour o f this 
hypothesis is the period o f heightened release after the first kainate stimulation. This hump 
is dose dependent and the amount released significantly different from the 50mM KCl 
treated slices, as is the shape o f this hump (see figures 4 .2  and 4.4). A possible flaw in
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this argument, though, is that this hump is not seen after S2 in either the ImM or the 
5mM kainate slices. The shape o f the ‘interpeak’ period is similar to the KCl treated 
slices, indicating no period o f heightened release. This disparity between the release after
51 and S2 also argues against an LTP like process, since the S2 would be expected to be 
both larger and longer lasting than the SI, whilst the release profiles suggest that the 
duration o f the S2 peak is o f the same time period as the S 1 peak.
Another possible intrepretation o f the hump is that the kainate (SI) stimulates the 
release o f other agents apart from glutamate that initially heighten release, but also affects 
the synapses in such a way that either there are more kainate receptors available at the 
plasma membrane, and hence kainate is more effective in releasing glutamate, or that 
more glutamate containing synaptic vesicles are available for release. Another potential 
explanation is that kainate caused the release from a slowly replenished pool such that the
52 stimulation is unable to act on this pool as it is depleted. Such a pool could be found 
in the astrocytes, which are known to contain excitatory neuroactive compounds in 
discrete releasable pools (ie the sulphur containing amino acids (Griffiths, 1993) and 
quinolinic acid (Swartz et aL, 1989)). These compounds have been shown to be agonists 
for different types o f glutamate receptors and hence release o f some or all o f these 
compounds may enhance release. Astrocytes have also been shown to release nonvesicular 
glutamate via the reversal o f the reuptake system (Szatkowski et a L , 1990), a process that 
is thought to be the mechanism whereby neurones release glutamate in a calcium 
independent manner (Barrie & Nicholls, 1988; McMahon et aL,  1988; Wilkinson & 
Nicholls, 1988, 1989). This release from the astrocytes was by the reversal o f the 
membrane potential in the in vitro studies, and this may occur by non-NMDA receptor 
stimulation o f the astrocytes in vivo (Glaum et aL, 1990; Stephens et aL, 1993;
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Holzwarth et aL, 1994; see Tiechberg, 1991) as well as by ischaemia, during which there 
is a change in the extracellular concentrations o f several ions including potassium. The 
importance or degree o f astrocytic involvement in the present system remaims to be 
determined.
Another possibility is that the kainate evoked release o f  glutamate is activating 
presynaptic mGluR’s. There are several reports that either direct stimulation o f mGluR 
receptors w ill stimulate release (Tibbs et aL,  1989; Herrero et aL,  199la,b) or that 
arachidonic acid will potentiate mGluR activity, that in turn potentiates AP4 induced 
release (Nichols et aL, 1993, Sanchez-Preisto et aL, 1993). There are reports that 
glutamate causes the release o f archidonic acid (Ueno et aL,  1988; Lazarewicz et aL, 
1990; Lynch & Voss, 1990) and this may be occurring in the present system. The mGluR 
activation may have 2  effects on the slice, firstly to enhance stimulated release (the 
hump), and secondly to alter the synaptic cytoskeletal organisation such that more 
glutamate is available for future release. It may be that the mGluR receptors are 
desensitised/down regulated during the S1:S2 interpeak period and hence unable to 
enhance the release in successive stimulations.
Elevated extracellular potassium is thought to mediate neurotransmitter release by 
generalised depolarisation o f the plasma membranes (both neuronal and non-neuronal). 
This may mean that as well as the excitatory transmitters, the potassium evoked release 
of inhibitory transmitters would antagonise the excitatory agents (causing the hump) 
released upon kainate stimulation. This might explain why slices stimulated with 5mM  
kainate and 25mM KCl behave as KCl stimulated slices and not kainate stimulated slices.
However, before the mechanism o f enhanced release is determined, it is important 
to determine that the enhanced pH] release is glutamate and not glutamine. Glutamate is
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converted to glutamine in astrocytes, which is in turn released into the extracellular space 
to be up taken at the synapses. It is possible, therefore, that the enhanced pH] release is 
just glutamine leakage. Whilst it is possible, the evidence to date does not confirm this 
in that the hump release is greater than SI evoked release (greater than 250% of SI). At 
present the cause o f this hump is not known, or the mechanism whereby kainate enhances 
further stimulations.
5.4 Adenosine
5.4.1 Release
Adenosine is present in both the intracellular and extracellular fluid, although it 
is concentrated intracellularly. Adenosine can be released through calcium dependent and 
calcium independent mechanisms, and there appear to be several possible sources for the 
former. Adenosine itself can be released following neuronal activity (Jhamandas & 
Dumbrille, 1980; Phillis gf A/., 1989; Hoehn & White, 1990a,b; C t i^ n e ta l ,  1992, Sciotti 
et ah,  1993; Ogilvy et ah,  1994), or it could be formed by the breakdown o f released 
ATP, which is present in most types o f neurotransmitter vesicle.
Hoehn & White (1990a) reported that in vitro adenosine is released in a calcium 
independent manner during the reuptake o f glutamate in hippocampal slice preparations, 
and Chen et ah,  (1992) and Ogilvy et al (1994) have shown that stimulation o f either the 
NM DA or the kainate receptors in vivo will result in an elevation o f extracellular 
adenosine. However in the case of ip kainate Ogilvy (personal communication) reported 
that the total elevation is only 35pmol in 4 x 20jlc1 samples (175% control) and this is 
lower than the extracellular elevations o f adenosine reported to occur during and after 
ischaemia (e.g. 2,650% basal, Phillis et ah,  1991). This discrepancy between the
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ischaemic induced and the kainate induced elevations in adenosine ( 1 0 - 2 0  fold) may 
explain the inability o f DPCPX to potentiate kainate induced toxicity (reported here) and 
the findings o f Rudolphi et a l ,  (1987), and Simpson et ah,  (1992) that theophylline 
potentiated ischaemic damage. Lekieffre et al. (1991) reported that inhibition o f  
receptors by theophylline (32mg.kg*^) enhanced glutamate release («200% ), but the 
enhanced release did not affect the degree o f  neuronal damage. The role and mechanism 
o f the adenosine A^  receptor modulating brain damage needs to be further examined.
5 .4 .2  Temperature
It has been known since the 1950’s that patient outcome is improved following 
neurosurgery if  the core body or brain surface temperature is cooled (Lougheed & Kahn, 
1955; Little, 1959; Negrin, 1961; Connolly et al., 1962). Indeed, it has now become a 
standard operating procedure to cool the patient during the operation.
Dietrich et al. (1991) reported that during an ischaemic insult in an animal model 
there is an increase in brain temperature. Prior to this report there had been debate within 
the literature over whether some agents were neuroprotective, in that there appeared to 
be disparity when experiments were repeated by other groups. It now appears that 
protection is affected depending on whether the experiments are performed under 
homeothermic control.
A number of groups have claimed that changes in body temperature can have a 
profound effect upon the extent o f neuronal damage following ischaemia (Welsh et al. , 
1990; Buchan & Pulsinelli, 1990; Freund et aL, 1992; Dietrich, et al., 1993b; see 
Dietrich, 1992; Ginsberg et ah,  1992,1993; for review). Mitani & Kataoka (1991) have 
reported that hypothermia can also significantly reduce the neuronal release o f glutamate
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and aspartate and hyperthermia increases their release. The temperature changes required, 
however, seem to be substantial (4-6°C), and the relevance o f temperature has been 
disputed by others (Welsh & Harris, 1991; Gill & Woodruff, 1990).
Whether or not there is a change in body/brain temperature during excitotoxicity, 
the above mentioned report by Mitani & Kataoka (1991) had to be considered since the 
working hypothesis o f kainate toxicity is based around the release o f glutamate. Synaptic 
transmission in general is affected by hypothermia in that neurotransmitter synthesis is 
inhibited and release and reuptake are decreased due to reduced membrane fluidity 
(Vanhoutteera/., 1981; Boels eta l . ,  1985; Haikalagf a /., 1986; Okuda^^a/., 1986; Graf 
ef al. , 1992). These were not the only considerations, as systemically administered purines 
can induce significant changes in body temperature to the extent that these may contribute, 
for example, to the anticonvulsant properties o f purines (Bowker & Chapman 1986).
The data in the present study indicate that whilst there is a significant, if  transient 
decrease in body temperature of kainate treated rats at 1 hour, this does not correlate to 
the final outcome o f the level o f pH] PK11195 binding. R-PIA does not alter significantly 
the body temperature o f the animal (although it appears to be reducing the kainate indueed 
drop at 1 hour). 8 -PT appears to block the R-PIA action on temperature, but this block 
is not absolute, and the temperature drop is delayed by two hours. When R-PIA is absent, 
8 -PT is unable to significantly alter the body temperature in any way, although there is 
an upward trend, with a non-significant reduction at 1 hour. Whilst there was an 
underlying trend towards a correlation between increasing temperature and increasing 
binding, this is only significant at 5 hours (figure 3.12). The importance o f these findings 
is unclear, with no significant changes o f temperature observed at doses o f R-PIA which 
provided substantial protection, making it unlikely that R-PIA is mediating its action by
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whole body hypothermia in the present study. It should be noted though that there could 
have been small changes in the brain temperature caused by R-PIA which would not have 
been observed by measuring the rectal temperature. To examine whether there had been 
any change in brain temperature an implanted thermometer would have been required, and 
this would have entailed surgery and a major altering of the experimental protocol. For 
this reason, brain temperature was not examined.
A report by Liu et al. (1993) was published after completion o f the temperature 
experiments which indicated that the kainate model o f toxicity was also highly sensitive 
to changes in body temperature in that hypothermia o f 8 °C, to 28'*C resulted in a 50% 
reduction in seizure duration and reduced neuronal loss in the hippocampal C A l and CA3 
layers in 12mg.kg‘^  kainate treated rats. The 6 mg.kg"  ^ kainate treatment resulted in a low  
seizure incidence rate without neurotoxieity. If the rats were treated with 6 mg.kg"  ^ kainate 
and hyperthermia was induced (b^ ’C to 42‘’C) this dose resulted in elevated seizure activity 
as measured by EEG and damage comparable to that induced by 12mg.kg'^ kainate in the 
hippocampus. In none o f the animals in the study in the present report was there any large 
change comparable to those reported by Liu et al., (1993) and so the relevance to the 
present study is still to be determined.
As the current hypothesis concerning ischaemic, or neurotoxin, induced neuronal 
loss is based on the observation that during a neurotoxic insult there is a period o f  
elevated extracellular glutamate concentration, the report by Mitani & Kataoka (1991) 
indicates the problems in comparing the effects o f neuroprotective agents in temperature 
regulated and unregulated experiments. Indeed, it is being suggested that attempts to 
prevent changes in brain temperature will impair the actual neurotoxic mechanisms that 
are being studied, hence nullifying the observations, and should not be performed.
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5.4 .3  Mechanism of Purine Action
5.4 .3 .1  Systemic Application o f A  ^ Agonists.
Adenosine or its more stable analogues have been shown to reduce neurotoxicity 
when co-administered into the hippocampus or striatum (Arvin et a l ,  1989; Connick & 
Stone, 1989; Finn et al.,  1991). When PIA was administered peripherally by Conniek & 
Stone (1989) there was a potentiation o f quinolinic acid induced damage, but this was 
thought to be due to hypotension, as it was possible to mimic this ‘toxicity’ with ganglion 
blockers. Roussel et al. (1991) reported that R-PIA did not protect against focal cerebral 
ischaemia induced by main carotid artery occlusion in spontaneous hypertensive rats 
(SHR). However, there are several differences in the pathological consequences in focal 
cerebral ischaemia between SHR and normal rats including a larger area o f damage in 
SHR as well as a reduced effect o f R-PIA on blood pressure. There are, however, reports 
that cyclohexyl-adenosine or the adenosine precursor 5-aminoimidazole-4-carboxamide 
riboside (AICAR) can reduce the degree o f neuronal damage following periods o f cerebral 
ischaemia (von Lubowitz et al., 1989; Clough-Helfman & Phillis, 1990; Forlon et al.,
1994), or enhance extracellular adenosine levels (White, 1994), findings which prompted 
the present study to reinvestigate the effects o f a systemically administered purine upon 
neuronal damage. The results reveal that R-PIA was able to protect substantially against 
the kainate induced damage, at a single administration of 1 0 /xg.kg'^, and that 25jwg.kg‘  ^
was able to protect when administered at any time 2 hour before to 2  hours after kainate 
administration. At a higher dose o f Img.kg'^ in combination with kainate, all treated 
animals died. An intermediate dose o f lOOjLtg.kg'^  produced neuroprotection that was 
indistinguishable from that o f 25^g.kg"^, but with a 33% fatality rate.
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The reports by Gustafsson and coworkers (Gustafsson et a l . , 1989 and Wiklund 
et al., 1989) indicate that there may be multiple subtypes o f the Adenosine Aj Receptor, 
differing in their K^’s for R-PIA, with what they term A^  ^ being found centrally (K^ 
1.2nM) and A^ y being found peripherally (K^ 17.3nM). It is interesting to note that it was 
the higher dose o f R-PIA that increased the mortality rate associated with the lOmg.kg'^ 
kainate and that the ‘peripheral’ A  ^ Receptor subtype has a higher than that o f the 
‘central’ Aj Receptor subtype. One o f the problems in systemic administration o f 
Adenosine A  ^ agonists, to combat neurotoxic insults, is that activation o f the peripherally 
located A^  receptors produces respiratory and cardiac disturbances that are potentially 
fatal. If both the existence o f two subtypes o f adenosine Aj receptor and the apparent 
neuro-protective action o f adenosine A  ^ agonists are confirmed, then centrally acting 
agonists to the Aj receptor could be a feasible therapeutic tool for combatting some types 
of neuronal damage, although the ‘effective therapeutic window’ might be o f shorter 
duration than is clinically useable (Stanimirovic et al., 1994).
5 .4 .3 .2  Systemic Application o f the A  ^ Agonist. APNEA
Only the Gustafsson group has been able to provide evidence for this 
classification. An alternative explanation for the R-PIA induced toxicity is that it may be 
aetivating the recently cloned A 3 receptor (Zhou et al. 1992). The presence o f an A3 
receptor and the finding that it is highly homologous (80%) with the Aj receptor (Zhou 
et al, 1992) underlies the importance in synthesising an agonist that is specific for Aj 
receptors, that is only centrally active.
This homology between the A^  and A3 receptors indicates that there is the 
likelihood o f agonists/antagonists for the A^  receptor acting on the A3 receptor and vice
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versa. The report by Fozard & Carruthers (1993) that R-PIA is able to activate the A3 
receptor in pithed rats, in conjunction with the observation that R-PIA augments the 
intrinsic kainate mortality rate at the higher doses used, prompted the study of the A3/A 1 
agonist APNEA. As with R-PIA there was a dose-dependent mortality rate, which 
appeared to be due to a marked increase in heart rate. The cause o f this is unclear 
although it is postulated that APNEA could release histamine from mast cells (Hannon & 
Fozard, 1994; Fozard personal communication) which in turn affects heart rate. The 
intermediate dose (Img.kg'^) gave a level o f binding that was not significantly different 
from the kainate group due to the low number o f survivors (2/6 treated). The lower dose 
of 300jLtg.kg'\ however, gave both a small but significant protection and an improved 
survival rate (7/8). As APNEA is able to act on the Aj receptor, and at the time of the 
experiment there was no A3 speeific antagonist, the A^  specific antagonist DPCPX was 
used. Although DPCPX is able to cross the blood brain barrier, and hence would be 
unable to distinguish between peripheral or central receptors, it was chosen in preference 
to the peripherally specific 8 -SPT (see later) as a personal communication indicated that 
8 -SPT was also able to antagonise the A3 receptor (Professor R. A. Olsson, University o f 
South Florida, Tampa USA).
Since the time o f the experiments there have been reports o f A3 agonists and 
antagonists. Compounds with polar C8  substitutions are the most selective, with DPCPX  
being a weaker antagonist (Jacobson et ah,  1994; Fozard and Olsson personal 
communications). However, in the present study the dose of DPCPX used was that o f 
50jLtg.kg“^ , a dose that does not potentiate kainate induced toxicity, but is able to prevent 
R-PIA protection. In this experiment it was found that DPCPX prevented any APNEA  
induced protection, suggesting that the protective action is caused by Aj activation.
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Further work with more specific A 3 agonists/antagonists in the presence or absence o f A^  
receptor activation is required. It may be, through examination o f the literature and with 
new and selective A3 agonists and antagonists, that many of the peripheral actions ascribed 
to the Aj receptor are mediated by the A 3 receptor.
5 .4 .3 .3  Mechanism o f Purine Mediated Protection.
Adenosine is found in nanomolar concentrations extraeellularly in the brain (30- 
300nM, Ballarin et al., 1991; Phillis et al, 1991) although the levels are raised 
substantially by ischaemia and glutamate receptor activation (Phillis et al, 1987; Hoehn 
& White, 1990a,b; Ch&netal,  1992; Dagani etal ,  1992; Ogilvy er <2 /, 1994). Adenosine 
receptors (both A  ^ and A 2) are found on neuronal and non-neuronal cells (Goodman & 
Snyder, 1982; Deckert & Jorgensen, 1988), as well as the vasculature and there are 
numerous reports that activation o f Aj receptors reduces ischaemic or excitotoxic brain 
damage (Arvin et al, 1989; Connick & Stone, 1989; von Lubitz et al, 1989; Alzheimer 
e ta l ,  1991; Finn e ta l ,  1991; Miller & Hsu, 1992; Rudolphi gf (7/, 1992; Simpson etal ,  
1992).
Adenosine may provide protection by several mechanisms, including vasodilatation 
of the central and peripheral vasculature, hyperpolarisation o f neuronal membranes, 
decreased oxygen consumption by decreased neuronal activity, increased glucose uptake, 
increased glycolysis in glia, as well as hypothermia (Nehlig et al, 1988; Miller & Hsu, 
1992; Rudolphi et al, 1992; Tominaga et al, 1992). As there appears to be no significant 
change in rectal temperature following systemic kainate/R-PIA treatment in the presence 
or absence o f 8 -phenyltheophylline, it seems unlikely that in this model hypothermia has 
a significant role.
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The mechanism o f the protection by R-PIA is not clear from this study. Assuming 
the even distribution o f R-PIA around the body, the lowest effective dose o f 10 jug.kg'  ^
would yield a mean tissue concentration o f approximately 24nM. This is close to the low  
Kd values for the Aj receptor (Gustafsson et a l , 1990; Baumgold et  al . , 1992) and would 
be entirely consistent with an action o f R-PIA which involved the selective activation of  
these sites. Baumgold et al (1992) reported that ex vivo binding o f R-PIA in mouse brain 
gave a Kd of 1.5 +  0.2nM  and a o f 398 ±  29fmol.mg protein'^ indicating that the 
R-PIA is able to cross the blood brain barrier and that the affinity of the adenosine Aj 
receptors is such that, at the doses given during the present report, the receptor would be 
activated.
A large proportion o f A^  receptors is believed to be located on the terminals of 
excitatory neurones, including those releasing acetylcholine and glutamate (Goodman & 
Snyder, 1982; Spignoli et al.,  1984; Fastbom & Fredholm, 1985; Dolphin & Prestwich, 
1985). Kainate causes the release o f radiolabelled and endogenous excitatory amino acids 
from intact neurones or synaptosomes (Ferkany et al.,  1982; Notman et al.,  1984; 
Connick & Stone, 1988), an effect which may contribute substantially to its excitotoxic 
properties (McGeer et al.,  1978).
The most likely explanation for the protection by purines is a suppression o f  
glutamate release. The mechanism o f this suppresion is unelear, in that adenosine Aj 
receptors have been shown to both reduce calcium current, by inhibiting activation of 
calcium channels (Schubert et al., 1986) and by increasing potassium current thereby 
hyperpolaring the synaptic terminals, both o f these methods would reduce glutamate 
efflux, and it is possible they are both aetivated at the same time.
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Heron et al (1992) have reported that ip R-PIA (20 jug.kg'^) given 30 minutes 
before and 10 /xg.kg'^ 30 minutes after significantly decreased glutamate release following 
a 20 minute period o f ischaemia. Cantor et al  (1992) reported that Aj agonists also 
significantly reduced the ischaemic release o f glycine in a dose dependent manner. The 
importance o f glycine in potentiating glutamate toxicity has been examined by several 
groups (Lerma et al, 1990; Patel et al, 1990; Wood et al, 1992). Glycine decreases the 
rate o f NM DA receptor desensitisation and the reports by Baker et al, (1991) and Globus 
et al, (1991) indicate that the elevation o f extracellular glycine remains high longer than 
that o f glutamate. The prolonged elevation o f glycine may therefore contribute to the 
delayed neuronal loss reported by other groups (Nakano et al, 1990; Haba et al, 1991). 
It is unelear whether kainate itself causes the release o f glycine.
Another possibility involves the transport o f kainic acid or a derivative across the 
blood brain barrier. It may be that the aetion o f R-PIA is that it is preventing/reducing the 
transport o f the neurotoxic compound into the brain and this action is reversed by the 
antagonist, and this needs to be examined further, although based on the behavioural 
observations this is probably not the case.
Reports by Phillis’ group (O’Regan et al., 1992b; Simpson et al, 1992) indicates 
that the A  ^receptor activation may potentiate neurotoxicity following an ischaemic insult, 
in that the A% agonist CGS21680 and the inhibitor CGS-15943A enhanced and inhibited 
the release o f glutamate elicited by 4VO ischaemia, respeetively. In the present model it 
was not possible to examine whether any A2 active agents affect neurotoxicity due to 
either lack o f specificity (agonists) or their inability to cross the blood brain barrier 
(antagonists) even when there is a good A2 :Ai ratio. Again this is an area that needs to 
be examined in more detail when speeifîc agents become available that can easily traverse
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the blood brain barrier.
5 .4 .3 .4  Purinergic Modulation o f Stimulated Release.
There are several reports in the literature that adenosine Aj agonists are able to 
reduce glutamate release in in vivo or in vitro studies and in ischaemic preparations 
(Corradetti et a l ,  1984; Fastbom & Fredholm, 1985; Burke et a l ,  1988; Arvin et ah,  
1989; Lekieffre et ah,  1991; Heron et ah,  1992; Miller & Hsu, 1992; Simpson et ah,  
1992, Lloyd et ah,  1994). A^  agonists are also able to inhibit the population peaks (PS) 
in hippocampal slices (Bartrup & Stone, 1988, 1990; Lupica et al., 1992, 1994; 
Hosseinzadeh, 1994; Schubert et ah,  1994), with antagonists enhancing the PS.
In the present study 5/LiM 2-chloroadenosine was unable to attenuate either the 
kainate or the 50mM KCl evoked release, even though this concentration would 
completely abolish PS (Hosseinzadeh, 1994, & personal communication). It is possible, 
though, that in the present study the Aj receptors are already fully occupied and active, 
even though the sliees were prepared in the same way as electrophysiological preparations. 
The use o f either an A  ^ antagonist or adenosine deaminase was expected to answer this 
question, and the adenosine A  ^ antagonist DPCPX was chosen in preference to adenosine 
deaminase. In electrophysiologieal studies cyclopentyl-theophylline (CPT) was able to 
potentiate PS size at a dose o f lOOnM (Hossein, personal communication), but as DPCPX  
is 10-20 fold more potent than CPT, a dose o f 5nM was used in the present study. As 
shown in the results section DPCPX was able to attenuate kainate evoked release in one 
group o f experiments (DPCPX washed out after S3) but not in the continuous DPCPX 
perfusion (present in S3 and S4). Given that the S3 of the continuous DPCPX perfusion 
has a large standard error o f the mean (50% of the mean) it may be that the DPCPX
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washout experiments are illustrating the action o f DPCPX on kainate evoked release, but 
this is uncertain and no real conclusion can be raised on the action o f DPCPX on kainate 
evoked release.
The findings that DPCPX significantly attenuated the 50mM KCl S4 stimulation 
in these slices was largely unexpected, in that Simpson et ah,  (1992) found O.lmg.kg'^ 
( «  140nM, intrahippocampally, based on figures reported by Baumgold et ah,  (1992)) 
inhibited ischaemia induced release, and the observations are as yet unexplained. Both the 
DPCPX washout and the DPCPX continuous perfusion experiments had the same effect 
on the S4, and this could be explained by the lipophilic properties o f DPCPX, that would 
allow for DPCPX to be affecting the S4 even if  the perfusion o f DPCPX had stopped. 
Why is DPCPX inhibiting glutamate release when all the evidence suggested that it should 
be enhancing the release? Although there is no clear answer, it may be the interneurones 
that provide clues. Henry finds that (J.L. Henry, personal communication) hippocampal 
interneurones are inhibited by adenosine A^  agonists. As most o f the interneurones in the 
hippocampus are inhibitory, then the antagonism of the Aj inhibition o f the inhibitory 
neurones would result in a net increase in inhibitory transmitter release. Even though there 
are presynaptic A^  receptors on excitatory neurones the disinhibition o f the inhibitory 
system may result in a net inhibitory action o f DPCPX provided the initial stimulus is 
submaximal. This is all conjecture, and the DPCPX effect may be an experimental artifact 
specific to exogenous transmitter release. Adenosine inhibits K^-evoked potassium release 
of G ABA from cerebral cortex slices (Hollins & Stone, 1980) but not from the C A l 
region o f the hippocampus (Burke & Nadler, 1988), and during ischemia in the cerebral 
cortex (O’Regan et ah,  1992a). To clarify the effect more experiments are required, 
studying the action o f DPCPX, over a concentration range against different types o f
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stimulus, on endogenous transmitter release. The study o f endogenous transmitter release 
would answer the question o f disinhibition o f the inhibitory system since DPCPX would 
be expeeted to enhance GABA release. Another possible explanation is suggested by 
O’Regan et a l ,  (1992) and Simpson et al.,  (1992), in that there might be an A 2 mediated
component to glutamate release and that DPCPX is affecting that. Use o f specific A2
agonists may clarify the situation.
In conclusion high KCl and kainate are able to release pH] glutamate in a 
concentration dependent manner. However the pattern o f release differs between the two 
stimuli, with kainate enhancing pH] glutamate release by an unknown mechanism, and 
this effect is not seen in slices treated with either a KCl stimulation or a kainate/KCl 
stimulation. More work is required to elarify the mechanism o f enhanced release, and also 
the paradox obtained when slices were perfused with DPCPX.
5 .4 .3 .5  Time Course o f R-PIA Protection.
When adenosine A  ^ agonists have been used to protect against ischaemic damage 
they have been almost invariably administered prior to the onset o f ischaemia (von Lubitz 
et al, 1989; Cantor et al, 1992; Simpson et al, 1992; see Rudolphi et al, 1992 for 
review). In the present work the effective window o f protection was found to span 4 hours 
(-2 to +2h). Protection obtained by R-PIA administration before kainate is probably due 
to the lipophilic properties o f the purine and its persistence in the brain. The protection 
within the first hour after kainate injection is probably due to the reduction in glutamate 
and glycine efflux reported by other groups (Cantor et al, 1992; Heron et al, 1992). The 
time course o f kainate penetration into the CNS and o f induced glutamate release has not 
been reported, but is probably quite rapid in view o f the fact that wet dog shakes are seen
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in all animals within 40 minutes o f systemic administration (Lothman & Collins, 1981), 
Seizure activity has a longer onset period than wet dog shakes (Heggli et al, 1981; 
Lothman & Collins, 1981) and thus may require higher intracranial kainate concentrations. 
When kainate lOmg.kg"^ is injected ip into anaesthetized rats there was a significant 
increase in intrahippocampal adenosine release as assessed by microdialysis (H. V. Ogilvy 
personal communication). This increase in adenosine occurred in the 2”*^ 20 minute 
fraction after kainate injection and lasted for a further 3 fractions, although none o f the 
individual fractions were significant. The shape o f the adenosine release resembled a bell 
shaped profile rather than the sharper profiles obtained by intrahippocampal kainate, 
indicating that the kainate was still exerting its effect for about 80 minutes after the 
injection. However, as these animals were anaesthetized with urethane, it is difficult to 
make a direct comparison with conscious animals.
5 .4 .3 . 6  Xanthine Blockade.
The protective effect o f R-PIA appears to be mediated by a conventional xanthine 
sensitive PI purine receptor (Burnstoek, 1978; Stone & Simmonds, 1991) since protection 
was fully prevented by co-administration o f 8 -phenyltheophylline. Indeed there was an 
apparent tendency towards an increase in damage in the presence o f this xanthine, though 
the effect was not large and was not statistically significant. This tendency might 
nevertheless indicate some blockade o f an endogenous adenosine mediated neuroprotective 
tone, and would be consistent with the finding that theophylline itself inereases the amount 
of neuronal damage following cerebral ischaemia (Rudolphi et a l ,  1987).
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5 .4 .3 .7  Central Versus Peripheral Blockade o f Adenosine Receptors.
DPCPX is a highly selective Aj antagonist (Bruns et al, 1987) which has low  
nanomolar affinity for the receptor (Kj =0.46nM ). A recent report by Baumgold et al, 
(1992) indicates that it can cross the blood-brain barrier. A dose o f 250 /xg.kg'^ DPCPX  
would be similar to an intracranial concentration o f 0.34^M  as calculated by Baumgold 
et al, (1992), and should completely block all A^  receptors with a degree o f A% blockade 
as well. At this dose as well as at the lower dose of 50jug.kg‘  ^ here, which should block 
the Al sites only, the present results demonstrate a complete inhibition o f the 
neuroprotection produced by R-PIA. This would be entirely consistent with the role o f Aj 
receptors in mediating inhibition o f endogenous amino acid release.
8 -SPT was administered to determine the importance o f peripheral vasodilatation 
on the neuroprotective effect o f R-PIA, since 8 -SPT cannot readily cross the blood-brain 
barrier: Baumgold et al.,  (1992) reported that there was less than 5% penetration into the 
brain after the administration o f 50mg.kg'k In the present work there was no effect o f 8 - 
SPT on pH] PK11195 binding when administered in the absence o f kainate and this dose 
was unable to block the R-PIA protection.
When 8 -SPT was administered with kainate and clonazepam the elevation in pH] 
PK11195 binding was highly significant when compared to the kainate and clonazepam 
group. One possible explanation for this could be that 8 -SPT is causing vasoconstriction 
which decreases the blood flow to the brain and increases neuronal metabolic stress and 
cell damage. An alternative explanation might be that as kainate causes a transient 
permeabilisation o f the BBB (Zucker et al, 1983; Saija et al, 1992) this permeabilisation 
would allow the 8 -SPT to cross the BBB and enhance the neurotoxicity in a manner 
similar to that reported by Rudolphi et al, (1987) for theophylline and DPCPX reported
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here. The main difficulty with such an explanation is that it does not explain why 8 -SPT 
did not prevent the protection by R-PIA. Therefore it is suggested that 8 -SPT does not 
penetrate into the CNS, but that it is a blockade o f vascular adenosine receptors, leading 
to a degree o f vasoconstriction, which enhances kainate toxicity. Such a possibility would 
be consistent with previous indications that any fall in blood pressure, and thus cerebral 
perfusion can potentiate excitotoxicity (Connick & Stone, 1989). Since neuronal 
depolarisation by kainate would result in the release o f adenosine locally, the greatest 
influence o f 8 -SPT would be expected to be in areas most susceptible to the toxin. There 
may also be some potentiation o f damage due to the increased brain reperfusion as the 
8 -SPT blockade o f adenosine receptors decays. Such reperfusion damage may be due to 
the formation of free radicals (see later).
The idea that peripheral blockade may be potentiating toxicity gains further support 
when the degree of damage caused by kainate and adenosine antagonists are expressed as 
a percentage o f the same day kainate binding (figure 3.17). In this case 250jug.kg’^  
DPCPX, Img.kg'^ 8 -PT and 20mg.kg"^ 8 -SPT all give similar degrees o f damage 
(approximately 150% kainate binding). As the DPCPX response is only seen at the highest 
dose, it may suggest that this is a non A^  response and may be due to blockade o f either 
the A 2 or A3 receptors. 8 -PT also has some A% action at the dose used in the present 
study, and the reports in the literature indicate that the A 3 receptor is sensitive to 8 -SPT 
blockade. All this indicates that blockade o f peripheral adenosine receptors (probably not 
the Aj subtype) potentiate damage caused by kainate. However, the finding that the 
blockade o f the R-PIA response by DPCPX is dose dependent raises the question o f 
whether adenosine is an endogenous neuroprotectant, as doses o f DPCPX that block the 
R-PIA responses should also potentiate toxicity and this dose not appear to be the case.
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A possible answer for this is that although kainate does stimulate the release of adenosine 
in the hippocampus (Ogilvy et aL, 1994), the levels achieved are insufficient to provide 
significant protection. Another point that should be borne in mind is that the half-life of 
R-PIA is probably far greater than that o f adenosine in the synaptic gap, and hence the 
‘pharmacological window’ is far greater than that o f adenosine. This may mean that whilst 
activation of central A^  receptors provides neuroprotection, blockade o f these receptors 
does not potentiate damage and the converse is true for the peripheral receptors.
5 .4 .3 . 8  Conclusions from the Purine Experiments.
In summary the present results indicate that the neuroprotective action of 
systemically administered R-PIA is via a centrally located A  ^ receptor with little or no 
contribution from the A2 or systemic Aj receptors at the microgram doses used in the 
present study. The finding that single low doses of R-PIA are neuroprotective up to 2 
hours prior to or following cerebral insult may suggest the use o f selective, lipid-soluble 
Ai agonists to be used prophylactically or post-ischaemically as they do not affect the 
basal release o f either the excitatory amino acids or glycine (Cantor et al, 1992). Although 
high doses of APNEA (A3 agonist) are able to provide a degree o f neuroprotection this 
appears to be acting via the A  ^ receptor as well.
5 .5 Other Possible Neuroprotective Drugs.
It appears that there are several possible sites o f action, whereby drugs can either 
reduce or abolish the damage caused by overstimulation o f the glutamatergic system. 
Possible pharmacological targets for therapeutic manipulation that have already been 
investigated include the NMD A receptor antagonists, calcium channel blockers, GABA^
1 6 2
agonists, GABAg antagonists and free radical scavengers. There is increasing interest in 
the role o f both dopaminergic and serotonergic pathways during periods o f ischaemia, and 
whilst these areas will also be discussed, it will not be to the same degree as the 
aforementioned targets.
5 .5 .1  NM DA Antagonists.
The release o f glutamate by kainate is considered to be the essential element in the 
current mechanism o f kainate toxicity. Analogy with the ischaemic studies indicates that 
it is the high extracellular glutamate that causes neurotoxicity, and that this glutamate is 
mediating its toxicity through the activation o f NMDA receptors (see Introduction - 
Neurotoxicity). Previous studies have shown that the blockade o f the NMDA receptor 
channels will reduce/abolish the ischaemic damage, but that these drugs tend to possess 
a relatively short (<5hours) duration therapeutic window (Choi & Rothman, 1990; 
McDonald & Nowak 1990; McCulloch, 1991). Several reports (Clifford et ah,  1990; 
W olf et a l ,  1991) have implied that systemically applied kainate induced toxicity can be 
blocked by noncompetitive NM DA antagonists (MK801 and MgSO^.VH^O respectively), 
indicating an NM DA receptor involvement, although kainate itself is not able to act 
directly upon NM DA receptors (Stone et al., 1981; Watkins & Evans, 1981).
Using the pH] PK l 1195 assay to evaluate the degree o f involvement o f the NMDA  
receptor in the mechanism of kainate induced toxicity, 3 different classes o f  
synthetic/exogenous NM DA antagonists were used (CPP - competitive, MK801 - 
noncompetitive, and MgSO^.VHgO - channel blocker). As predicted all these agents were 
neuroprotective, and as CPP is highly specific for the NMDA receptor, this supported the 
earlier findings that there is an NM DA component to kainate toxicity. What was not
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expected was that at the highest doses tested they all afforded virtually complete 
protection.
Moncada et a l ,  (1991) reported that the competitive NM DA antagonist, CPPene, 
was effective against centrally administered kainate. This report together with those o f  
Fariello et a l  (1989), Clifford et a l  (1990) and W olf et a l  (1991) would suggest that 
both routes result in the overstimulation o f the NM DA receptor, and, by analogy with the 
ischaemic models, would mean that the kainate model is an alternate model for ischaemic 
study.
The reports by Bartrup & Stone (1988, 1990) indicate that adenosine binding to 
the Ai receptor requires magnesium, whilst Lloyd et a l  (1989) found that the effect of  
2CA on neonatal rat spinal cord was magnesium sensitive. If this is true in vivo as well 
as in vitro then there may be an Ai component to the MgS0 4 .7 H2 0  protection as well as 
just the known NM DA receptor blockade. Further work would be required to determine 
whether this is the case.
5 .5 .2  Tryptophan Metabolism.
Various groups have reported that products from the metabolism of tryptophan 
confer varying degrees o f protection against excitotoxic insult (Germano et al, 1987, 
Lekieffre et al, 1990, Wu et al, 1991). Tryptophan is a starting product for several 
pathways, two o f which are the kynurenine and serotonin pathways. In the kynurenine 
pathway tryptophan is converted to quinolinic acid through several enzymic reactions (see 
figure 5.1). The products o f several o f these reactions are reported to be neuronally 
active, with possible neuromodulatory actions. Kynurenine and kynurenic acid are both 
reported to be antagonists to the glycine modulatory site o f the NM DA receptor (Kessler
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Figure 5.1.
Enzymic pathways o f tryptophan metabolism, and kynurenic acid and quinolinic 
acid synthesis.
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et a l ,  1987; Watson et aL,  1988; Kessler et a l ,  1989), whilst quinolinic acid is an 
agonist at the NM DA receptor (Perkins & Stone, 1985). If the activity o f some o f the 
enzymes were altered then the system might produce an overabundance o f either an 
agonist or antagonist to the NM DA receptor. In the case o f Huntington’s Chorea there is 
a reported increase in the amount o f kynurenic acid in the primary motor cortex (Connick 
et a l ,  1989), although Beal et a l ,  (1990) failed to observe these changes. Reports of 
quinolinic acid concentrations in the brain indicates that there may be no change in HD 
patients (Renoylds et a l ,  1988; Schwarcz et a l ,  1988).
In a recent study Fukui et a l  (1991) determined the rate o f transport of 
kynurenines across the blood brain barrier, and found that only tryptophan and kynurenine 
could cross at useful therapeutic rates. Swartz et al, (1990), showed that ip perfusion o f  
either kynurenine or tryptophan produced a significant increase in extracellular kynurenic 
acid (as assessed by microdialysis and HPLC analysis o f the perfusate). In the case of L- 
kynurenine, there was a 30-40 fold increase in basal levels with lOOmg.kg'^ L-kynurenine 
90-210 minutes after injection. lOOmg.kg'^ L-tryptophan did not produce such a marked 
effect, a 10- fold increase being seen 6  hours after injection. In both cases the increase 
in kynurenic acid could be prevented by aminooxyacetic acid (AO A A), which is known 
to inhibit kynurenine transaminase (which converts kynurenine to kynurenic acid, 
Spéciale et aL, (1990)). AGAA alone can cause lesioning, and this lesioning can be 
prevented by NMDA antagonists (McMaster et al,; 1991, Beal et al,; 1991), suggesting 
that under normal situations the kynurenate/ quinolinate balance is tightly regulated to 
prevent any excessive NM DA receptor activation. Systemic kainate has been reported to 
elevate the hippocampal kynurenic acid, not during the period o f neurotoxicity but after 
1 month, and as there is an invasion o f glia following kainate induced toxicity this has
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been suggested as the cause of the increase o f kynurenic acid (Wu et at., 1991). However 
several reports from Beal’s laboratory (Swartz et aL, 1990; Miller et ah, 1992) indicate 
that administration o f kynurenine and not kynurenic acid will increase intra-striatal 
kynurenic acid concentrations 30-40 fold within 2-3 hours. If the organic acid transport 
inhibitor probenecid is coadministered this increase was almost 600 fold (Miller et al . , 
1992), indicating that the use o f probenecid concentrates kynurenic acid in the 
extracellular fluid.
All of these findings prompted the investigation into whether systemically 
administered tryptophan metabolites would enhance the endogenous kynurenine levels and 
improve neuroprotection. Kynurenic acid was only used in a single pilot experiment, 
based on the dose regime used by Germano et al. (1987). In that report 300mg.kg'^ 
kynurenate was administered at fo and and provided 50% protection against
bilateral carotid artery occlusion. In the present kainate model, though, there was no 
protection afforded, and the reports by Fukai et al, (1990) and Swartz et al., (1990) that 
kynurenate is unable to cross an intact BBB provides a possible explanation for the 
differences. In an ischaemic model the BBB is rendered relatively permeable to blood- 
borne compounds, and although the report by Saija et al, (1992) indicates that kainate also 
causes a permeabilisation of the BBB this is only transient, and so kynurenate is unable 
to traverse it. This conclusion is supported by the observations reported earlier (section 
4 .3 .3 .5 ) that 8 -SPT (another compound that is unable to traverse the BBB) is also unable 
to prevent R-PIA mediated neuroprotection in the kainate model.
The effectiveness o f kynurenine was time dependent, with no protection seen when 
150mg.kg‘^  was administered at t  ^ but there was a dose dependent effect when 
administered at to hours- The tg administration gave significantly reduced levels of binding
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at a dose o f 75mg.kg"^ ie lower than the dose used in the t.4 hours experiment. The finding 
that kynurenine was not neuroprotective when administered at t^ hours was unexpected, as 
reports in the literature indicated that there would be significantly elevated levels in the 
hippocampus by the time kainate would be expected to be acting. A re-evaluation o f the 
1-4 hour experiment in conjunction with intrahippocampal microdialysis in conscious animals 
might provide a possible explanation for this discrepancy.
Tryptophan was only tested at a single dose and time point 200mg.kg'^ at t^ hours, 
and gave no significant neuroprotection, although the sample size was small. Further work 
is required to determine whether tryptophan does afford any neuroprotective activity, as 
the literature indicates, and both time course and dose response experiments need to be 
performed.
The location o f kynurenine transaminase has recently been reported to be vesicular 
but glial, not neuronal, in origin (Roberts et ah,  1992; Du et al., 1993), and also to be 
activated by neuronal signals (Turski et aL, 1989). Kynurenate has been reported to be 
released from this glial pool by glutamate (Wu et aL, 1992), and has led to the term 
‘gliatransmitters’ being used for neuro-active compounds that originate from the non­
neuronal pool. If the glia are releasing kynurenate following glutamate release, this would 
provide an intrinsic antagonist to switch o ff the NMDA receptors. Quinolinate is also 
reported to be released from glia (Spéciale & Schwarcz, 1993) and would provide another 
pool o f NMDA agonist. It may be that quinolinate is the natural agonist for the NM DA  
receptor activation, whilst the AMPA and kainate receptors are activated by glutamate, 
and this method would allow for NM DA receptor activation even during periods o f low  
neuronal stimulation.
Several groups have reported that glia are able to synthesize and release sulphur
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containing amino acids (SAA) (Grandes et aL,  1991; Tschopp et ah,  1992; Zhang & 
Ottersen, 1992, see Cuénod et a l ,  1993), although Griffiths and co-workers (Dunlop & 
Griffiths, 1990; Grieve & Griffith, 1992; Griffith et a l ,  1992) reported that SAA ’s are 
also derived from a neuronal source. There are several different SAA ’s and there are 
reports that they are agonists for different glutamate receptors (Dunlop & Griffiths, 1990; 
Ito et aL,  1991; Provoni et aL, 1991). Griffith’s group (Dunlop & Griffiths, 1990; 
Griffith, 1993), have shown by HPLC analysis that several SAAs are released during 
periods o f neuronal activation, and this, with Klincnik et a L , (1992), supports the earlier 
reports o f Do et al. (1986a,b). The presence o f several different glutamate agonists and 
kynurenate in releaseable pools may allow for further specific activation o f a receptor 
subtype, beyond that seen with the different affinities glutamate has for its receptors.
5 .5 .3  GABAergic Modulation.
During excitotoxicity the balance between the excitatory and inhibitory systems is 
altered, such that inhibitory systems no longer regulate the release o f excitatory 
transmitters (Milgram et aL,  1991). This disinhibition o f the inhibitory systems during 
periods o f excitotoxicity could also be caused by over-stimulation, but in this case 
resulting in decreased inhibitory transmitter released. There are reports in the literature 
(Bliss et aL, 1986; Nadler et al, 1990) that during periods o f high frequency stimulation 
o f the Schaffer Collaterals, axons that run from the CA3 region and synapse on the CAl 
dendrites in the hippocampus, there are both enhanced EPSPs and reduced IPSPs. The 
enhanced EPSPs have been shown to be due to activation o f NM DA receptors while the 
reduced IPSPs are due to presynaptic GABAg receptor activation that reduce the release 
o f G ABA from the inhibitory interneurones (Bliss et al . , 1986; Davies et al . , 1990, 1991;
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see CoUingridge, 1992; Bliss & Collingidge, 1993 for reviews). This pattern will result 
in the formation o f long term potentiation (LTP).
If this is the case in pathological circumstances as well, then drugs that enhance 
the inhibitory system might also prove to be effective neuroprotective agents. One such 
drug that appears to do this is chlormethiazole (CMZ). Although the actual site o f action 
o f this drug is unknown, it does potentiate the action o f G ABA and prolongs the channel 
opening o f the GABA^ receptor (Harrison & Simmonds, 1983, Moody & Skolnick, 1989; 
Cross et aL, 1989). At present this drug has been shown to provide protection at doses 
less than are used in present treatment for alcohol dependency (see Green & Cross, 1994 
for review), and up to 6 hours post ischemia (both FI and GI models) (Cross et aL, 
1991; Baldwin et aL,  1993a; 1994). When the drug was delivered against 
intrahippocampally injected NM DA, a focal ischaemic model, it was found to be less 
effective and have a shorter therapeutic window (Cross et aL,  1991). It was to see 
whether CMZ was effective against a model o f global ischaemia that it was used in the 
present study.
CMZ at lOOmg.kg"  ^ would provide virtually complete protection against MCAO 
induced ischaemia and in the present study also produced the same degree o f  
neuroprotection (see figure 3.28). In the present study, though, there was also a marked 
sedation when administered with lm g.kg“^ clonazepam. Rats are unable to maintain their 
body temperature when sedated and hypothermia is reported to offer a degree of 
neuroprotection (section 5 .4 .2). This means that in the CMZ treated animals some/all of 
the neuroprotection could have been through the reported hypothermic neuroprotective 
mechanism. Further studies need to be performed to see whether this is the case, with 
dose studies at different doses o f clonazepam, as the sedation may have been potentiated
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by the higher dose o f clonazepam, and the temperature monitored. A further study was 
performed using 2 lower doses o f CMZ (30 or 10 mg.kg’ )^ in animals treated with 
0.2mg.kg'^ clonazepam. Again these animals showed a marked sedation, but this lasted 
less than 1 hour, and unlike the higher dose there were also observable behaviour 
disturbances that were similar to those o f the kainate controls. The 30mg.kg"^ dose gave 
approximately 75% protection, whilst the lOmg.kg"^ was close to the estimated ED50 
(10.635m g.kg‘ )^. This ED50 value o f CMZ is lower than that reported by Cross and Green 
(personal communication) of 35mg.kg'^ in an MCAO model.
However, the disinhibition o f the GABAergic system is not only due to stimulation 
of the GABAq receptor but may also be by stimulation o f the adenosine Aj receptor 
(Prof. J. Henry, personal communication). Whilst this action o f adenosine to inhibit the 
release o f G ABA would appear to be contradictory to adenosine’s neuroprotective action 
it might indicate that the GABAergic system has only a transient protective effect (if any) 
and overstimulation would soon render the GABAergic system inoperable (as is seen in 
LTP , see earlier). This does not mean that GABAergic drugs are not potentially 
therapeutically useful against ischaemia, provided long lasting GABAergic agents are 
used, and indeed there are a few reports in the literature o f GABA^ agonists being used 
to reduce ischaemic brain damage (Brailowsky et aL, 1986; Sternau et aL,  1989; Hara 
et a l ,  1991; Lyden & Hedges, 1992; Lyden & Lonzo, 1994).
5 .5 .4  Free Radicals.
It is known that during an ischaemic insult the glutamate is initially released from 
calcium dependent (vesicular) pools, but as the severity o f the insult increases the calcium- 
independent pool (cytoplasmic/astrocytic?) o f glutamate becomes the main source of
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extracellular glutamate (Sandberg et al., 1986; McMahon et al., 1988; Wilkinson & 
Nicholls, 1988; Ikeda et aL, 1989; Wilkinson & Nicholls, 1989; Rubio et aL, 1991, 
Ogata et aL, 1992). In this type o f insult NMDA antagonists are effective in reducing the 
size o f infarct but are not able to provide complete protection. Indeed, all neuroprotective 
agents are only about 95 % effective at best. This raises the question o f why they are not 
completely neuroprotective if  the damage is mediated through glutamate?
A possible answer is that there is a process that is not dependent on glutamate to 
cause neurotoxicity. Respiratory failure is a main candidate for this non recoverable 
component o f neurotoxicity, although there has recently been interest in the role o f free 
radical (PR) generation in neurotoxicity and respiratory failure (see Kogura et aL, 1985; 
Kontos & Povlishock, 1986; Schmidley, 1990; LeBel & Bondy 1991; Pazdernik et aL, 
1992; Coyle & Puttfarcken, 1993; Evans, 1993; Olanow, 1993; Phillis, 1994; for 
reviews).
The current theories o f excitotoxicity indicate that there is an increase in the 
activity o f various enzymes involved in the production o f FRs, e.g . phospholipase A% 
(Clemens et al., 1991), superoxide dismutase (Lafon-Cazal et aL, 1993), thromboxane 
synthetase (Pettigrew et aL,  1989; Sadoshima et aL, 1989), xanthine oxidase (Kinuta et 
aL,  1989). Several vitamins are reported to be FR scavengers, either in the lipophilic or 
lipophobic enviroments (e.g. vitamin E and vitamin C respectively), and are 
neuroprotective (Sato et aL, 1993). Uemura et aL, (1991b) reported that after focal 
ischaemia there was a significant reduction in glutathione, cysteine and ascorbic acid. This 
means that during ischaemia, the limited FR scavenger systems are overloaded and the 
enhanced activities o f the FR producing enzymes result in cytotoxic levels o f FRs. In the 
present study only vitamin C was given to the animals, as they can synthesise both
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vitamins naturally. Future studies should be performed using guinea pigs, as they lack the 
enzyme (gulonolactone oxidase) that converts L-gulonolactone to L-ascorbate.
In the present study vitamin C was found to confer neuroprotection in both a time 
and dose dependent manner, with maximal protection when administered at either t.j o^ur 
or to hour at a dose of 50mg.kg'^ ip.
There are several possible mechanisms by which ascorbate is preventing kainate 
induced neurotoxicity, the first that kainate is being reduced by ascorbate to 
dihydrokainate, a compound that displays very little affinity for the kainate receptor (Ki 
=  7.4jnM, London & Coyle, 1979), but is a HAGU inhibitor (~175)uM , Bieziere & 
Coyle, 1978, Johnston et al., 1979). In this scenario, as the dose o f ascorbate is increased 
the ratio o f kainate to dihydrokainate decreases. At the low doses this would mean that 
glutamate is released by kainate and the re-uptake is inhibited by dihydrokainate, and 
hence increased neurotoxicity. At the higher doses though, when there is more 
dihydrokainate to kainate, less glutamate is released and so less neurotoxicity occurs, even 
though the re-uptake is inhibited. However, NMR studies performed by Professor Kirby 
(Department o f Chemistry), indicate that ascorbate is unable to reduce kainate when 
analysed in saline for upwards o f 5 days, and hence this scenario is unlikely, although 
direct measurement of kainate in the CNS would be required to confirm/refute this 
conclusion.
The second possibility is that ascorbate is preventing the penetration o f kainate into 
the CNS and hence protecting neurones by preventing their exposure to kainate. Whilst 
microdialysate studies o f CNS kainate levels are required the behavioural observations 
suggest that kainate is entering the CNS, as the animals display all the ‘classical’ kainate 
behavioural disturbances.
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A third possibility is that ascorbate has a biochemical action itself. Ascorbate could 
be acting at several different locations both pre- and post- synaptically, including a) 
glutamate uptake (Cammack et aL, 1991, 1992), b) blockage o f dihydropyridine calcium 
channels (Ebersole & Molinoff, 1992), c) the redox site o f the NM DA receptor complex 
(Levy et aL, 1990; Aizenman & Reynolds, 1992) to reduce current (Majewska et aL, 
1990) and d) a free radical scavenger (Sciamanna & Lee, 1993).
The electrophysiological results, performed by Dr. M.J. Higgins (Department of 
Pharmacology), suggest that the interaction with the NM DA receptor is not sufficient to 
prevent the induction and maintenance o f LTP, ie the neuroprotective action is probably 
not through this mechanism, (although Majewskae et al. (1990) found that ascorbate 
inhibited NM DA currents at similar ascorbate concentrations). Beal et al. (1988) used 
intracerebral quinolinic acid to induce neurotoxicity in the cerebral cortex and found that 
neither allopurinol (250mg.kg“^ ) nor ascorbate lOOmg.kg"  ^ attenuated the damage 
significantly. Although we did not examine whether ascorbate is acting through enhancing 
the uptake system or blockade o f calcium channels, the results o f  Beal et al. (1988) would 
suggest that this is not the case, in that the ascorbate appears to be acting at some point 
prior to NM DA receptor activation, although Majewska & Bell (1990) found that 
ascorbate protected cortical neurones from NM DA or glutamate mediated toxicity. Whilst 
it is not clear how ascorbate is exerting its neuroprotective action, the evidence to date 
thus suggests that ascorbate is acting as a free radical scavenger in the kainate model 
system.
There are various methods to generate free radicals, including the oxidation of 
xanthine to uric acid by xanthine oxidase to produce superoxide and the dismutation to 
hydrogen peroxide (reactions 1.1 to 1.3), the interaction o f superoxide with nitric oxide
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to produce hydroxyl radicals (reactions 1.4 and 1.5), and the interaction o f superoxide 
with iron. This is possible if  there is a haemorrhagic component to the ischaemic insult 
in which case the superoxide would be converted to the cytotoxic hydroxyl radical by the 
following reactions:
0 \  +  — >  O2 +  (5.1)
+  Fe^+ >  HO- +  OH +  Fe^+ (5.2)
If the enzymes responsible for dismuting superoxide or hydrolysing hydrogen 
peroxide are inactive or functioning at reduced efficiency then there would be an increase 
in the intra- and extracellular concentrations o f these toxic free radicals. This would place 
increasing importance on the free radical scavenging systems, and there is evidence that 
during a neurotoxic insult, these systems are overwhelmed (Uemura et a h , 1991b). There 
is increasing evidence to suggest that kainate toxicity is also mediated through the 
generation o f free radicals (Dykens et a l ,  1987; Putfarcksen et a l ,  1993; Baran et a l ,  
1994). There are several pieces o f circumstantial evidence to support this hypothesis. The 
first is that in familial ALS there is a subpopulation o f sufferers who have mutations in 
the gene encoding the Cu/Zn superoxide dismutase enzyme (SO D l), although the result 
of the mutation is unclear (Rosen et aL, 1993). Non-NMDA agonists have long been 
implicated in both ALS and Guam Disease, and indeed one o f the candidate ‘envirotoxins’ 
(BMAA) is an agonist for the AMPA receptor.
The second piece o f evidence is the neuroprotective action o f the xanthine oxidase 
inhibitor allopurinol and its metabolite oxypurinol. In the present study, allopurinol was 
able to prevent kainate induced neurotoxicity at the dose o f 175m g.kg'\ a dose that was 
ineffective in the report by Beal et ah,  (1988). This result does, however agree with 
other reports that allopurinol, administered systemically, is able to attenuate the damage 
caused by a variety o f neurotoxic insults including ischemia (lansek et a l . , 1986; Martz
1 7 5
et al.,  1989; Mink et al., 1991; Williams et al., 1992) and kainate addition to cortical 
cultures (Dykens et al.,  1987).
However, allopurinol is not a specific inhibitor o f XO and this may explain the 
lack o f protection reported by some groups (Betz et ah,  1991; Hegsted et ah,  1991; 
Lindsay et ah,  1991). There are now several reports from Phillis’ group that oxypurinol 
is neuroprotective (Lin & Phillis, 1991,1992; Phillis & Sen, 1993; Sen et ah,  1993; and 
given its greater specificty for XO than allopurinol (Spector, 1987), would indicate that 
XO generated FRs are probably involved in neurotoxicity.
5 .6  Mechanisms o f Kainate Toxicity.
5 .6 .1  Glutamate Mediated Component.
The current theory on the mechanism of kainate toxicity is that it is the release of 
vesicular glutamate that is neurotoxic. The kainate acts on presynaptic receptors to cause 
depolarisation and releases vesicular glutamate, which acts postsynaptically to activate the 
non-NMDA receptors and relieve the voltage block on the NM DA receptors. The 
hyperstimulation o f NM DA receptors causes an influx o f Na"^  and Ca^ "^  and through 
various steps eventual cell death (see section 1.3.3, figure 1.2 and table 1.1).
5 .6 .1 .1  Evidence for Glutamate Component
There are two areas o f evidence to support the involvement o f NMDA receptors 
in the kainate toxicity. The first is that kainate releases glutamate in a dose dependent 
manner (Ferkany et ah,  1982; Notman et ah,  1984; Connick & Stone, 1988), and that 
in cell cultures the concentration achieved is sufficient to activate NM DA receptors and 
induce neurotoxicity. The second is that several reports (Fariello et ah,  1989; Clifford et
176
ah,  1990; Lerner-Natoli <3/£7/. 1991; Moncada e /a /.,  1991; W olf e / «/., 1991; Lehmann 
et a l , , 1993) including the findings in the present report, indicate that NMDA antagonists 
(MK801, TCP, CGS19755, CPP and MgSO^) all attenuate the kainate neurotoxicity with 
their effectiveness dependent on the route o f delivery o f kainate and the target tissue 
(Rogers & Tilson, 1990).
5 .6 .1 .2  Evidence Against Glutamate Component.
There are however several problems with this hypothesis. The main one is that the 
concentrations required for kainate to induce depolarisation in hippocampal slices (ED50 
1-lOjnM, (Stone, 1985,1990)) is low micromolar, whilst in vitro release o f glutamate 
requires millimolar concentrations in hippocampal slice preparations (Ferkany & Coyle, 
1983a,b; Palmer et ah,  1992), as well as in vivo kainate-evoked release (Hamberger et 
ah,  1986; Ogilvy et ah,  1994)
There are several possible explanations for these discrepancies between the 
biochemical and pharmacological methods. The first is that they are just variations 
dependent on the methodology, although this is probably not the case with the 
hippocampal slice preparation in that it requires micromolar kainate concentrations to 
depolarise but millimolar kainate to release glutamate (Ferkany & Coyle 1983a,b; 
Connick, 1987).
A second is that glutamate release is caused by activation o f the low affinity 
kainate receptor (50mM, Henley, 1994), which may be the AMPA receptor, and that the 
‘true’ mechanism o f kainate toxicity is mediated through the high affinity kainate receptors 
(5nM) independent of vesicular glutamate release. This may explain why the striatum is 
not sensitive to systemic kainate but is to intracerebral or intraventricular injections, in
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that higher concentrations would then be achieved at the site o f injection, sufficient to 
initiate neurotoxicity mediated by the low affinity receptors.
A third possible explanation is that the release o f glutamate is a secondary, not a 
primary consequence of kainate receptor activation. If this is the case, then the source of  
the released glutamate may not be vesicular in origin, but may be from blockade o f the 
high affinity glutamate uptake (HAGU) systems. It is known that kainate blocks HAGU 
in a dose dependent manner (Biziere & Coyle, 1978; Johnston et ah,  1979) and if  this is 
occurring in the in vitro preparations, then the increase in extracellular glutamate may be 
from a buildup in basal glutamate efflux and not stimulated release, this is unlikely 
though, given the concentrations used to inhibit HAGU (IC50 302ju,M, Johnston et aL, 
1979).
Another possibility is that the release o f vesicular glutamate is not cytotoxic. Since 
a finite amount would be released, the uptake systems would still be functional, (provided 
the CSF is normal) and the kainate receptors would probably desensitise over a short 
period. If this is the case, then it argues for the involvement o f non-vesicular glutamate 
for neurotoxicity. The probable source o f this glutamate is the cytoplasmic pool ( «  lOmM 
Nicholls & Atwell, 1990).
5 .6 .2  Free Radical Mediated Component.
The findings o f Dykens et aL 1987, and ourselves that allopurinol is able to 
attenuate kainate induced neurotoxicity, indicates that superoxide generation by xanthine 
oxidase plays some role in the kainate neurotoxicity. Puttfarcken et al . , (1993) report that 
kainate is able to cause lipid peroxidation in cerebral granule cell culture, and by inference 
increased free radical production, although whether the free radical production precedes
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or is in parallel to the lipid peroxidation is not known. All these findings suggest that 
kainate toxicity may be caused by processes that are occurring in addition to the glutamate 
release, as observed by Kato et aL,  1991.
5 .6 .3  Proposed Mechanism o f Kainate Mediated Neurotoxicity.
The proposed mechanism o f kainate toxicity in the hippocampus following systemic 
administration is as follows: kainate activates both pre- and postsynaptic receptors and 
results in a transient release o f glutamate from presynaptic vesicular pools. This released 
glutamate is rapidly removed from the synaptic cleft before it reaches toxic concentrations 
by the active HAGU systems. At the same time as the glutamate release, the kainate 
receptors are causing activation o f a calcium dependent protease to enzymically convert 
xanthine dehydrogenase to xanthine oxidase. The xanthine oxidase converts xanthine to 
uric acid and an FR anion (reaction 1.5). Due to some mechanism not yet understood, the 
free radical scavenger enzymes and systems are not able to cope with this increase in 
superoxide anions and hydroxyl radicals and singlet oxygen radicals start to form 
intracellularly. As the concentrations increase the phospholipid bilayers start to be 
permeabilised by uncontrolled peroxidation. This permeabilisation o f the plasma 
membrane would allow the efflux o f cytoplasmic glutamate into the synaptic cleft and the 
surrounding area. At this stage, the damage would be propagated both by kainate induced 
free radical formation and hyperstimulation o f NMDA receptors. This mechanism would 
allow for the action o f various agents that are neuroprotective against kainate 
neurotoxicity, eg RPIA, allopurinol, MgSO^, MK801 and kynurenines. The adenosine Ai 
agonist (RPIA) would be hyperpolarising both the pre- and post-synaptic membranes to 
prevent kainate induced depolarisation, whilst the A  ^ antagonist DPCPX, would prevent
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endogenous adenosine activation. Allopurinol would reduce the production o f superoxide 
anions and ascorbate would oxidise any free radicals formed. The NMDA antagonists 
would be acting after the initial cell loss and would be attenuating the spreading glutamate 
induced toxicity (and this is summarised in figure 5.2). Whilst there is no direct support 
for this hypothesis, the time courses reported both here and in BeaTs paper (Beal et al., 
1988), would suggest that free radical damage occurs prior to glutamate release, and that 
R-PIA is hyperpolarizing the kainate receptor containing neurones initially, before acting 
post synaptically to modulate the NM DA receptor containing neurones. MK801 has a 
relatively long therapeutic window in ischaemic models (4 hours plus), and would be 
expected to have a similar window in the present study.
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99-,Wet dog sMgkes (SHTg)
-► [ïSerotonin behavioural syndrome (SHT^a) ??_]
Seizures (inhibition of GABA%)
Aciivatioii of glutamate receptors
: K p r i a i d # l a r i s a t i o n
Glutamate release
Cell death Free radical foritiatibn / release
Other transmitter release
Excitatory 
(eg; Ach, 5HT)
Inhibitory 
(eg: Adenosine, GABA)
Kainic
Fig 5.2 Current mechanisms of kainate induced neurotoxicity , and potential
sites o f intervention.
Key- 1: 5HT antagonists, to block the behavioural side effects.
2: Anticonvulsants to reduce/abolish seizures and possibly secondary
damage.
3: Glutamate receptor antagonists, to inhibit this activation. The
NMDA site appears to be the main receptor involved in the ensuing 
toxic cascade.
4: Voltage dependant calcium channels. Blockade of these channels
will reduce calcium influx into cells.
5: Inhibition of glutamate release. Targets for this include calcium
channel blockers, and agonists for kappa-opioid, GABA^ or 
adenosine A  ^ receptors.
6 : Inhibitory transmitter agonists will reduce toxicity, while
antagonists appeal* to enhance it. Receptors appear to be the 
GABA^ or adenosine A  ^ targets here.
7: Inhibition of toxic depolarisation. Targets for this include non-
NMDA and NMDA receptor antagonists, inhibitory receptor 
agonists and calcium and sodium channel blockers.
8 : There may be activation of non-glutamatergic neurones, whose
depolarization will release other neuroactive agents into the site of 
injury. Possible targets here have yet to be identified.
9: Inhibition of free radical formation. Targets here include
phospholipase A 2 and xanthine oxidase.
10: Free radical scavengers. Targets here include both the O2 /H2 O, NO 
derived radicals and preoxidised lipids.
?: Possible connections to unknown role in toxicity.
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5.7  Areas o f Further Research.
The work presented above indicates that the neurotoxic action of kainic acid could 
be prevented by various endogenous neuromodulators and exogenous drugs. More 
histology is required though before it is certain that the apparent lack o f gliosis is truly 
neuroprotection. Several other areas also need to be examined including;
1) the treatment of the animals with pH] kainate to ensure that it is entering the 
brain, possibly sampled by microdialysis;
2) improved in vivo and in vitro release studies, using microdialysis and brain slice 
perfusion, in both cases analysing the perfusate by HPLC for purines and amino 
acids. The in vitro studies could also be used with pH] and [^ ''C] labelled 
compounds (possibly glutamate and adenosine), although care should be taken 
in the exogenous transmitter release experiments;
3) the importance o f the serotonergic pathways in the mediation o f neurotoxicity;
4) whether free radical production is a cause or an effect o f kainate induced 
toxicity; and
5) determining whether any of the previously used agents can protect against 
centrally administered excitotoxins (kainate, NMDA, quinolinic acid, the plant 
neurotoxins BO A A and BMAA), ischaemic insults (both focal and global) or 
possibly chronic aluminium treatment.
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Abstract.
Systemic injection o f the glutamate analogue kainic acic produces a regional and 
cellular pattern of neuronal loss in the central nervous system which mimics that produced 
by transient global ischaemia or repeated convulsive seizures. It has previously been 
found, by measuring the binding o f a glial marker ligand, that analogues o f adenosine, 
such as R-N6~phenylisopropyladenosine (R-PIA), can prevent kainate induced damage at 
doses as low as 10 /ig .k g '\ i.p. The use o f gliotic markers, however, is open to 
misinterpretation, and the present work was designed to re-examine purine protection 
against kainate using histological methods. The results show that R-PIA, at a dose o f 25 
fxg.kg'^ i.p. in rats, can protect against the neuronal damage caused by kainate in the 
entorhinal cortex, septum and amygdala as well as the hippocampus. This protection could 
be completely prevented by the simultaneous administration of l,3-dipropyl-8- 
cyclopentylxanthine, indicating the involvement o f A1 receptors in the protection.
2 3 3
INTRODUCTION:
Evidence from a variety o f sources indicates the involvement of excitatory amino 
acids in several CNS disorders. These include seizure disorders, since the use o f 
antagonists at either N-methyl-D-aspartate ( N M D o r  non-NMDA receptors 1 ,^72,83,86 
can abolish or reduce the severity o f convulsions in animal models o f epilepsy, as well 
as disorders in which the most prominent feature is neuronal degeneration. The neuronal 
damage resulting from focal cerebral ischaemia, for example, can be prevented by agents 
which block the neurotoxic effects o f amino acid agonists applied into the CNS 37,38,64-66,71
The glutamate analogue, kainic acid, originally attracted much interest because of 
its ability to produce axon-sparing lesions in the brain raising the possibility that it 
might represent a useful tool in the study o f neuronal communication. In addition, kainate 
is able to cross the blood-brain barrier to a limited extent, causing neurotoxicity after 
parenteral injection 1 >‘•3 ,44,52,70,75^
The regional distribution of the neurotoxicity produced by systemically 
administered kainate bears marked similarities to some pathological conditions, leading 
to the use o f systemic kainate as a model for the development of appropriate 
pharmacological therapies. In particular, parts o f the limbic system exhibit a high 
sensitivity to kainate induced damage. The nature and pattern o f damage resembles 
closely that seen to follow global ischaemia or temporal lobe epilepsy <^>34,36,52,69  ^ while 
being quite different from that seen in focal ischaemia paradigms 24>‘M,48 has also been 
remarked that the regional pattern o f kainate-induced neuronal damage is similar to that 
seen in Alzheimer’s disease
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The similarity between kainate and ischaemic neuropathology is consistent with the 
view that during episodes o f cerebral ischaemia, the tissue hypoxia results in a release of 
endogenous glutamate and aspartate 7>",4i,5i,67,6s ^hich can then activate NM DA and non- 
NM DA receptors to cause further excitation and transmitter release. This cycle o f events 
may develop and persist over many hours since agents able to disrupt the cycle, for 
example by blocking amino acid receptors, are effective in the prevention o f neuronal 
damage even when applied several hours after a transient cerebral insult
An alternative approach to breaking the depolarisation\release cycle is to suppress 
amino acid release and several groups have now reported on the ability o f adenosine, 
or its metabolically stable analogues, to prevent amino acid induced neuronal damage 
2,20,33,53^  Adenosine is an ubiquitous agent which exerts a number o f actions on neurones 
with the common consequence o f depressing neuronal function Thus via activation 
of A1 receptors the nucleoside directly hyperpolarises neurones by increasing potassium 
conductance it suppresses the excitatory actions o f some neurotransmitters such as
acetylcholine and it inhibits the release o f excitatory, but not inhibitory transmitters
50,81,87 ^  combination o f these effects probably accounts for the ability o f adenosine
analogues to block the amino acid release and neurotoxic effects o f kainic acid.
The systemic administration o f the purine derivative R-N^-phenylisopropyl- 
adenosine (R-PIA) can prevent the hippocampal damage produced by systemically injected 
kainate This occurs at doses as low as 10 ^g.kg'^ i.p. and can be demonstrated with 
R-PIA injection up to 2 hours after the administration o f kainate. However, the 
neurotoxicity produced by kainate in these latter studies was assessed using the binding 
of the peripheral benzodiazepine site ligand PK11195 as a reflection of the gliosis
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occurring in response to neuronal damage. The measurements were also confined to the 
hippocampus.
In view o f the success o f the neuroprotection seen in those studies we have now 
extended the investigation to report a direct histological examination o f the interaction 
between kainate and R-PIA. Such an examination overcomes the objection made to 
binding studies that R-PIA may simply prevent gliosis and not modify neuronal damage 
itself. It also allows the examination of the extent of protection throughout a number of 
brain regions other than the hippocampus.
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METHODS:
A ll experiments employed 8-10 week old male Wistar rats, 190-280g, which were 
kept under standard conditions. Animals were injected intraperitoneally with drugs in a 
volume not exceeding 1 ml.kg h Kainic acid was dissolved in saline, and R-PIA in 
methanol. In all cases vehicles were used as control injections and all animals were 
pretreated with clonazepam (0.2m g.kg‘^ ) i.p. 10 minutes prior to kainate injection. The 
animals were allowed to recover, and were killed 7 days later.
Tissue fixation.
After 7 days all the animals in the four groups were given an overdose o f sodium 
pentobarbitone (5 ml o f 60 mg.ml'^) and perfusion fixed with 40% formaldehyde, glacial 
acetic acid, absolute alcohol in the ratio 1:1:8, v \v  (FAM), using the method described 
by Brown & Brierley Briefly the animals were placed in the supine position and 
heparinised (1000 lU.kg"^). A thoracotomy was performed, and a cannula introduced into 
the ascending aorta via the left ventricle. Physiological saline was infused into the animal 
at mean arterial blood pressure for 5-10 seconds after incising the right atrium. This was 
followed immediately by 200ml o f FAM fixative at the same pressure. After infusion the 
rats were decapitated and the head was stored and fixed at 4®C for at least 12 hours. The 
brain was then removed and the left cerebral hemispheres marked with indelible ink. The 
hindbrain was detached by a cut through the midbrain and the cerebral hemispheres were 
cut into five coronal slices, each 2mm thick. The brain stem was cut at right angles to its 
long axis into slices 2mm thick and the cerebellum into 2 slices perpendicular to the folia 
on the dorsal surface o f each hemisphere. Bilateral blocks o f brain were embedded in 
paraffin wax and sections 7-8 um thick were stained by haematoxylin and eosin and by
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a method combining cresyl violet and Luxol fast blue. An Sfxm section was examined by 
conventional light microscopy at X400 magnification, at the level o f the mid dorsal 
hippocampus, by three observers (PAJ, DGM & TWS) semi-blind, and the lefthand 
hippocampus was scored for percentage damaged/dead neurones in the cell layer. The 
hippocampus was examined at 5 sites, (as indicated in figure 1) corresponding to the C A l, 
CA2, CA3a, CA3b and CA4 regions. Zero damage, but disruption o f  the cell layer was 
scored as 10% damage, whilst complete loss o f the cell layer in the field o f  vision was 
scored as 100% damage.
Due to the small n-number used in the control group (n==2), only the kainate and 
kainate/R-PIA were statistically analysed using Student’s t-test.
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RESULTS
The injection o f kainate induced a series o f behaviours similar to those described 
previously and which include wet dog shakes, hind-limb abduction, Straub tail and 
excessive salivation. These were observed in all animals receiving kainate, irrespective 
of the treatment received. The administration o f clonazepam prevented the occurrence of 
tonic-clonic seizure activity.
Neuropathology 
Macroscopic description
Adequate perfusion was achieved in all animals as shown by the lack o f blood in the 
blood vessels and both firmness and pallor of the brain.
Microscopic changes
As judged by the absence o f blood in the vessels, good neuronal morphology, and the 
absence o f the cytological artefacts (the "dark cell" and "hydropic cell" perfusion 
fixation appeared to be adequate in all animals.
a). Control-saline group 
No histological abnormalities were seen in either o f the two animals within this group.
b). Kainate group
Evidence o f neuronal damage was present in each o f the 11 specimens within this 
group. Affected neurones were more angular in shape, showed loss o f nuclear detail and 
shrinkage and marked eosinophilic staining of cytoplasm with loss o f Nissl substance.
There was marked swelling o f associated dendrites, appearances being typically those
seen in "dendrosomatotoxic" but "axon sparing" lesions In the least severely affected
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areas neuronal damage was restricted to single neurones or small clusters o f neurones 
separated by normal cells; in the most severely affected areas neuronal changes were 
observed in a larger proportion of the neurones, the associated neuropile o f which had a 
loose texture and stained only lightly with eosin. Apart from slight swelling o f astrocytes 
no changes were present in glia. In those areas where all or most o f the neurones were 
affected the endothelium of some o f the small blood vessels was prominent.
No histological abnormalities were seen in one o f these animals. In the remaining 
ten specimens, the distribution of lesions was similar and symmetrical. Principal sites of 
involvement were the subfrontal cortex including the pyriform cortex, the cortex related 
to the rhinal fissure and the cortex o f the inferomedial quadrant o f each frontal lobe 
immediately in front o f the genu o f the corpus callosum, the entorhinal cortex, each 
amygdaloid nucleus, and the nuclei o f each septum principally medial but also lateral 
groups. The hippocampus was involved in all animals but to a variable extent. In the least 
affected animals there was the occasionally damaged cell in C A l sector compared with 
those animals in which the hippocampi were extensively involved when there was 
involvement o f C A l, CA3 and CA4, the greatest damage always being in C Al followed 
by CA3 and then CA4. In none o f the animals was there more than moderate damage in 
the CA2.
In none o f the animals was there any involvement of the basal ganglia and in 2 of the 
11 animals changes were present in the upper brain stem (in one there were foci of 
neuronal damage in the periaqueductal grey matter and in another animal there was 
extensive change within each substantia nigra.
In none of the animals was there involvement o f the cerebellum.
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c). Kainate/PIA group
No abnormalities were seen in the brains o f 2 o f the 4 animals o f this group. The 
pattern o f the damage in the 2 affected animals was similar although they differed in 
severity, and in both animals it was similar to that already described in the kainate group
Relative extent of neuronal damage.
The left side-handed hippocampus was scored for percentage damage, as there was 
symmetry in damage in both hippocampi (within »  10% damage).
C A l Cell laver damage.
Neither the control group, or the kainate/R-PIA group showed any damage in the 
C A l cell layer (0 ±  0 n = 2  and 4 respectively), but there was 49.09 ±  12.82% damage 
in the kainate treated animals (p < 0 .0 1  versus the kainate/R-PIA group. Student’s t-test 
see figure 2). The kainate group 4 animals had 90-100% damage in the C A l cell layer.
CA2 Cell Laver
As with the C A l cell layer, both the control and the kainate/R-PIA groups 
displayed no damage, whilst the kainate group showed 50% damage in one animal, with 
0-30% in the rest, (including disruption o f the cell layer). The damage caused by kainate 
(10.91 ±  4.76%) was significantly different from the kainate/R-PIA group (p < 0 .0 5 ) see 
figure 3.
(group b). I
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CA3 Cell Layer
The CA3 cell layer displayed a marked regional variation in the degree o f damage 
with the angle being damaged to >70%  in six o f the kainate group, but in the cell layer 
after the angle only >30%  in one o f the kainate group (this animal had 90% damage in 
both the C A l and CA3a regions). This variation in the degree o f damage between cells 
in the angle and in the cell layer succeeding the angle, resulted the angle being termed the 
CA3a and the cell layer after the angle the CA3b (see figure 1).
In one of the control animals there was a slight disruption o f the CA3a cell layer 
but no change in the CA3b cell layer ( 5 + 5  and 0 +  0% respectively, see figures 4A, 
4D & 4E).
Kainate caused 54.55 +  11.23% damage in the CA3a but only 13.64 +  3.105 in 
the CA3b, (see figures 4B, 4D & 4E). Unlike its action in the C A l region R-PIA was 
unable to prevent kainate induced damage in both the CA3a and CA3b regions (27.5 +  
21.36% and 5 +  2.89% respectively, see figures 4C, 4D & 4E). However, in the case 
of the CA3a region this was probably due to one animal having 90% damage whist the 
rest had <20%  damage. In the CA3b region the p value was tending towards significance 
(p = 0 .069). In both cases more animals are required to confirm/refute the assumption that 
R-PIA is not protecting the CA3 regions.
CA4 Cell Layer.
As with the CA2 region there was <20%  damage in all kainate treated animals 
bar two (both o f which had 90% damage). There was no damage with either control or 
kainate/R-PIA treatment but one R-PIA animal did display a disrupted cell layer). The
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kainate treatment was not significantly different from either o f the other groups, (see 
figure 5).
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DISCUSSION
Previous studies o f kainic acid neurotoxicity using the peripheral benzodiazepine site 
ligand PK11195 as a marker for reactive gliosis are open to the criticism that 
apparently protective agents may not actually modify the occurrence or extent o f neuronal 
damage, but may simply prevent the ghotic reaction. The present work, however, reveals 
that this is not the case with R-PIA, since this agent is able to prevent histologically 
demonstrated kainate-induced neuronal damage.
The cellular damage seen here following the systemic administration o f kainate 
resembles closely that reported in previous studies '*3,44,47,70,73  ^ Damaged neurones appear 
dark and shrunken but in less affected areas o f the CNS are found intermingled with 
normal cells. In more severely affected regions most neurones degenerate and vascular 
endothelium appears prominent. There appears to be some upper limit to the degree of 
damage, however, since even in the CA3 region only about half the neurones exhibited 
signs o f damage. In a previous study Strain & Tasker reported that with a systemic 
dose o f even 32 mg.kg'^ o f kainate, only 59% o f CA3 neurones were killed. The 
neuronal changes are similar to those which have also been reported using in vitro studies 
o f kainate induced damage*.
Regional distribution
The kainate treatment produced signs o f damage in a number o f subcortical areas, 
most notably the hippocampus, entorhinal cortex, septum, dorsomedial thalamus and all 
nuclei o f the amygdaloid complex. This regional distribution is again entirely consistent 
with that described in detail in earlier histological studies 43,44,70,73 also parallels results 
obtained when the degree o f neuronal activation is assessed directly using the 2-
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deoxyglucose method The similarities using 2-deoxyglucose involve not only the 
increased activity in entorhinal, septal and amygdaloid areas, but extends to the greater 
sensitivity o f CA3 pyramids compared with CA4 and CA2 cells. The distribution is also 
consistent with the view that systemic kainate reproduces the pattern o f neuronal damage 
occurring in some human epileptic conditions
The pattern o f hippocampal damage deserves a closer examination. As reported in 
previous histological studies, the CA4 region was affected by systemic kainate less 
severely than C A l or CA3, and CA2 was essentially unaffected. However, the C Al 
region tended to be damaged more consistently in the present work, and often to a greater 
degree than CA3. This represents a difference from earlier findings o f Franck,^® Nadler 
et al. and Cook & Crutcher but may be explained simply by different sensitivities 
in the animal strains used or the use of different doses o f kainate. Previous studies have
Ioften employed doses o f 12 to 32 mg.kg"  ^ kainate, and Balchen et al.^ have pointed out 
that the size o f dose can determine the pattern o f hippocampal damage: the higher the 
dose, the less the damage seen in C A l. This may be the result o f the CA3 region being
%exceptionally sensitive to kainate. The density of kainate binding sites is higher in CA3 
than in any other region o f the CNS, and this correlates with a higher sensitivity to the 
excitatory effects o f the compound '^^ ’38,76 ^  higher dose o f systemic kainate may therefore 
cause such a rapid excitation, inactivation and death o f CA3 cells that the Schaffer 
collateral projection, which is believed to be necessary for the destruction o f CAl 
neurones becomes inactive^. This sequence probably explains the consistent finding that 
local intrahippocampal or intraventricular injections of kainate destroy the CA3 region 
selectively and induce almost no damage in C A l. In our study a relatively low systemic 
dose o f 10 mg.kg'^ kainate was employed, in combination with clonazepam, in order to
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minimise seizure activity and thus confine the effects o f kainate to direct activation of 
neurones. It is possible, therefore, that in this situation a less dramatic activation o f CA3 
cells may have permitted a greater degree o f C A l neuronal damage.
The use o f clonazepam was introduced in previous studies because interest in 
peripheral benzodiazepine binding was limited to the hippocampus, and it had been 
reported that diazepam could suppress behavioural seizures and distant neuronal damage 
while having much less, if  any, inhibitory effect on the hippocampal toxicity o f kainate 
5,16,43 the present study, however, clonazepam did not diminish the pattern o f 
distribution or the severity o f neuronal damage seen with kainate in any brain region, 
despite the almost total suppression o f overt seizure behaviour. While the explanation o f  
this is unclear, it is possible that the profile o f action of diazepam, used in earlier studies, 
differs from that of clonazepam. Certainly the dose o f clonazepam used here is around one 
tenth to one hundredth the dose o f diazepam, yet it fully blocked the seizures. Clonazepam 
may thus have a higher ratio o f antiseizure to neuroprotective activity. Alternatively, the 
difference may simply reflect our deliberate choice o f the minimum dose o f clonazepam 
needed to suppress behavioural seizures, a consideration which was not evident in earlier 
studies.
Protection by R-PIA.
The ability o f R-PIA to prevent kainate induced neurotoxicity supports the previous 
work involving the use o f PK11195 as a marker for reactive gliosis and is consistent 
with studies from other laboratories which have demonstrated protection by 2- 
chloroadenosine against excitotoxin induced damage or by cyclohexyladenosine 
against ischaemic damage
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Purines may be able to afford protection by virtue o f their ability to hyperpolarise 
neurones directly to a level at which calcium influx is minimal. However, it seems 
probable that an inhibitory action on synaptic terminals is importantly involved. It is clear 
from studies in which the destruction o f afferent pathways reduces kainate induced 
excitation and neurodegeneration that intact terminals are required for excitotoxicity 
34,43,49,55,57,61,62,76^  j-giguit from 3. ptesynaptic action o f kainate to evoke the release
o f other compounds such as glutamate and aspartate which are primarily responsible for 
the subsequent degeneration, or it may indicate the need for such presynaptic factors to 
exert a permissive action on the effects of kainate.
The former is made more likely by direct demonstrations o f the release of 
glutamate and aspartate by kainic acid *^ ’32,s9,8s by the reports o f kainate receptors on 
synaptosomal preparations o f CNS tissue Such an involvement o f released amino acids 
would help to account for the frequent observation that kainate induced damage can be at 
least partially prevented by antagonists at NMDA receptors **’3o,s4 ^hich would be 
activated by glutamate released from terminals. Indeed, since kainate may also release 
glutamate from glial cells these may provide an additional source o f potentially toxic 
amino acids.
Adenosine and its analogues are known to act at A1 nucleoside receptors to 
suppress the release o f a variety of neurotransmitters including glutamate 
acetylcholine dopamine and peptides. This activity could therefore lead to the
blockade of amino acid release induced by kainate, and the protective effect observed 
here. It is certainly relevant that other agents which can suppress the release o f excitatory 
amino acids, such as the pyrimidine derivative BW1002C87 (5-(2 ,3 ,5-trichlorophenyl)- 
pyrimidine-2,4-diamine-1 ,1-ethanesulphonate) and kappa opiate receptor agonists are able
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to prevent neuronal damage in studies o f ischaemia
In summary, this study has confirmed the neuroprotective activity o f the purine 
analogue R-PIA against neurotoxicity induced by systemic injections o f kainic acid. In 
view o f the similar pathology o f kainate damage and that resulting from transient global 
ischaemia or repeated seizures in humans, it would appear that purines may represent a 
promising avenue for the development o f clinically useful neuroprotectant agents.
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Figure 1:
Areas of the hippocampus analysed for neuropathological.
Legends: CA =  Cornu ammonis subfields, mf. -  mossy fibres, sc. 
collaterals.
Schaffer
2 5 6
AB
.......... . .
m m g
UNMK#
Figure 2. Examination of CAl cell layer
A) control (saline/methanol injected) animal
B) lOmg.kg'* kainate/methanol injected animal
C) lOmg.kg-’ kainate/25mm.kg-* R-PIA } H & E stained, x330
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Figure 2D. Analysis of damage in the C A l cell layer.
Columns indicate mean ±  sem. ** p < 0 ,0 1  versus kainate group, Student’s t-test.
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Figure 3.
Analysis o f damage in the CA2 cell layer.
Columns indicate mean ±  sem, * p < 0 .0 5  versus kainate group, Student’s t-test.
2 5 9
AB
m
C Ï
Figure 4. Examination of CA3 cell layer
A) control (saline/methanol injected) animal
B) lOmg.kg'^ kainate/methanol injected animal
C) lOmg.kg-i kainate/25mm.kg-^ R-PIA } H & E stained, x530
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Figure 4D.
Analysis of damage in the CA3a cell layer.
Columns indicate mean +  sem.
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Figure 4E.
Analysis o f damage in the CA3b cell layer.
Columns indicate mean ±  sem. +  p < 0 .069  versus kainate group, Student’s t-test.
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Figure 5. Examination of CA4 cell layer
A) control (saline/methanol injected) animal
B) lOmg.kg-i kainate/methanol injected animal
C) lOmg.kg'* kainate/25mm.kg-^ R-PIA } H & E stained, x330
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Figure 5D.
Analysis o f damage in the CA4 cell layer.
Columns indicate mean ±  sem. * p < 0 . 0 5  versus kainate group, Student’s t-test.
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